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Abstract 
 
Anterior Gradient-2 protein (AGR2) has recently been linked to the onset of several 
pathologies including asthma and inflammatory bowel disease.  Most interestingly, it 
has been discovered to influence the transformation of cells and metastatic growth 
essential to cancer development, and has subsequently been linked to the 
development of resistance to anti-cancer therapeutics.  AGR2 protein is 
overexpressed in a diverse range of human cancer types, and has been detected 
secreted into the extracellular milieu.  Thus, AGR2 protein represents a compelling 
pro-oncogenic signalling intermediate in tumour emergence and endurance.  This 
thesis presents an interdisciplinary approach including structural biology, cell 
biology and synthetic biology, and clinical studies to shed more light on the role of 
AGR2 in cancer development.  Synthetic cell based reagents were developed to 
define the dominant pathways that are reprogrammed in a cell as a result of AGR2 
synthesis.  A cell panel was engineered incorporating the AGR2 (and mutants 
thereof) allele into the AGR2-null A375 cell line.  These tools were then coupled to 
quantitative proteomics (SILAC) to unravel the mechanism whereby introduction of 
AGR2 alters cell phenotype, allowing identification of dominant pathways affected 
by AGR2 signalling.  Using pathway analysis tools, the dominant pathway 
suppressed by wt-AGR2 expression highlighted the p53-signalling axis.  DNA 
damage induced p53 stabilisation and p21 induction by cisplatin treatment confirmed 
the influence of AGR2 gene expression.  Further data analysis identified the outlying 
protein expression changes identified by SILAC was the anti-viral cell cycle 
regulator TSG101 (tumour susceptibility gene 101), and confirmed by 
immunoblotting.  Transfection and silencing studies of TSG101 confirmed that 
TSG101 attenuates p53 function.  These data provide a mechanism to explain the 
most dominant pathways reprogrammed by AGR2 expression, incorporating ER 
stress response, proliferation markers and p53 pathway attenuation. 
Further advances were made in analysis of the function, regulation, and drugability 
of AGR2 protein.  Assays were devised to define the subunit structure of AGR2 as a 
 
  xxi 
dimer unit; subsequent functional studies defined intrinsically disordered motifs that 
regulate stability of the dimer.  A two-site sandwich microtiter assay (
2S
MTA) was 
designed to screen for self-peptides and mutations that regulate oligomer stability. 
These assays were used to identify the first biochemical property  of AGR2 being 
that the dimer unit is required for maximal binding to the AAA+ protein, and well 
characterised AGR2 interactor, Reptin. In addition, based on this dimeric structure, a 
novel solution based dimerisation assay was developed to identify natural products 
that are able to disrupt the dimer suggesting that AGR2 itself can be targeted in 
principle with small molecules for therapeutic purposes.    
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1.1.1 Overview of the Molecular Basis of Cancer 
The term cancer groups a broad spectrum of diseases states, sharing one collective 
manifestation: the uncontrolled, unregulated growth of cells into a malignant tumour 
mass.  Cancer accounts for 13% of worldwide mortalities (1) and incidence is 
predicted to rise due to an aging population (1;2).  This demonstrates the importance 
of developing our understanding of oncogenesis through novel research in the fields 
of biochemistry and biomedicine.  The emergence and maintenance of tumours 
broadly requires the coupling of dysfunctional gene regulation with epigenetic 
abnormalities (3), resulting in a diverse variety of molecular signatures whose 
resultant events drive carcinogenesis.  The exact mechanism whereby cells acquire 
these malignant phenotypes is not yet fully understood, yet the heterogeneity of 
tumour genomes indicate that cells accumulate mutations over time, and the 
dominant ones conferring a selective advantage are evolutionarily conserved (4).  
Mutations in pro-oncogenes release the restriction on growth promoting, or anti-
apoptotic, genes resulting in oncogenes.  Conversely, mutations in tumour-
suppressor genes, whose normal function is to constrain cell proliferation within 
appropriate margins, result in inactivation and loss of function (5-8).  Additionally, 
tumourigenesis can also be linked to changes in gene expression not accompanied by 
mutations in the DNA blueprint of the cell (9;10), termed epigenetics.  Epigenetic 
mechanisms modulate gene expression by altering the accessibility of DNA to 
transcription factors; well studied examples include histone modifications (11) and 
DNA methylation (12;13).  Consequently, transcription initiation and gene 
expression can be misregulated, resulting in disruption of cell homeostasis and 
aberrant cell growth. 
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1.1.2 Hallmarks of Cancer 
Cell immortality, constitutive chronic proliferation, avoidance of growth suppressive 
factors and apoptosis, an ability to invade into surrounding tissues and the capacity to 
activate angiogenesis (6), together with the more recently described, deregulation of 
cellular energetics (Warburg Effect (14)) and circumvention of the immune system 
(15) have been defined, and subsequently researched, as key traits central to the 
definition of cancer (Figure 1-1).  These coupled to the compound micro-
environment together with normal cells, compliant cancer stem cells and altered 
extracellular matrix demonstrate the intricacies of the complex web which drive the 
cancer phenotype (16).  Genetic and epigenetic mechanisms give rise to altered 
protein expression levels, expression of mutant proteins, and deletion of regulatory or 
housekeeping proteins, and resultantly feed into cancer promoting pathways 
including growth factor response, metabolic pathways, transcriptional and 
translational machinery, protein degradation and apoptosis (6;15). 
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Figure 1-1: An illustration of summarised evolution of a normal health cell into a malignant 
tumour.  Adapted from (6;15).   
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1.1.3 Cancer Therapeutic Strategies 
Despite the disentangling of the key hallmarks of cancer, the heterogeneity and 
diversity of cancer causing mutations and survival mechanisms of cancer cells 
presents a difficult challenge for the research and development of novel cancer 
therapeutics.  Developing our understanding of subcellular pathways implicit in cell 
growth, survival and transformation has provided a rich source of targets for 
developing strategies for novel cancer therapeutics (17). 
 
1.1.3.1 Broad action, pro-apoptotic chemotherapeutics 
As studies develop our knowledge of the molecular basis of tumour progression, 
biomacromolecular anticancer therapeutics that can target these features have been 
developed.  Paclitaxel is one example of an anti-cancer drug targeting key 
misregulated pathways prevalent in cancer progression.  Paclitaxel targets the 
microtubule component, tubulin, stabilising the polymeric structure of the 
cytoskeleton preventing disassembly during mitosis (18).  As a result, cells are 
arrested at the mitotic checkpoint, G2/M (19), and subsequently prevented from 
completing cell division and directed toward apoptosis (20). Comparatively, cisplatin 
is used therapeutically to inhibit cell proliferation by targeting DNA. Cross-linking 
DNA results in the blocking of DNA replication (inhibiting cell proliferation), and 
activating DNA repair pathways eliciting apoptotic events (21).   Bortezomib instead 
targets the 26S proteosomal subunit (22), preventing the recycling of misfolded or 
aberrant protein expression.  As a result, cells activate stress response pathways 
which inevitably lead to apoptosis.  These chemotherapies act on the broad 
understanding that as cancer cells are replicating more than normal cells, they require 
more cytoskeletal rearrangement, more DNA replication and have in increased rate 
of protein recycling respectively. Theoretically, driving cancer cells towards an 
apoptotic pathway allows tumour growth to be controlled.  However, since these 
processes are not only limited to cancer cells, but shared with normal cells also, off-
target and side effects would not be unexpected.  
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1.1.3.2 Drug compounds specifically targeting cancer-associated 
mutations  
Drugs with more specific targets and modes of action have also been developed, 
these tend to target specific protein cofactors such as kinases, specifically ATP 
binding sites incorporated into these enzymes, and cell surface receptors mutated in 
carcinogenesis.  The discovery of the mutation of functions regulating protein kinase 
activity in cancers (23) has emerged as one of the mechanisms whereby cancer cells 
circumvent normal physiological control, making it a suitable specific target for anti-
cancer therapeutics.  Mutated kinases provide a selective advantage to cancer cells 
compared to normal cells resulting in an ‘oncogene addiction’ phenomenon (24), 
where cells are reliant on a few genes for the maintenance of the malignant 
phenotype.  A mutation, such as the DNA translocation which forms the BCR-Abl 
fusion protein, allow the encoding of a mutated, constitutively active tyrosine kinase 
which drives unregulated cell division through the activation of a number of cell 
cycle controlling proteins and enzymes (25).   Imantinib is an example of a drug 
developed specifically targeting this single aberrant tyrosine kinase, inhibiting 
phosphorylation of substrate proteins necessary for the cell signalling cascade that 
drives cell proliferation (26).  Several other examples of protein kinase mutations in 
cancer are evident including epidermal growth factor (EGF) receptors (27) and 
BRAF (28).  Targeted therapeutics can also specifically bind cell surface proteins on 
mutated in cancer.  Trastuzumab, a monoclonal antibody therapy which interferes 
with the overexpressed HER2/neu cell surface receptor (29), constricts the over-
activation of EGF receptors and downstream activation of proliferative pathways, 
arresting the cell in G1 phase of the cell cycle.  These drugs target cancer cell specific 
targets, therefore demonstrate an increased affinity for aberrant cells, compared to 
the more broadly acting drugs (30).  However, due to the diversity of cancer, these 
drugs are only useful in disease exhibiting a specific mutation limiting their 
therapeutic potential to particular classes of cancer manifestation. 
A key objective of cancer research is to develop our understanding of novel drug 
targets, to broaden the range of therapeutic interventions available, particularly when 
cancers show resistance (31) or do not respond to current options. 
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1.1.3.3 Protein-protein interactions and hub proteins as emerging 
cancer therapeutic targets 
The complex webs of protein networks that fuse together to form the molecular basis 
of all cellular functions are presenting a promising emerging basis for rational anti-
cancer drug design (32).  The connectivity between these molecular components and 
dysfunction therein, translates into the global expression of disease.  An interactome 
describes all of the molecular interactions regulated by a specific protein of interest 
(33;34), highlighting that some central ‘hub’ proteins interact with hundreds of 
partners to form the highly connected axes of cell signal transduction. Small 
manipulations, or mutations, in the promiscuity or expression of these hub proteins 
can have a significant effect on the normal homeostatic mechanisms of a healthy cell.  
A mutant variant of a hub protein could be considered to rewire the signal 
transduction mechanism of a cell, through the protein-protein interaction landscape, 
contributing to cancer-promoting activity.  Indeed, genes identified which are 
associated with, and responsible for, tumourigenesis have a high likelihood of 
encoding hub proteins (32). 
The tumour suppressor protein, p53, has been described as a key hub protein, 
mediating gene expression, cell cycle regulation and regulation of apoptosis and 
senescence (35).  p53 interacts with in excess of 300 interaction partners (36), and is 
the most frequently mutated or deactivated in one in every two human cancer 
incidences (37).  This provided the basis for the development of the p53-reactivating 
drug PRIMA-1 (p53 re-activation and induction of massive apoptosis-1) (38), which 
selectively covalently inhibits the growth promoting, mutated p53 gene product, 
promoting apoptosis and death of the aberrant cell. 
Molecular chaperones form another target for anti-cancer drug compounds utilising 
protein-protein interaction networks.  Chaperone proteins are essential in the 
maturation of nascent peptide chains to form proteins, and in the response of cells to 
stressful stimuli in order to maintain cellular homeostasis and promotion of cell 
survival (39).  The heat-shock protein 90 (Hsp90) is widely reported to be a hub 
protein involved in cancer related protein folding pathways including p53, BRAF 
and AKT (35;40).  Cancer cells are regularly exposed to proteotoxic stress, through 
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the increase in protein synthesis and accumulation of unfolded or misfolded proteins, 
therefore they become dependent on the role of chaperone proteins for proliferation 
and division of cells (41;42).  Accordingly, inhibitors of Hsp90 have been developed, 
geldanamycin and 17-AAG (17-allylamino-17-demethoxygeldanamycin) (43), which 
target the ATP-binding pocket of Hsp90, blocking ATPase activity and controlling 




p53, named after migrating 53 kDa on a SDS-PAGE gel despite a molecular mass of 
43.7 kDa, was first published in 1982 as a protein forming physical interactions with 
transforming protein SV40-T-antigen of a DNA tumour virus (47), allowing 
perturbation of normal cell signalling pathways and promoting replication of viral 
DNA.  Subsequent intensive research has identified p53-mutation (48) or deletion 
(49)  as a central event in the predisposition of 50% incidences of cancer.  However, 
some cancers never select for p53 mutations, and yet exhibit a functionally inactive 
p53 protein (50).  These carcinomas utilise mutation independent mechanisms.  The 
common theme is the sequestration of wild-type p53 protein away from the nucleus 
resulting in abrogation of normal suppressive action (51-54).  
Molecular characterisation studies of p53 protein have begun to disentangle the 
structural motifs or p53 which modulate its described functions. 
 
1.2.1 p53 structure  
Despite a high degree of disorder in the predicted structure of p53, the 393 amino 
acid residue protein presents several modular domains giving insight into its activity 
(Figure 1-2A and 1-2B).  The (i) N-terminal region incorporates two transactivation 
domains required for interaction with transcriptional machinery such as p300 (55), 
and also provides a binding site for the p53-regulating protein, mouse double minute 
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 1 – Introduction  8 
2 (MDM2) (56).  Additionally the (ii) core DNA binding domain of p53 incorporates 
several conserved domains (Box II, III, IV and V) (57;58) involved in direct DNA 
contact, and is the site of most tumourigenic mutations (48) (Figure 1-2C). The (iii) 
tetramerisation domain of p53 describes the α-helical motif necessary for the 
oligomerisation of p53 monomers into the collective transcriptionally active 
functional unit (59-63), and can also function as a protein docking site regulating 
protein-protein interactions (64-66).  Finally, the C-terminal (iv) regulatory domain 
forms a further protein docking site for regulation of p53 activity (67;68) 
The high level of disorder has resulted in the core domain and tetramerisation 
domain of p53 being structurally characterised individually (69;70).  It is important 
to note, that significant effort has been directed at the post-translational 
modifications of these modules affecting activity of the protein, including 
ubiquitination and ubiquitin-like modification (neddylation, sumolation), 
methylation, acetylation and, most significantly, phosphorylation.  Phosphorylation 
and acetylation of the C-terminal domain allosterically stimulate DNA binding to the 
core domain (71;72), whereas N-terminal post-translational modifications fine tune 
p53 activity, often in response to stress (73). 
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Figure 1-2 p53 protein structure.  (A) Illustration of the modular structure of p53 domain 
organisation highlighting the transactivation domain (TAD, blue), the DNA-binding domain (green), 
the tetramerisation domain (TET, orange) and the C-terminal domain (CTD, grey). (B) The primary 
sequence of human p53, with domains coloured as above.  (C) Cartoon model of three core DNA 
binding domains of p53 interacting with DNA (PDB code: 1TUP (74)).   
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1.2.2 p53 function 
1.2.2.1 p53 as a hub protein 
All proteins interact with other molecules in order to carry out their perceived role, 
however, a small number of proteins, hub proteins, form relationships with hundreds 
of interacting partners resulting in a focal point of the interaction network (75).  This 
promiscuity indicates the complexity of the function of these hub proteins.  p53 is 
described as an example of a hub since it interconnects numerous signalling 
pathways signifying the diversity of functions with which p53 has been implicated.  
The interactome of p53, that is all of the published protein-protein interactions, now 
exceeds 300 partners (36) providing a broad database within which p53 signalling 
can be interrogated.  It is evident from such a broad range of interaction partners that 
slight modification in the gene, the expression of the gene product or the subcellular 
localisation of p53 protein can have significant downstream consequences for the 
cell.     
 
1.2.2.2 p53 tumour suppression function 
Mammalian cells have evolved mechanisms to tightly control the maturation of cells 
during important functions such as regeneration, replenishment and growth.  
Concurrently, inaccuracies in gene expression arising from DNA replication errors, 
metabolic activities and environmental factors, are remedied through complex, 
controlled cellular repair systems.  If significant DNA damage has occurred, cells 
can enter two possible states: (i) an irreversible, non-dividing arrested state, termed 
senescence, or (ii) cells can commit suicide through a process known as apoptosis  (a 
third process of autophagy, or ‘self-eating’, the processing of bulk degradation using 
the lysosomal machinery, is reportedly also thought to play some role (76)).  Due to 
the reported prevalence of mutation of the  p53 allele of human cancer biopsies (48), 
studies have been undertaken  to decipher the growth controlling properties of this 
master inhibitor of tumour development (77;78).   Under normal circumstances, p53 
is a protein with an extremely short half-life (79), its expression is tightly controlled 
and excess protein rapidly sequestered.  Surfeit protein is recycled by targeting for 
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ubiquitination by the ring-finger ubiquitin E3 ligase MDM2, and trafficked out of the 
nucleus to be degraded by the 26S proteosome (80) (Figure 1-3A).   
In response to DNA damage by ultraviolet light (81) and γ-radiation (82), p53 forms 
a central node whose expression is stabilised by post-translational modifications, 
predominantly kinase and acetyltransferase activity which phosphorylate and 
acetylate respectively, and this stabilisation mediates cell cycle arrest at G1 (82).  p53 
tetramerises and accumulates in the nucleus (83), leading to subsequent 
transcriptional activation of p53 target genes (Figure 1-3B).  Growth arrest is 
principally induced via the best characterised of p53-dependent downstream targets, 
p21-WAF1 (84).  Elevated levels of p21 inhibit the cyclin E/cdk2 and cyclin A/cdk2 
kinases preventing the phosphorylation of client proteins promoting cell cycle 
progression (77;85).    Of the approximately 150 gene targets of p53, most are 
associated with cell cycle arrest, apoptosis, and DNA repair, which maintain the 
integrity of the cell (86) (Figure 1-3B).  Key transcriptional targets include the Bcl-2 
proteins p53-upregulated modulator of apoptosis (PUMA) (87), NOXA (88), BID 
(89) and BAX (90), while suppressing the anti-apoptotic genes Bcl-x and survivin 
(91;92), along with other members of the pro-apoptotic machinery.  Bcl-2 proteins 
perform their pro-apoptotic function by initiating processes such as caspase 
activation and mitochondrial outer membrane permeabilisation (MOMP) (93;94), 
whereby key structural components of the cell are disrupted.   
Apoptosis is firmly established as the central mechanism of control of damaged cells 
preventing aberrant cell growth.  However, none of these gene targets can fully 
explain the pro-apoptotic effects of p53 (91) indicating that p53 acts via multiple pro-
apoptotic pathways.  Intriguingly, apoptosis can also be mediated independently 
from transcription (52;95-99).  Cytosolic and mitochondrial localised p53 interacts 
with members of the Bcl-2 family, BAK, BAD and BAX (100) to modulate the 
activation of apoptosis.  This response protects the cell from uncontrolled 
proliferation and neoplastic transformation following genotoxic stress.    
Further, p53 can also prevent tumour development independently from apoptosis.  
PUMA knockout mice do not exhibit uncontrolled proliferative growth (101), 
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indicating that the p53 anti-tumour response is more complex than promoting 
defective cell death. p21-WAF1 (84), GADD45 and 14-3-3σ proteins, induced by 
p53, can activate a reversible cell cycle arrest (82;84;102) to pause cell growth to 
allow repair.  Subsequently, senescence is triggered if the repair is not successful 
(103).  
p53 also limits proliferation through the inhibition of new blood vessel formation 
through upregulation of anti-angiogenesis factors vascular endothelial growth factor-
A (VEGF-A) and hypoxia inducible factor 1α (HIF-1) (104-106).  Thereby, p53 can 
influence the distribution of nutrients and oxygen in a controlled manner. 
  
Structural and Functional Interrogation of Anterior Gradient-2 




Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 1 – Introduction  14 
Figure 1-3 The published roles of p53 under normal physiological conditions and following 
stress-inducing conditions.  (A) Under normal, undamaged cellular conditions, p53 is maintained at 
a low level of expression.  Gene expression constitutively suppressed and surfeit protein is labelled for 
proteosomal degradation through ubiquitination by MDM2. (B)  In contrast under stressful conditions, 
p53 is transcriptionally activated and protein turnover is suppressed allowing enrichment of p53 
protein in the cell.  This active p53 translocates to the nucleus, allowing interaction with DNA and 
upregulates the expression of gene targets involved in several cellular repair pathways.  
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1.2.2.3 p21 involvement in p53 signalling 
p21 was identified as a p53-responsive target in a screen to identify p53 target genes, 
subsequently described as WAF1 (wild-type p53 activated fragment 1) (84) and is a 
multifunctional protein implicit in cell cycle arrest, apoptosis and promotion of 
differentiation and cellular senescence.  However, its role is most defined in the p53 
pathway where p21 is a direct transcriptional target of p53, and is strongly induced 
by DNA damage in cells expressing wild-type p53 (107).  It has been characterised 
as a cyclin dependent kinase inhibitor, induced by p53, and shown to mediate p53-
dependent cell cycle arrest at the G1/S checkpoint by inhibition of the activity of 
cyclin/CDK2 complexes (108).  The p21 promoter contains five p53-binding sites at 
positions -4001, -3764, -2311, -2276 and -1391 base pairs (109) and at least one of 
these sites is required for p53-dependent induction after DNA damage (110;111).  
p21 protein levels are regulated at the post-translational level by proteosome 
mediated degradation by ubiquitin-dependent and –independent means (112;113).   
p21 is also thought to have a regulatory role in the nuclear localisation of p53, 
driving a positive feedback loop of p53 expression (114).  
 
1.2.2.4 Misregulation of p53 in cancer 
Inactivation of p53 can occur by genetic deletion, or down regulation of the 
expressed protein, or more dominantly, in the mutation of the genomic p53 blueprint, 
resulting in a protein with aberrant functions (48).  p53 mutants are widespread in 
cancer, and hot spots of mutation have been identified, and map in particular to 
regions of the core DNA binding domain (35).  Mutant alleles of p53 are often 
dominant over the wild-type, and in these cases the gene product with aberrant 
function may act as an oncoprotein (36).  Since these mis-sense mutants offer a 
survival advantage, such that mutant p53 inactivates normal sequence specific DNA 
binding (‘transcriptionally-inactive’), promoting cell proliferation and suppressing 
the homeostatic function of wild-type p53, these are commonly selected for.  Studies 
characterising mutant p53 alleles have provided key insights of the roles of mutant 
p53, and inversely wild-type p53, in the field (36); including (i) unfolded, mutant 
p53 accumulation in the nucleus of cancer cells in vivo (115), (ii) mutant p53 
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dominates wild-type p53, by forcing unfolding of the wild-type protein and the 
formation of hetero-tetramers (116), (iii) mutants lack sequence specific DNA-
binding activity (117), and (iv) mutant p53 exhibits a distinct interactomic landscape 
compared to the wild-type (118;119). 
However, some cancers maintain the wild-type p53 allele, or mutation occurs late in 
carcinogenesis such as colorectal cancer (120) and glioblastoma multiforme (121), 
yet have disrupted p53-dependent function.  This provides an indication that a 
secondary mechanism exists to ablate p53 function.  Under normal conditions, wild-
type p53 is predominantly kept inactive in the vast majority of human cells, however 
a variety of stresses induce p53 activation and resultant p53-dependent activity.  Cell 
stresses such as DNA damage, oncogene activation and hypoxia have been 
uncovered as regulators of p53.  These regulators are not thought to heavily influence 
p53 at the transcriptional level, but rather modulate the level of available p53 protein 
by changing the half-life of the protein (122).  The best understood, and most 
important, degradation pathway of p53 occurs via the ubiquitin-proteasome system, 
in which p53 is a substrate for the E3 ubiquitin ligase, MDM2 (80).  E3 ligases 
function in an enzymatic cascade, with an E1 and E2 enzyme, which catalyse the 
transfer and covalent linkage of a ubiquitin molecule to lysine residues of the 
substrate protein, signalling for translocation to the proteosome and subsequent 
degradation (123).  MDM2 also contains a signalling sequence similar to the nuclear 
export signal of various viral proteins (124) and after binding to p53, signals for its 
nuclear export (125;126).  Therefore, the availability and activity of MDM2 is an 
important factor in the normal control of p53 activity, maintaining the tight 
regulation in healthy cells under normal conditions.  The mouse model containing a 
gene knockout mutant of MDM2 describes an embryonic lethal phenotype, which 
can be rescued by subsequently knocking out of p53 allowing live births (127).  The 
transcription of MDM2 is controlled in an auto-regulatory feedback loop by p53, 
which acts to upregulate MDM2, thus p53 expression acts to negatively regulate 
itself via an autoregulatory feedback mechanism (80).  This interplay influences a 
vast array of molecular pathways in humans including autophagy, DNA damage 
response, differentiation, senescence, cell-cell interactions, apoptosis and metabolism 
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(36).  Studies have confirmed that the over expression of MDM2 in vitro acts to 
block p53-mediated cell cycle arrest and apoptosis (128).  This is reflected in clinical 
studies of tumours, predominantly soft-tissue tumours, osteosarcomas and 
oesophageal carcinomas among others, where MDM2 acts to suppress wild type p53 
activity, and is associated with increased cell proliferation and tumour volume. (129-
131).    
 
1.2.2.5 Therapeutic targeting of p53 
Based on these understandings of p53 as a tumour suppressor and its misregulation in 
tumours, there are two key ways to target p53 for therapeutic treatments of cancer: (i) 
the inhibition of mutant p53 and (ii) reactivation of wild-type p53.  Specifically 
targeting mutant p53 allows the binding and silencing of oncogenic function, a 
methodology which has been successfully utilised in the development of the drug 
CP-31398 (Pfizer) (132-134), enabling the activation of p53-dependent transcription, 
apoptosis, cell cycle arrest and reduction in tumour growth in mice.  Mutant p53 can 
also be targeted by structure based drug design and in silico modelling, specifically 
targeting individual mutants such as the Y220C p53 mutant binding pocket to 
reactivate p53-dependent activity (135).  The cysteine substitution forms a pocket 
which does not affect the overall structure, but demonstrates reduced functional 
activity (35), and the development of the molecule PhiKan059 can bind and 
inactivate p53-Y220C (135;136).  Actively targeting amino acid residues deemed 
essential for function has yielded the mutant-p53 targeted therapeutic PRIMA-1 (38).  
PRIMA-1 modifies reactive cysteines to reactivate p53 function.  This strategy is 
hugely resource consuming due to the breadth of different cell types, 
microenvironments and mutations that exist.  Variations in selective pressures 
driving the selection of mutation may be essential in the understanding of targeting 
mutant p53.   
In wild-type p53 expressing cancers, many strategies focus on MDM2, to reactivate 
p53 transactivation, cellular localisation and mRNA translation (137;138).  Nutlins 
were the first small molecule drugs targeting the MDM2-p53 interaction, allowing 
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dissociation of components (139;140) and subsequent inhibition of tumour growth 
(141;142).  A small molecule screen of novel p53 reactivators identified RITA 
(reactivation of p53 and induction of tumour cell apoptosis)(143-145), initially 
thought to disrupt the MDM2-p53 interaction, however, RITA also induced DNA 
damage (143;144) suggesting the mode of action of RITA is more complex than 
initially described.  Importantly, RITA could downregulate p53 inhibitors MDM2, 
and WIP1, resulting in p53-mediated cell death (146).  However, due to the vast 
complex interactome of MDM2 (36), some of which functions independently of p53, 
off target effects may be common.  In fact, some studies have suggested that small 
molecule-induced interaction with MDM2 may in fact fuel metastasis by interfering 
with the regulation of other MDM2 substrates (e.g. Slug) (147).  The degradation of 
Slug, an invasion promoter, is mediated by MDM2-controlled ubiquitination and 
proteosomal targeting.  Thus, silencing of MDM2 allows stabilisation of Slug, and 
subsequent promotion of cancer cell invasiveness (147).   
There are obvious difficulties in understanding the possible therapeutic strategies of 
p53 reactivation in cancers.  It is therefore imperative to develop our understanding 
of the protein landscape surrounding p53, through mutations, interactors and 
regulatory proteins.  Analysing how these correlate to p53-dependent activity, 
normal cellular function and cell homeostasis and whether these compounds might 
indirectly be useful of therapeutic strategies to reactive p53 function.   
 
1.3 Anterior Gradient-2 
 
Broad research approaches into possible roles of anterior gradient-2 protein (AGR2) 
have been undertaken since its discovery as a developmental factor in 1989 (148) and 
consequential learning of its role in the specification of cement gland and forebrain 
in developing embryos (149).  Subsequent studies have implicated AGR2 in a range 
of pathways and pathologies described herein.  Specifically, and most relevantly, 
AGR2 was identified as a negative regulator of p53 (150), driving approaches to 
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understand it as a potential chemotherapeutic target for the reactivation of p53-
dependent activity in cancer.  Firstly, I present a summary of the discovery and 
evolution of AGR2, and related proteins, before analysis of studies of AGR2 roles 
and implications in human diseases.  
 
1.3.1 AGR2 in development and limb regeneration 
AGR2 belongs to the wider family of anterior gradient proteins, containing several 
members including the ancestral member XAG-2 (Figure 1-4).  The anterior gradient 
genes, XAG-1, XAG-2 and XAG-3, were first discovered in Xenopus laevis, and 
named according to their specific expression patterns during early development 
(148;151;152).  XAG-2 was further validated by efforts to characterise novel genes 
required for the development of X. laevis embryos (149).  The gene was described as 
being specifically synthesised in the cement gland of developing embryos during the 
late gastrula stages, encoding a secreted protein whose transcriptional levels were 
upregulated in response to organiser-secreted molecules chordin, noggin, follistatin 
and cerebrus gene products.  As such, the protein was incorporated into a pathway 
involved in ectodermal patterning of X. laevis embryos defining a role of XAG-2 in 
specification of dorsoanterior ectodermal fate.  XAG-2 expression is a required 
determinant in the definition of the Xenopus ectoderm to form structures including 
the forebrain and the cement gland (149).  A homologous gene to XAG-2, namely 
XAgr2, was identified as strongly expressed in the Xenopus cement gland, and 
additionally in the otic vesicles which later develops to the cochlea, and notochord, 
particularly in the tailbud and neurula stages (153).  This gene was found to have 
greater homology to human and mouse AGR2 than XAG-2 (153). 
Anterior gradient proteins were brought to the attention of the wider developmental 
community when the Notophtalmus viridescens (newt) homologue, nAG, was 
identified as the first ever cofactor with the ability to promote limb regeneration 
following amputation (154).  Newt limbs regenerate from dedifferentiated fibroblast, 
muscle, skeletal and Schwann cells into an earlier stem cell form, yet cofactors 
influencing re-differentiation are poorly understood.  Post limb amputation, severed 
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axons retract inward from the wound then grow back along the new nerve sheath.  
This nerve sheath is comprised of nAG-expressing Schwann cells as the blastema, 
the regenerating pleuripotent cells, divide.  nAG was discovered as a secreted ligand 
for the surface GPI-anchor protein Prod-1 (by yeast-2-hybrid studies) (154), where 
Prod-1 is a critical determinant of the proximodistal identity of regenerating limb 
structures by mediating cell-to-cell interaction of tissues (155).  nAG is highly 
expressed in the wound epidermis at the surface of the amputated/regenerating limb.  
When cells isolated from the blastema are cultured in vitro, nAG protein acts as a 
mitogen to promote cell proliferation.  Further, when nAG is artificially expressed in 
the regenerating limb which has been denervated, removing the Schwann cells, this 
results in the re-establishment of missing glands, and strikingly, the regeneration of 
the proximal-distal axis and the formation of digits.  This indicates that nAG, 
secreted by nerve cells of the regenerating limb, specifically acts to differentiate limb 
shape and structure (154). However, for completeness, studies should be undertaken 
to silence nAG expression in vivo in the newt limb following amputation using gene 
editing in situ with TALENs (transcription activator-like effector nuclease) (156).  
This recently published technique would not have been available to researchers at the 
time of publication.  The role of anterior gradient proteins in limb regeneration has 
since been widened to other amphibians as well as newts, and has been described as 
having a universal role in body appendage regeneration in amphibians (157). 
 
1.3.2 AGR2 homologues in other vertebrates 
The expression of homologues of XAG-2 in further vertebrates have been described 
(Figure 1-4).  In zebrafish, Dario renio, zAG-2 was identified in most organs 
containing secretory cells, including epidermis, olfactory bulbs, otic vesicles, 
pharynx, oesophagus, pneumatic duct, swim bladder, and intestine (158), and within 
the stomach is required for the terminal differentiation of goblet cells of zebrafish 
embryos (159).  mRNA transcripts of two AGR2 homologues were observed as 
differentially over-expressed in healthy Atlantic salmon (Salmo salar) and salmon 
which were affected by amoebic gill disease (160).  These mRNA were cloned and 
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sequenced, and shown to be predominantly expressed in the gill, intestine and brain 
of healthy fish.  In the gibel carp, Carassius auratus gibelio, the AGR2 homologue 
was shown to be expressed in the mucus secreting hatching gland, and later the 
pharynx, swim bladder and pronephric duct.  In the mature carp, AGR2 expression 
was primarily localised in the intestine, ovary and gills (161). 
In mice, initial transcript analysis revealed expression of the AGR2 homologue 
(mAGR2, GOB4) in the intestines, colon and stomach of the fully grown mouse 
(162). Murine models of normal mice, germline and inducible AGR2 knockout mice, 
along with in vitro cell models have begun to describe the role of mAGR2 in normal 
tissue.  AGR2 expression is localised to distinct cells of the highly folded epithelial 
lining of the small intestine.  Several cell types compose the small intestine including 
nutrient absorbing enterocytes, and cells with key secretory cell lineages of the 
goblet, Paneth and enteroendocrine (163) (also described in zebrafish goblet cells 
(159)) . Murine AGR2 is strongly expressed in these differentiated goblet, Paneth 
and enteroendocrine cells, as well as intestinal progenitor and stem cells (164).  Gene 
silencing studies, utilising AGR2-specific siRNA knockdown have described AGR2 
as performing a role in the maintenance of intestinal homestasis, with respect in 
particular to goblet and Paneth cells (165;166).  AGR2 depletion, results in the loss 
of the goblet cells function to secrete intestinal mucus (165), and significantly 
changes the morphology of these cells (165;166).  AGR2 was immunostained 
residing in the ER of these secretory epithelial cells and is essential for the in vivo 
production of the intestinal mucin, MUC2 (165).  The study by Zhao et al. (166) 
describes additional aberrations causing symptoms in the small intestine of AGR2 
knockout mice, the Paneth cells morphology was drastically altered, and severe 
intestinal inflammation reported.  Specifically, the Paneth cells display atypical 
localisation, with differentiation spanning the entire length of the small intestine.  
Subsequently, agr2 -/- mice displayed severe inflammation of the small intestine, 
consistent with the role of Paneth cells in the inflammatory response (167;168).  
Furthermore, loss of AGR2 expression results in disruption of enterocyte homestasis, 
reducing proliferation, increasing apoptosis and blunting of villi (166).  Furthermore, 
elevated endoplasmic reticulum stress response is present in cells lacking AGR2, in 
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some intestinal cell types.  Interestingly, phenotypically, AGR2 knockout mice 
present symptoms resembling human Crohn’s disease, suggesting a role of AGR2 in 
the aetiology of inflammatory bowel disease (discussed in 1.3.5.3). 
These studies present convincing data, indicating that AGR2 and its homologues are 
not exclusively secretory proteins, but in higher vertebrates function intracellularly, 
in this case in the proper maturation of proteins in the ER. 
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Figure 1-4 Phylogenetic tree of the Anterior Gradient family of proteins adapted from Chevet et 
al (169).  ClustalW alignment of the 41 related proteins deduced amino acid sequences derived from 
the public databases.  Colours represent which category each homologue relates to (blue: AGR2, 
green: AGR3 and red: ERP18/AGR1).  Figure created using the Interactive Tree of Life (iTOL) web 
server (http://itol.embl.de/).  
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1.3.3 Human AGR2 
1.3.3.1 Gene architecture and regulation 
The agr2 gene emerges during the evolution of the chordates, with agr3, from the 
founder gene ERP18 (AGR1), and is confined to vertebrates.  There has been no 
expansion of agr2 and agr3 genes in vertebrates, indicating that strict selection 
pressures exist in maintaining essential functions during evolution by natural 
selection.  The human agr2 gene spans 50 kb of genomic DNA, located to 
chromosome 7p21.3 (170), and codes for two mRNA isoforms containing eight 
exons and seven introns, and both isoforms contain the same open reading frame 
(169).  An annotated model of agr2 exhibits an additional 5’ exon, confirmed by RT-
PCR in a tissue panel (171).  The genes for agr2 and agr3 lie in close proximity on 
chromosome 7, and share 71% similarity, yet show little redundancy (172).  A 
luciferase reporter gene construct driven by the agr2 promoter assay indicated that 
the forkhead box transcription factors FOXA1 and FOXA2 increased luciferase 
activity thus may regulate the transcription of AGR2 mRNA (171).  In addition, the 
agr2 promoter region also exhibits a binding site for hepatic nuclear factor 1, related 
to the FOXA1 and FOXA2 regulators (171). Further chromatin immunoprecipitation 
(ChIP) studies identified binding sites for the oncogene ZNF217, NF-κB and SOX9 
within the agr2 promoter region (169;173).  The increased transcription of agr2 in 
response to oestrodiol, and subsequently with the anti-oestrogen drug tamoxifen 
(174;175), together with its co-expression with oestrogen receptor molecules in 
breast cancer cell lines (176), and induction by androgens (177) complete the known 
molecular regulators of agr2 transcription.  Additionally, physiological stresses of 
serum starvation, coupled with oxygen restriction induced agr2 transcription five-
fold (178).  Conversely, this study also interrogated specific inhibitors to known 
transcriptional regulatory pathways ERK1/2, JNK, p38 and PI3K and only ERK1/2 
inhibition resulted in a reduction of agr2 mRNA expression (178).  Tunicamycin (an 
inhibitor of N-linked glycosylation), DTT (reducing agent) and thapsigargin (a 
SERCA, sarco/ER Ca
2+
 ATPase inhibitor), all promoters of ER stress, were 
uncovered as inducers of agr2 transcription (177;179).  Recently, agr2 has also been 
described as tumour growth factor-β (TGF-β) responsive in pancreatic cells, whose 
expression can be downregulated by SMAD4 induction (180).   
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1.3.3.2 AGR2 protein structure 
The agr2 gene product translates to a 175 amino acid residue protein, with a 
predicted molecular mass of 19,979.2 Da and a predicted pI of 9.03 (ExPASy 
Compute pI/Mw. http://web.expasy.org/compute_pi/).  A sequence alignment of 
AGR2 reveals 54% identity and 71% similarity to XAG-2, and 91% identity and 
96% similarity to murine AGR2 (181).  The primary structure and recent research 
into the structural motifs of AGR2 highlight several important characteristics of the 
expressed protein (Figure 1-5).  The N-terminal 45 amino acid residues exhibit high 
levels of predicted disorder (DisoPred2, http://bioinf.cs.ucl.ac.uk/index.php?id=806) 
(182) (Figure 1-5A).  Regions of intrinsic disorder are particularly enriched in 
proteins involved in protein-protein interactions, cell signalling and transcription 
(183).  Further bioinformatical analysis of the primary protein structure identifies a 
20 amino acid residue hydrophobic endoplasmic reticulum leader sequence 
incorporating a signal peptidase cleavage site at ala-20/lys-21 (184;185) (SignalP 4.1 
Server, http://www.cbs.dtu.dk/services/SignalP/) (Figure 1-5B).  This leader 
sequence motif targets nascent polypeptides directly from the ribosome to the ER 
membrane, via a signal recognition particle (SRP) before co-translational cleavage of 
the motif by a signal peptidase, allowing protein access to the ER lumen.  This 
process is thought to be essential for the correct maturation of the nascent 
polypeptide into mature folded protein (186).   Biochemical studies transfecting the 
unprocessed (full-length AGR2) and the signal peptide cleaved mature protein have 
suggested distinct subcellular distribution (187).  This would not be unsurprising, as 
transfected protein lacking the N-terminal leader sequence would not be directed to 
the ER lumen, and instead would demonstrate mislocalisation to the cytosol, nucleus 
and/or mitochondria. 
Despite reported secretion during development of lower vertebrates, human AGR2 is 
predicted as exhibiting and ER localisation, due in part to the N-terminal leader 
sequence, but complemented by a C-terminal putative ER-retention tetra-residue 
sequence, KTEL (Figure 1-5B).  This motif is conserved from Xenopus to humans so 
assumed to be essential for function (188).  The classical canonical H/KDEL motif 
has been well studied in higher vertebrates (189), yet divergence is not uncommon.  
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Subsequent studies have compiled a Prosite motif (ExPASy, 
http://prosite.expasy.org/) of (K/R/H/Q/S/A)(D/E/N/Q)EL, which describes the 
possible carboxy-terminus peptide sequence that results in ER residence (188).  Early 
studies determined that the H/KDEL motif is recognised by receptor proteins resident 
in the Golgi complex, which interacts with the client protein and triggers retrograde 
transport back to the ER lumen (190).  Controversially, despite H/KDEL being well 
described as an ER trafficking motif, a few examples of human proteins exist where 
proteins exhibiting this motif demonstrate a non-ER distribution. Ones such example 
is the cytosolic and nuclear localisation of the KDEL-containing protein calreticulin  
(191).  It remains unanswered how these proteins can evade ER retention, whether it 
is through an error rate of the KDEL receptor molecules, active secretion or whether 
KDEL-expressing proteins are released by necrotic cells. The implications of 
divergence from the canonical sequence results in altered affinity, in this case 
reduced, for the three known KDEL receptors which recognise the motif (192;193).  
As a result, the KTEL motif provides some plasticity in the subcellular localisation, 
and release from the ER, of AGR2 protein, which may be essential for dynamic 
protein function in response to physiological conditions (187;188).  Recently, Gupta 
et al. have shown that the KTEL is essential for AGR2 for the AREG induction 
function of AGR2 (194), since KTEL deletion causes secretion and loss of function 
yet mutation of KTEL to KDEL does not rescue the function (188).  This suggests 
that the KTEL motif is essential for AGR2 function, not only for conferring 
subcellular distribution.    
Coupled to the N-terminal leader sequence and the KTEL motif, AGR2 demonstrates 
a single variant of the thioredoxin fold (TX), E/D-CXXS-Q motif which 
taxonomically describes the protein as being a member of the protein disulphide 
isomerase (PDI) family (Figure 1-5B).  The presence of one to four classical TX-
motifs facilitates oxidative/reductive reactions central to the appropriate shuffling of 
disulphide bonds during protein maturation (195).  Curiously, the CXXS motif is 
divergent from the di-cysteine thioredoxin-fold, W-CXXC-K, exhibited by the 
founder ERP18 protein, and has been implicated in disease development through the 
covalent trapping of disulphide shuffling intermediates (196).  This motif is not 
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restricted to AGR2 however, it is shared with two other PDIs/ER-proteins Eug1p and 
ERP44 (197;198).  More recent research has described and characterised the 
existence of a substrate binding loop (amino acid residues 104-111) which forms the 
octa-residue docking site for the interaction between AGR2 and the AAA+ protein 
Reptin (199).  Mutations in AGR2 at the junction codons of the loop at Phe-104 and 
Tyr-111 attenuate Reptin binding to the protein.  This region maps to a comparable 
region of ERP18, and has been proposed to represent a substrate binding site for 
client proteins for the molecular chaperone function of ERP18 (196;200).  During the 
scope of this thesis, truncated AGR2 (residues 41-175) has been structurally 
characterised by NMR (PDB code: 2LNS) and described as a homodimeric 
molecule, with a Kd of 8.83 μM, mediated through intermolecular salt bridges 
involving Gln-60 and Lys-64 (201).  However, a further intermolecular disulphide 
interaction between the two cysteine-81 residues is reported (202;203), and thought 
to be necessary for the biochemical interaction with BiP/GRP78 (202). 
Indeed, possible roles of AGR2 are complex since AGR2 subcellular localisation is 
highly disputed, with ER (179), nuclear (187;188), cell surface and extracellular 
distribution (204) all being reported.  Human AGR2 is strongly expressed in tissues 
of the lung, stomach, colon, prostate and small intestine, organs which contain mucus 
secreting cells, or function as endocrine organs (Table 1-1) (205).  AGR2 may also 
be involved in epithelial barrier function as the AGR2 promoter regulators are 
grouped into a family which are typical for epithelial goblet cells (171).  AGR2 is 
also published to be expressed in the fetal liver, and the expression pattern conserved 
in the adult (206); with the protein present in tall columnar but not cuboidal cells of 
the intrahepatic, hilar and extrahepatic biliary tree (207).  The differentiation of 
biliary epithelial cells lining bile ducts requires the acquisition of the columnar and 
mucus secretory phenotype (207).  These observations have let to the assumption that 
AGR2 may have a role in the differentiation of biliary tree cells. 
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Figure 1-5 Structural determinants of human AGR2. (A) The N-terminal 45 amino acid residues 
indicate a high level of predicted protein disorder.  (B) Schematic illustration of motifs present in the 
structure of AGR2, highlighting (a) a putative cleavable hydrophobic N-terminal signalling sequence, 
(b) the diverged thioredoxin-like CXXS motif, (c) the substrate binding loop fine mapped for the 
interaction of AGR2 with Reptin (199) (d) ER-retention motif recognised by KDEL receptors in the 
Golgi apparatus for retrograde transport to the Endoplasmic reticulum.   
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Table 1-1 The expression of AGR2 in normal human tissues.  Immunohistochemical staining is 
grouped into high (red), moderate (grey) and weak (green) categories.  Data derived from the Human 
Protein Atlas (http://www.proteinatlas.org/) and Brychtova et al. (153) 
 Normal Tissue Staining by 
Immunohistochemistry 
Cell Type Protein Expression 
Appendix Glandular cells Strong 
Breast Glandular cells Weak 
Bronchus Respiratory epithelial cells Strong 
Cerebral cortex Neuronal cells Moderate 
Cervix, uterine Glandular cells Strong 
Colon Glandular cells Strong 
Corpus, uterine Glandular cells Strong 
Duodenum Glandular cells Strong 
Epididymis Glandular cells Strong 
Oviduct Glandular cells Strong 
Gall Bladder Glandular cells Strong 
Kidney Cells in tubules Moderate 
Lung Alveolar cells Moderate 
Nasopharynx Respiratory epithelial cells Strong 
Pancreas Exocrine glandular cells Moderate 
Placenta Trophoblastic cells Moderate 
Prostate Glandular cells Strong 
Rectum Glandular cells Strong 
Seminal vesicle Glandular cells Strong 
Small intestine Glandular cells Strong 
Stomach Glandular cells Strong 
Tonsil Squamous epithelial cells Moderate 
Urinary Bladder Urothelial cells Strong 
 
1.3.4 Core biochemical functions of AGR2  
Research into the structural elements and subcellular distribution of AGR2 has 
highlighted possible functions for evaluation.  Further, several groups have, using a 
variety of techniques, begun to map the interactome of AGR2 protein (Table 1-2).  
These data are presented and discussed, supported by further studies, to outline the 
current understood biochemical roles of AGR2 (Figure 1-6). 
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Table 1-2 The interactome of AGR2.  Data collated from literature indicating all of the published 
protein-protein interactions of AGR2.  Techniques are abbreviated to Y2H (yeast-2-hybrid) and CoIP 
(co-immunoprecipitation). 
Gene name Function Method Reference 
DAG1 
Links the cytoskeleton 
and the extracellular 
matrix 
Y2H 






Fletcher et al. 
(2003)(172) 
PROD1 
Axotolt homolog for 
human CD59 
Y2H 
Kumar et al. (2007) 
(154) 
KDELR KDEL receptors CoIP 
Raykhel et al. (2007) 
(192) 













CoIP Ryu et al. (2013) (202) 
HECTD1 E3 ubiquitin ligase 
CoIP  
Y2H 
Yu et al., (2012) (208) 




Y2H Unpublished data (169) 
CKAP2 
Cytoskeletal-linked 
protein involved in 
mitosis 








Y2H Unpublished data (169) 




Y2H Unpublished data (169) 
NRXN3 
Controls adhesion and 
receptor signalling 




Y2H Unpublished data (169) 
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1.3.4.1 Endoplasmic reticulum related functions of AGR2 
The most conspicuous motif of AGR2 that has been used in the taxonomic 
classification and therefore subsequent studies of function is the presence of the 
thioredoxin-like fold identified by Persson et al. (209).  Coupled to the degenerative 
ER retrieval motif, ER localisation has been speculated and reported (179).  The 
endoplasmic reticulum contains a network of chaperones facilitating the appropriate 
maturation and folding of proteins targeted for the secretory pathway (210).  The 
oxidoreductases, protein disulphide isomerases (PDIs) and ER proteins (ERPs) are 
key components of this process (195;211).  The PDI class of proteins are essential in 
many biological processes.  These proteins are microenvironmentally regulated to act 
as enzymes to catalyse disulphide bond formation and isomerisation in newly 
synthesised cysteine containing substrates, preventing the formation of illicit 
intermediates and subsequent aggregated proteins.  The presence of the canonical 
active motif residues, CXXC, contains two free thiol groups at each of the cysteine 
residues allowing reduction, shuffling and oxidation of disulphide bonds (212).  
PDI/ERP family members contain one to four of these TX domains (195;213;214) 
suggesting the complexity, and specificity of the ER folding machinery (209).  The 
CXXS motif of AGR2 possesses lower activity associated with disulphide bond 
reorganisation, but may contribute to the isomerisation of existing disulphide bridges 
allowing the completion of specialised function (215;216).  If PDI substrates are not 
appropriately folded, mis-folded proteins may accumulate in the ER instigating ER 
stress and eventually cell apoptosis (217).  Although thioredoxin activity of AGR2 
has never been observed in vivo or in vitro (169), AGR2 has been implicated in the 
formation of mixed disulphides in the maturation of cysteine rich glycoprotein, 
intestinal mucin, MUC2 (165) and MUC1 (180). 
Recently, AGR2 has been described as performing a pivotal role in the control of 
endoplasmic reticulum homeostasis (179).  In this study, AGR2 was identified bound 
to newly synthesised cargo proteins in a proteomic analysis of isolated ER-bound 
ribosomes.  This indicated that AGR2 was associated with nascent protein chains co-
translationally, when they were translocated to the ER lumen.  Further, it was shown 
that AGR2 expression could be controlled by the unfolded protein response (UPR), 
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and that silencing of AGR2 disrupts the components of the ER-associated 
degradation machinery, resulting in a reduction in cells ability to cope with acute ER 
stress (179).  Complementary to this, data suggest AGR2 induction in pancreatic 
tumour cells regulate the expression of several other ER chaperones, namely PDI, 
CALU and RCN1, proteins of the ubiquitin-proteosome degradation pathway (HIP2, 
PSMB2, PSMA3, PSMC3 and PSMB4) and lysosomal proteases (cathepsin B and 
cathpsin D) (204).  Further mechanisms incorporating AGR2 to the UPR signalling 
pathway arises in the recent publication by Ryu et al. who describe AGR2 forming a 
homodimer, via an intermolecular disulphide bond, and show it to be essential in the 
interaction with BiP/GRP78, and resultant attenuation of ER stress induced cell death 
(202).   
 
1.3.4.2 AGR2 as a cell growth effector 
AGR2 over expression has been described in multiple human cancers (discussed in 
detail in 1.3.6.1).  In vitro and in vivo studies have demonstrated that AGR2 
promotes tumour growth, and AGR2 expression induces anchorage independent 
growth in soft agar assays (164;218;219), yet the mechanisms whereby AGR2 
exhibits these affects is not fully appreciated.   
One hypothesis is that AGR2 can induce the expression of the epidermal growth 
factor receptor (EGFR) ligand amphiregulin (AREG) via the Hippo pathway co-
activator Yap-1 (194).  AREG has previously been implicated as a growth promoter 
through in vitro and in vivo studies (220;221), and can interact with EGFR, albeit 
with lower affinity than epidermal growth factor (EGF) itself (222), activating the 
EGF pathway to stimulate cell growth, proliferation, and differentiation (223).  In 
this study, when AGR2 levels were experimentally suppressed, exogenous AREG 
expression is able to rescue the transformed phenotype.  Also, AGR2 does not 
function to activate any other known EGFR ligands and that activation resulted in 
increased phosphorylation of both EGFR itself and AKT downstream of the receptor.  
The Hippo pathway serves to regulate cell proliferation and apoptosis, and function 
in regulating organ size (224).  Repression of the Hippo pathway leads to Yap-1 
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protein dephosphorylation and resultant translocation to the nucleus where it acts to 
inhibit apoptosis and promote cell division (225;226).  Dong et al. (194) propose that 
AGR2 expression acts to dephosphorylate Yap-1, and subsequent induction of 
AREG, however, the specific molecular mechanism by which AGR2 achieves this is 
still under study.  The coupling of AGR2 to both the Hippo and EGF signalling 
pathway however, gives an insight into the complexity of AGR2 function. 
The second hypothesis is that AGR2 functions as an effector molecule to silence p53 
growth suppressive function (150).  The exogenous introduction of over expressed 
AGR2 into a cancer cell model can, while not altering cell-cycle parameters (150), (i) 
enhance cell survival in a clonogenic assay, similar to the loss-of-function p53 
HIS175 allele (150), (ii) reduce p53 dependent transcriptional activity, using p300 
activation as a readout, to a similar extent as the p53 regulator MDM2 (150), (iii) 
attenuate phosphorylation at p53 –activating phosphorylation sites (Ser15 and 
Ser392) following ultraviolet induced DNA damage (150), (iv) redistribute p53 such 
that ‘active’ p53 is excluded from the nuclear compartment, and localised to the 
cytosol in an ‘inactive’ environment (187)).  In criticism, these studies were carried 
out in cell lines which do not normally express neither AGR2 nor p53, however a 
further study uncovered that 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a toxin 
and human carcinogen (227) that attenuates the p53 response to DNA damaging 
agents (228;229) induces AGR2 mRNA (six-fold) and protein (four-fold), further 
implicating the role of AGR2 in p53 inhibition (230).  These data suggest that AGR2 
functions as a survival factor promoting cell proliferation, and sequestering cells 
from p53-induced apoptotic events. 
Transient silencing of AGR2 inhibits cell growth, cell-cycle progression and induces 
cell death (231).  One study investigated the downstream intracellular signalling 
pathways following AGR2 suppression in a variety of breast cancer cell lines and 
identified modulation of cyclin D1, c-myc, and E2F1, supporting inhibitory effects 
on cell growth and cell cycle (231).  
  
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 1 – Introduction  34 
 
 
Figure 1-6 Schematic of the described regulation and functions of AGR2 
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1.3.5  Disease associations of AGR2 
1.3.5.1 Implications of AGR2 overexpression in the aetiology of asthma 
Aside from cancer, AGR2 gene has been shown to be over expressed following 
allergen exposure in murine models of asthma (232).  Using qPCR and 
immunohistochemical validation it was determined that AGR2 is constitutively over 
expressed in the model, and primarily localised to the goblet cells of the lung.  
Subsequently, based on the accepted role of AGR2 in the maturation of intestinal 
MUC2 (165), AGR2 was analysed to investigate whether there was a relationship in 
the synthesis of the airway mucins MUC5AC and MUC5B (233).  AGR2 was shown 
to be co-expressed in the same cells as MUC5AC and MUC5B, and was shown to 
co-immunoprecipitate with MUC5AC.  agr2 -/- mice were used to determine the role 
of AGR2 in allergic airway disease, where it was elucidated that allergen challenged 
AGR2-null mice had >50% suppressed expression of the respiratory mucins 
compared to endogenously expressing wild-type mice (233).  The reduction of 
secreted mucin was accompanied by increased proportion of mucin contained within 
the ER of secretory cells and evidence of ER stress in the airway epithelium.  It is 
therefore assumed that AGR2 overexpression in asthma allows maturation and 
overproduction of respiratory mucins MUC5AC and MUC5B.  As a result, mucus 
hypersecretion causes airway occlusion which is a major pathophysiologic feature of 
asthma (234;235).  In a further study in human lung epithelial cells, the authors 
discovered that interleukin-13 (IL-13) silencing had a downstream effect on AGR2 
and MUC5AC levels (236), and a murine model study agreed that AGR2 protein 
expression is significantly higher in the asthmatic model. Also, MUC5AC and AGR2 
were discovered to be induced by IL-13, drug induced silencing of IL-13 led to a 
decrease in the expression of both AGR2 and MUC5AC, suggesting that IL-13 may 
perform an upstream regulatory role in this particular pathway (237) and implicates 
AGR2 in a new model of inflammatory respiratory disease. 
 
1.3.5.2 Association of AGR2 with inflammatory bowel disease 
The chromosomal location of AGR2, 7p21.3 (170), maps to a key susceptibility 
region of the human genome for inflammatory bowel disease (238;239).  The 
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described role of AGR2 in mucus production led to its evaluation as a candidate gene 
for inflammatory bowel disease (171).  It was discovered that single nucleotide 
polymorphisms (SNPs) in the 5’ region of AGR2 are associated with an increased 
susceptibility for ulcerative colitis (171).  As highlighted previously, studies have 
subsequently found that AGR2 expression is essential in goblet cell function and 
development (166), and that AGR2 knockout in murine studies disrupted the 
production of protective mucin (165).   These mice suffer the onset of diarrhoea and 
increased risk of ulcerative colitis (165). The intestines of patients suffering from 
inflammatory bowel disease often exhibit significant symptoms of ER stress (240).   
The role of AGR2 in the secretory pathway, and relief or ER stress, reviewed above, 
support the finding that in normal functioning of the cell controlled AGR2 
expression is a requirement for the appropriate maturation, localisation and secretion 
of extracellular glycoproteins.  Dysfunction, through mutation, over expression and 
under expression has indicated significant pathological effects. 
 
1.3.6 Cancer and cancer related pathways 
1.3.6.1 AGR2 overexpression in human cancer 
AGR2, and its close homologue AGR3, protein have been documented as being over 
expressed in a wide range of human cancers involved in both the onset and in 
progression of neoplasia (Table 1-3).  Primarily concerning hormone dependent 
cancers such as breast (172;175;176;178;184;205;219;241-244), prostate 
(177;205;245;246) and ovarian (247-250), but also significantly in non-hormone 
dependent cancers such as tumours of the oesophagus (150;251), gastro-intestinal 
tract (252) and lungs (27;253).  As described previously, AGR2 exhibits the basic 
features of an onco-protein, due to pro-growth and cell survival enhancing activity 
(150;175).  Intriguingly, deletion of the 10 C-terminal amino acid residues, those 
harbouring the ER-retention site, prevented clonogenic growth stimulation (175) 
indicating a role in tumourigenesis of the ER localised protein and survival 
signalling.  Coupled to this, the inhibition of p53 (150), and the promotion of p53 
nuclear exclusion (187) in UV-induced DNA damaged cells, presents a candidate 
protein whose role in tumourigenesis warrants in depth study. 
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The role of AGR2 in cancer was first correlated to survival in a proteomics screen of 
pre-malignant lesions from Barrett’s epithelium, a pre-neoplastic oesophageal 
disease caused by damage from acid reflux providing a selection pressure for 
survival factors leading to the transformation of normal cells (150;254).  
Polypeptides from AGR2 were found to be significantly overexpressed compared to 
normal oesophageal tissue, suggesting some role of AGR2 in the stress response of 
the cell, and further validated as influencing p53 activity.  AGR2 had previously 
been identified as co-expressed with the oestrogen receptor in breast cancer cell lines 
(176), and it was shown that the agr2 gene was responsive to oestrogen signalling 
(175). 
In breast cancers, AGR2 is associated with poor prognosis (175;241) and a malignant 
metastatic phenotype (241).  In ovarian cancers, mucinous cancer biopsies show 
particular increased AGR2 expression by immunohistochemistry (248;249), but also 
in endometriod cancers (247;255), and predicts poor prognosis in high-grade serous 
tumours (256).  A high concentration of AGR2 in the extracellular plasma has been 
associated with both serous and non-serous ovarian cancer (247).  High expression 
levels of AGR2 are also reported in prostate carcinomas (257;258), both 
intracellularly and secreted into the blood (259) and urinary secretions (245) of 
patients, and studies are now ongoing as to whether AGR2 could be used as a 
minimally invasive prognostic marker of prostate disease.  Recent reports suggest 
that the FOXA1 and FOXA2  transcription factors are likely to be involved in AGR2 
expression in prostate cancer, coupled to the inverse correlation of AGR2 levels with 
ErbB3 binding protein 1 (EBP1), an endogenous negative regulator of androgen 
receptor signalling, which may allow the invasive character of prostate tumours 
(260;261).  AGR2 is associated with poor survival of prostate cancer patients (246), 
and silencing of AGR2 in prostate cancer cell lines redact the survival enhancement, 
allowing cells to enter senescence (262). 
Despite the androgen-receptor activation of AGR2 levels, elevated levels of AGR2 
have also been linked to non-hormone related oncogenesis and cancer progression.  
Levels of AGR2 mRNA have been found to be significantly enhanced in pancreatic 
cancer tissue compared to paired normal tissue; a 14-fold increase is reported (218).  
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This study is complemented by further investigation describing AGR2 as being a 
cofactor in the promotion of initiation and progression of pancreatic intraepithelial 
neoplasia (180).  AGR2 protein was also detected in the pancreatic juices of pre-
malignant neoplasia of the pancreas (263;264).  AGR2 elevation is also reported in 
gastric cancer cells (252) and in colorectal cancer (265).  In lung adenocarcinoma, 
AGR2 was isolated from the serum of patients (266), to such an extent that 94% of 
lung adenocarcinomas exhibited upregulated AGR2 expression (267).  In non-small 
cell lung adenocarcinomas this trend continues (253;268). 
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Table 1-3 Correlation of AGR2 expression in human cancer 
Cancer Type AGR2 Manifestation Reference 
Breast (adenocarcinoma) Overexpression/Upregulation Fletcher et al., 2003; Duran 
et al., 2008 
 Associated with ERBB2 
tumours 
Duran et al., 2008 
 Poor Prognosis Barraclough et al., 2009; 
Hrstka et al., 2010 
 Metastasis Fletcher et al., 2003; Liu et 
al., 2005; Barraclough et 
al., 2009  
Colorectal Poor prognosis Valladares-Ayerbes et al., 
2012 
Gastric Metastasis Lee et al., 2011 
Lung Overexpression Fritzsche et al., 2007; 
Chung et al., 2012 
Oesophageal (Barrett’s 
Premalignant) 
Overexpression Pohler et al., 2004 
Ovarian (mucinous) Upregulation Park et al., 2011 
 Overexpression  Gray et al., 2012 
 High plasma concentration Edgell et al., 2010 
Ovarian (other) Poor prognosis Darb-Esfahani et al., 2012 
 Overexpression/Upregulation Armes et al., 2013 
Pancreatic Overexpression/Upregulation Barry et al., 2012; 
Ramachandran., 2008) 
 Secreted into pre-malignant 
neoplastic juice 
Chen et al., 2010; 
Makawita et al., 2011 
 Promotes 
initiation/progression of 
pancreatic epithelial neoplasia 
Norris et al., 2012 
Prostate Overexpression in serum Kani ei al., 2013 
 Overexpression/Upregulation Kristiansen et al., 2005; Bu 
et al., 2011 
 Metastasis Hu et al., 2012 
 Poor prognosis Zhang et al., 2007 
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1.3.6.2 AGR2 in metastasis 
A key nature of AGR2 highlighted in many studies is, not only the effect of AGR2 in 
growth promotion (Section 1.3.4.2), but also the detection of AGR2 in excretory 
systems such as blood serum and urine, suggesting that AGR2 may act in a paracrine 
or autocrine manner.  This prometastatic role of AGR2 is broadly accepted.  Since its 
detection in a gene expression screen of cancer cell lines identifying candidate 
markers for metastasis (269), subsequent interactomic studies have demonstrated that 
AGR2 directly interacts with two transmembrane proteins involved in cell-cell 
contact or cell-matrix interactions in C4.4A and alpha-dystroglycan (Table 1-2) 
(172). Transfection of AGR2 into a benign rodent mammary cell line transforms the 
cells to the metastatic phenotype, and it was suggested that AGR2 positive cells 
expressed enhanced adhesive properties (219).  Subsequently, AGR2 knock down in 
both non small cell lung carcinoma and pancreatic cancer cells compromised 
anchorage independent growth in vitro and the growth of xenografted tumours in 
vivo (164;166).  AGR2 expression has also been reported in the proliferation, 
migration and invasion of head and neck squamous cell carcinoma (270).  
Additionally, ovarian cancer indicates increased plasma concentrations of AGR2 in 
plasma (247), cell models of which overexpressing AGR2, demonstrate upregulated 
gene expression of proteins involved in cell proliferation, invasion and angiogenesis, 
and suppressed negative regulators of these processes (249).  Further, AGR2 was 
also shown to have differential expression in metastatic gastric cancer cells, 
compared to non-metastatic cells (252).  Finally, in stress conditions, resembling the 
tumour microenvironment, for example serum depletion and hypoxia, AGR2 was 
identified as upregulated in a screen together with other pro-survival, pro-invasive 
and angiogenic genes (178).  The role of AGR2 in metastasis is of significant 
interest, as successful metastases requires activation of genes that promote cell 
survival in environments of pathophysiological stress, therefore the necessity to 
characterise this metastatic marker has emerging clinical significance. 
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1.3.6.3 Correlation of AGR2 expression and drug resistance 
The clinical significance of AGR2 is heightened, by the evidence that AGR2 can 
mediate cytotoxic drug resistance in tamoxifen, doxorubicin and cisplatin-resistant 
tumours (Table 1-4).  The use of the anti-oestrogen, tamoxifen, to treat human breast 
cancers is widespread; however intrinsic resistance to the drug is a major problem.  
Identification of oestrogen responsive genes which are induced by tamoxifen yet play 
a survival role is a key aim in the study of tamoxifen drug resistance (271).  AGR2 
expression is elevated rather than inhibited in response to tamoxifen treatment (175).  
In contrast, in cancer patients treated with the anti-hormonal, oestrogen suppressor 
drug  Letrazole, the AGR2 gene was one of the top down regulated genes in biopsies 
from post-treatment patients who had responded well to the drug, suggesting that 
resistance to anti-oestrogens might correlate to failure to suppress AGR2 (175).  
Secondly, a label-free proteomics approach, PaCIFIC, was employed to screen for 
dominant proteins induced by tamoxifen treatment.  AGR2 was highlighted as the 
protein whose expression was induced to the second greatest degree (174).  At the 
molecular level, it was demonstrated that the tamoxifen induced expression of AGR2 
was a direct effect of oestrogen receptor-α activation by chromatin 
immunoprecipitation.  Elevated oestrogen receptor-α was bound to the AGR2 
promoter in the presence of oestrodiol or tamoxifen and the AGR2 promoter was 
activated using a luciferase reporter assay (175).  Recent data, using an RNA 
interference library, suggests that AGR2 is activated by the phosphoinositidine-
dependent protein kinase 1-AKT (PDPK1-AKT) signalling pathway in response to 
tamoxifen treatment (272). 
Proteomic analysis studies, supported by cell based MTT assay, have also implicated 
AGR2 over expression in resistance to the DNA damaging agents doxorubicin and 
cisplatin in vitro (174;175;248).  AGR2 has also been implicated in anti-oestrogen 
resistance comparing fulvestrant-sensitive and –resistant T47D cell lines (273)   
Conversely, AGR2 expression is reduced in docetaxel-resistant tumours (274).  
Ongoing studies have begun to develop tools for anti-AGR2 therapeutic leads and 
detection of AGR2 in clinical tissue samples for diagnostics, including the 
publication of an AGR2 interacting peptide aptamer (TXIYY) (187;275).    
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Table 1-4 Studies highlighting AGR2 in therapeutic cancer drug resistance 
Drug Role of AGR2 in Resistance Reference 
Tamoxifen Induced by tamoxifen, 
Overexpression in resistant 
tumours 
 
Hrstka et al., 2010; Hengel 
et al. 2011 
Cisplatin Mediates resistance in 
xenograft models 
 
Hengel et al. 2011; Gray et 
al., 2012 
Doxorubicin Overexpressed in resistant 
tumours 
 
Hrstka et al., 2010; Hengel 
et al. 2011 
Docetaxel Reduced expression in 
resistant tumours 
 
Zhao et al., 2009 
Fulvestrant (Anti-oestrogen 
therapy) 
Upregulated in resistance 
cell line (with cathepsin D) 
 
Huber et al., 2004 
 
 
1.3.7 Anterior Gradient-3 
The chromosomal location of Anterior Gradient-3, also known as AGR3, HAG-3 and 
BCMP-11, is contiguous with AGR2 at 7p21.1-3.  AGR3 shares 71% sequence 
similarity with AGR2 (Figure 1-7) and the expressed product shares the CXXS core 
motif thought to be required for disulphide bond formation (209).  AGR3 was first 
identified as a protein present in breast cancer membrane fractions (184).  Follow-up 
studies indeed identified AGR3 as co-expressed with AGR2 in breast cancer tissues 
with a strong correlation with oestrogen receptor α status (172).  Yet expression of 
AGR3 is not coupled to AGR2 in prostate cancers indicating a lack of redundancy.  
It is necessary to indicate, that gene/protein studies of AGR2 highlighted, AGR3 was 
not found to be induced by oestrogen (176) (however in recent studies androgen-
responsiveness has been reported in prostate cancer cells (276)) or tamoxifen (174), 
or as an inhibitor of p53 (150;275), thus there is no indication whether AGR3 shares 
the oncogenic nature attributed to AGR2.  As a result, there has been limited data 
published on AGR3, despite the interest in AGR2 in health and disease.  We have 
previously published data investigating the expression of AGR3 in ovarian cancer 
(248), to identify a suitable clinical model for the study of AGR3 function.  Through 
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the development of well characterised monoclonal antibodies specific for the AGR3 
protein, and not AGR2, we identified that (i) AGR3 does not co-localise to the 
endoplasmic reticulum to the same extent as AGR2 protein, (ii) AGR2 is over-
expressed in four different types of human primary ovarian cancer, (iii) AGR3 and 
AGR2 exhibit coupled expression in mucinous ovarian cancer, but uncoupled in 3 
other types of primary ovarian cancer and (iv) that AGR3 can mediate drug resistant 
growth in an isogenic cancer cell panel (248).  
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Figure 1-7 Sequence alignment of human AGR2 and AGR3 indicating high levels of similarity 
and conservation of protein sequence.  Alignment carried out using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and shading by BoxShade 
(http://www.ch.embnet.org/software/BOX_form.html).   
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1.4 Aims 
The aims of these studies were to broadly investigate the hypothesis of Anterior 
Gradient proteins as novel oncoproteins.  This was targeted through the engineering 
of a well characterised isogenic cell line panel providing reagents for the study of the 
effect of the expression of the Anterior Gradient genes in cell growth and the 
response to drug induced DNA damage (Chapter 3).  Subsequently, these 
experimental cells could be examined for consequential changes at the transcriptional 
level through gene expression studies, and thorough analysis of changes in the 
dynamic protein landscape.  Proteomic studies, utilising novel mass spectrometry 
methodologies coupled with bioinformatical pathway analysis tools, were applied to 
gain information regarding the previously unclear biochemical functions of AGR2, in 
terms of normal cellular function and the connection to oncogenesis, prior to 
comprehensive biochemical validation of identified cofactors (Chapter 4). 
Structural approaches were also undertaken to identify the functional role and 
bioactive modulators of the recently discovered homodimeric complex of AGR2 
(201-203) (Chapter 5).  This required the development and optimisation of reagents 
for, and the inception of, a novel two site microplate format assay targeted at 
describing the oligomeric status of AGR2.  Exploitation of this assay allowed the 
confirmation of structural motifs of the protein which can allosterically 
destabilise/stabilise the complex and others which are essential for the interacting 
interface of the dimer.  By means of a library of natural compounds, potential leads 
for compounds disrupting of the quaternary protein structure were highlighted.  
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Chapter 2: Materials and Methods 
 
2.1 Reagents and chemicals 
 
All reagents were purchased from Sigma Aldrich unless otherwise stated.  Tissue 
culture reagents including Dulbecco’s modified eagle medium (DMEM), Roswell 
Park Memorial Institute (RPMI) and Trypsin were purchased from Gibco, Life 




Sorvall RC-5C plus and Eppendorf 5415R were used for all centrifugations.  DNA 
and RNA concentrations were measured using a NanoDrop spectrophotometer 
(Thermo Scientific) at A260.  Bradford protein determination assay was read using a 
PerkinElmer Victor
3
 1420 multi-label plate reader with 595 nm filter.  SDS-PAGE 




radioactive isotope labels were visualised through the use of Phosphoimager (Storm 
840, Amersham Biosciences).  Enhanced Chemiluminescence (ECL) based ELISA 
experiments were read using a Fluroskan (Ascent FL).  800 nm fluorophore-
conjugated antibodies were detected using the 800 nm channel of an Odyssey SA 
plate reader (Licor).  PCR was performed using a DNA Engine Dyad Peltier thermal 
cycler (BioRad) and quantitative real-time PCR using MJ Research PTC-200 Peltier 
thermal cycler (BioRad). 
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2.3 Microbiological Procedures 
 
2.3.1 Growth of bacterial cultures 
Overnight cultures were prepared with 5-200 mL of LB broth media supplemented 
with the appropriate selective antibiotic (100 µg/mL ampicillin or 50 µg/mL 
kanamycin) and inoculated with colonies from either a glycerol stock or single 
colony isolation from a bacterial culture dish. The cultures were incubated overnight 
at 37°C with constant agitation (220 rpm).  Sterile culture vessels were at least four 
times the volume of culture to allow sufficient aeration. 
Luria-Bertani (LB) broth 
1 % (w/v) Tryptone 
1 % (w/v) NaCl 
0.5 % (w/v) Yeast extract 
Dissolved in distilled water and sterilised by autoclaving at 121°C for 20 minutes 
 
To prepare the culture plates the LB agar plates, 1.5% (w/v) bacto-agar was added to 
LB media.  LB agar was melted in a microwave oven and allowed to cool 
sufficiently.  Cooled agar was supplemented with appropriate selective antibiotic (50 
µg/mL kanamycin or 100 µg/mL ampicillin) and poured into 100 mm Petri dishes 
(Sterilin) with a convective air current from a Bunsen burner, and left to cool. 
Culture plates were stored at 4⁰C for no longer than one month.  Subsequently plates 
were warmed to 37°C for 1 hour prior to plating.   
 
2.3.2 Glycerol stocks 
For long term storage of the bacterial cultures, glycerol stocks were prepared.  800 
µL of an overnight bacterial culture was mixed thoroughly with 200 µL of sterile 
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80% glycerol, transferred to a cryotube (Nunc), snap frozen in liquid nitrogen and 
stored at -80°C. 
 
2.3.3 Preparation of competent cells 
Bacterial cells were inoculated into 5 mL of LB and incubated overnight at 37⁰C 
with shaking at 220 rpm.  The culture was diluted 1:200 into 100 mL of LB and 
incubated at 37⁰C until the optical density at 600 nm (OD600 nm) reached 0.6.  Cells 
were centrifuged (20 minutes at 4⁰C, 4000 rcf) to pellet prior to being resuspended in 
15 mL of ice cold Buffer 1 and incubated on ice for one hour.  Cells were centrifuged 
again, as above, and pellet resuspended in 4 mL of ice cold Buffer 2 before 
incubation on ice for 15 minutes.  Cells were aliquotted, in 50 µL volumes, into pre-
chilled microcentrifuge tubes, snap frozen in liquid nitrogen and stored at -80⁰C. 
Buffer 1 Buffer 2 
100 mM RbCl2 10 mM MOPS pH 6.8 
79 mM MnCl2 10 mM RbCl 
30 mM CH3COOK pH 7.5 13.5 mM CaCl2 
13.5 mM CaCl2 15% Glycerol 
15% (v/v) Glycerol pH adjusted to 6.8 and filter sterilised 
pH adjusted to 5.8 and filter sterilised  
 
2.3.4 Heat shock transformation of E. coli 
50 µL of competent cells (BL21 or DH5α E. coli, stored at -80°C) were thawed on 
ice. Bacteria were inoculated with 100-500 ng of plasmid DNA and incubated on ice 
for 30 minutes. The bacteria were heat-shocked at 42°C for 45 seconds in a water 
bath or heat block and returned to ice. Bacterial cell culture was then made up to 1 
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mL with LB media and cells recovered by incubation for 1 hour at 37°C (220 rpm). 
200 µL of transformed cells were plated onto agar plates (supplemented with 
appropriate antibiotic) and incubated at 37°C overnight. 
 
2.4 Molecular Biology Techniques 
 
2.4.1 Amplification, purification and quantitation of plasmid 
DNA 
An isolated bacterial colony was picked from a selective LB-agar plate and 
inoculated into 5 mL of LB, containing a selective antibody if required, and grown 
for several hours at 37⁰C with constant agitation at 220 rpm.  Following incubation, 
the starter culture was diluted into 250 mL of LB (containing selective antibiotic if 
necessary) in a sterile flask and returned to the incubator for a further 16 hours.  The 
bacterial culture was centrifuged at 4⁰C for 15 minutes at 6000 rcf to pellet and the 
supernatant discarded.  Plasmid DNA was extracted from bacteria using plasmid 
DNA MaxiPrep kit (Qiagen) according to the manufacturer’s instructions.  If a lower 
yield of plasmid was required, plasmid DNA MiniPrep kit (Qiagen) could be used to 
extract DNA directly from the bacterial starter culture.  Once purified, plasmid DNA 
was eluted from the purification column in nuclease-free water and stored at -20⁰C.  
The concentration of extracted DNA was quantified using the NanoDrop. 
 
2.4.2 Agarose gel electrophoresis for the separation of DNA 
Agarose gels were prepared by mixing electrophoresis grade agarose (Life 
Technologies) with 1× TAE buffer to a final concentration of 1% (w/v).  The mixture 
was heated in a microwave oven to melt the agarose.  The agarose was cooled, and 
inoculated with 1:10,000 dilution of SYBRSafe dye (Life Technologies).  The 
solution was poured into a prepared agarose gel casting tank, comb inserted, and the 
gel allowed to set at room temperature.  Once set, the gel was submerged in 1× TAE 
buffer.  DNA samples were mixed with the 6× loading buffer, to a final 
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concentration of 1× of loading buffer.  DNA standards were loaded (100 b or 1 kb 
ladder, NEB) and samples pipetted into wells of the gel, and the agarose gel was run 
at 100V for 60 minutes, or until bands were adequately separated.  The bands were 
subsequently visualised under blue light (Safe Imager 2.0, Life Technologies) using 
Syngene (Genesnap). 
1 × TAE Buffer 6× DNA loading buffer 
40 mM Tris 0.25% bromophenol blue 
1 mM EDTA 0.25% xylene cyanol FF 
pH adjusted to 8.0 15% Ficoll 
2.4.3 DNA Sequencing 
DNA was sequenced using the Big Dye Terminator V3.1 Cycle Sequencing Kit 
(Applied Biosystems).  The reaction was prepared as follows, then subject to thermal 
cycling as described:  
Sequencing Reaction Thermal cycling conditions 
2 µL of 5× Sequencing Buffer Big Dye 
Terminator V3.1 
1 - 96⁰C for 1 minute 
1 µL of Big Dye Terminator V3.1 Cycle 
Sequencing Kit 
2 - 96⁰C for 10 seconds 
300 ng of DNA template 3 – 50⁰C for 5 seconds 
1 µL of sequencing primer (10 µM) 4 - 60⁰C for 4 minutes 
Final volume adjusted to 10 µL with 
nuclease-free water 
5 – Repeat cycles 2-4 for 25 cycles 
 6 – Hold at 4⁰C 
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Sequencing primers used included stock primers of T7 forward, V5 reverse and M13 
forward and reverse, as necessary from plasmid map.  Following PCR, 2.5 µL of 125 
mM EDTA and 30 µL of 100% ethanol were added to the sequencing reaction to 
precipitate DNA.  The mix was vortexed and incubated for 15 minutes at room 
temperature.  Samples were centrifuged for 20 minutes at 13200 rpm and the 
supernatant aspirated.  The samples were briefly spun again to remove residual 
solvent.  The DNA pellet was washed with 70% ethanol, and centrifuged for 5 
minutes at 13200 rpm, and supernatant discarded before a final centrifugation and 
removal of remaining ethanol.  The DNA pellet was then air dried and sequences 
analysed by Sequencing Service of Source Biosciences.  Alternatively, at least 100 
ng of purified plasmid DNA was sent in liquid form to the sequencing service that 
carried out an optimised protocol similar to above.  
 
2.4.4 Cloning 
2.4.4.1 Gateway cloning 
One method of cloning the DNA sequence of the gene of interest into a plasmid was 
using the Gateway cloning system (Life Technologies).  The manufacturer’s protocol 
was followed.  This required the PCR generation of the gene of interest flanked by 
attB sites, followed by a BP reaction into an entry clone (pDONR221), and finally 
the LR reaction into the expression vector.  Briefly, primers (Sigma) were designed 
to incorporate the attB recombination sites into the PCR product (Table 2-1), and 
contained 18-25 bases corresponding to the 3’ and 5’ ends of the gene to be cloned, 
as below. Following PCR amplification and BP reaction the amplified gene was 
recombined into the pDONR221 backbone. 
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Table 2-1 Primers designed and synthesised for the generation of PCR fragments of genes on 
interest with attB1 and attB2 sites for Gateway cloning.  Red: Poly-guanine required for attB 
recombination, Green: attB1 or attB2 sites, Orange: Kozak sequence (assists in the initiation of 
translation in eukaryotic cells), Black: gene sequence specific to gene of interest.  




















Using stock DNA constructs of AGR2-pDONR 221 and AGR3-pDONR 221 (a kind 
gift from Dr E. Murray), a Gateway LR reaction was prepared using 100 ng of entry 
clone, with 150 ng of the destination vector (pcDNA3.2/FRT/V5) and TE buffer 
adjusted to a final volume of 8 µL.  2 µL of LR clonase enzyme was added, mixed 
and incubated overnight at 25⁰C.  Following the incubation, 1 µL of proteinase K 
solution was added and the mixture incubated at 37⁰C for 10 minutes to stop the 
reaction.  1 µL of the reaction was transformed into DH5α E. coli and plated on LB-
agar plates supplemented with 100 µg/mL ampicillin.  Single colonies could be 
isolated and grown in 5 mL LB supplemented with 100 µg/mL ampicillin prior to 
MiniPrep isolation of DNA. Plasmids were then sequenced using the T7 forward and 
the V5 reverse primers (Source Biosciences).   
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2.4.4.2 Conventional cloning using restriction enzymes 
An alternate method of cloning of the sequence of interest into the required vector 
was using restriction enzymes and a ligation protocol.  Briefly, the desired sequence 
was first amplified by PCR using primers flanked by appropriate restriction sites, 
followed by restriction enzyme digestion of both PCR product and vector and 
subsequent ligation of digested vector and insert. 
Primers were designed to incorporate 18-25 bases specific to the N-terminal and C-
terminal portion of the protein to be cloned, and the appropriate restriction sites 
chosen according to the multiple cloning site (MCS) present in the desired vector.  It 
was sometimes necessary to incorporate additional nucleotide bases to ensure that the 
gene of interest was in frame relative to the plasmid backbone.  Finally, primer 
sequences were modified to obtain a GC content of 40-60% and a melting 
temperature in the range of 60-80⁰C.  A list of primers used is presented in Table 2-
2. 
Table 2-2 Primers used in cloning of AGR221-175 and AGR2-Δ45 into pEHISTEV  highlighted in 
are the specific sequences recognised by restriction enzymes Nco1 (yellow) and Xho1 (red) 
Vector Target Primer sequence (5’-3’) 









PCR was used to amplify the gene from a template DNA source.  The PCR reaction 
was set up as follows: 
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12 µL 2× Pfu Mastermix 
2.5 µL Band Doctor (part of Pfu Mastermix kit) 
50 ng Template DNA 
1.25 µL Forward Primer (10 µM stock) 
1.25 µL Reverse Primer (10 µM stock) 
Adjusted to 25 µL with nuclease-free water. 
The thermocycling conditions were prepared as follows: 
1. 95⁰C for 2 minutes 
2. 95⁰C for 20 seconds 
3. 58⁰C for 40 seconds 
4. 72⁰C for 2-5 minutes (1 minute per 2 kb) 
5. Repeat steps 2-4 for 25-35 cycles 
6. 72⁰C for 5 minutes  
7. Hold at 4⁰C 
Following PCR, 5 µL of the PCR product was separated on a 1% agarose gel to 
ensure amplification of a product of the correct size, and to confirm quality.  The 
remaining PCR product was cleaned using PCR Clean-Up kit (Qiagen). 
After clean up of the PCR product, both PCR product and vector were digested using 
restriction enzymes and buffers (NEB).  Digest reactions were prepared as below: 
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Double digestion of vector Double digestion of PCR product 
1 µg of plasmid 30 µL of PCR product 
5 µL NEB Buffer 5µL NEB Buffer 
5 µL of BSA (if required) 5 µL BSA (if required) 
1 µL Restriction enzyme 1 1 µL Restriction enzyme 1 
1 µL Restriction enzyme 2 1 µL Restriction enzyme 2 
Adjusted to 50 µL with nuclease-free water Adjusted to 50 µL with nuclease-free water 
 
To control for restriction enzyme inactivity, single digest reactions were also 
prepared to ensure that the enzymes were active under the conditions used.  The 
digests were incubated for 3 hours at 37⁰C in a water bath or heat block.  Following 
digestion, complete reaction volumes were supplemented with 6× loading buffer and 
separated on a 1% agarose gel.  Bands were visualised under blue light and single 
bands corresponding to double digested vector and insert excised then extracted from 
the agarose gel matrix using Gel Extraction kit (Qiagen) according to manufacturer’s 
instructions.  DNA was eluted with nuclease-free water and quantified by NanoDrop. 
Ligation reactions were then prepared to join together the digested insert and vector 
in the correct orientation.  Using T4 ligase (Promega), and following the 
manufacturers guidelines, 100 ng of digested vector was use and the amount insert 
calculated using the following formula:  
Insert (ng) =  
vector (ng) × size of insert (kb) / (size of vector (kb) × molar ratio (insert/vector)  
 
A 1:1 molar ratio of insert to vector was most commonly used. 
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The ligation reaction was prepared: 
1 µL T4 Buffer 
X ng insert 
100 ng Vector 
1 µL T4 ligase  
Adjusted to 10 µL with nuclease-free water 
 
For control purposes, conditions were set up which lacked insert to control for re-
ligation of vector.  The ligation reactions were incubated for 16-48 hours at 4⁰C.  The 
complete 10 µL was transformed into E. coli DH5α and plated on LB-agar plates 
with selective antibiotic.  Following selection, several colonies were picked, grown 
in 5 mL culture and subject to MiniPrep prior to plasmid sequencing. 
 
2.4.4.3 Site-directed mutagenesis 
Specific mutations were also cloned in plasmids to challenge the function of specific 
amino acid residues, or motifs, of the AGR2 protein.  The desired change at the DNA 
level was made in synthesised primers (Sigma), before PCR amplification of the 
mutant gene within the plasmid.  The primers used to make specific changes are 
presented below (Table 2-3): 
  
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 2 – Materials and Methods  57 
Table 2-3 Primer sequences derived for site-directed mutagenesis  codons highlighted in red are 
mutated from the template plasmid  
Mutation Primer sequence (5’-3’) 
FRT-STOP Forward: ATGGAGAAAATTTAGGTGTCAGCA 
Reverse: TGCTGACACCTAAATTTTCTCCAT 
FRT-AGR2-KDEL Forward: CTCAAGTTGCTGAAGGATGAATTGTAGGACCC 
Reverse: GGGTCCTACAATTCATCCTTCAGCAACTTGAG 














   
A PCR reaction using the mutant primers was prepared as follows 
12.5 µL 2× Pfu mastermix 
2.5 µL 5× Band Doctor 
50 ng template DNA 
1.25 µL forward primer (10 µM) 
1.25 µL reverse primer (10 µM) 
Adjusted to 25 µL with nuclease-free water. 
These reactions were subject to the following thermocycling program: 
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 1. 95⁰C for 1 minute 
2. 95⁰C for 50 seconds 
3. 55⁰C for 1 minute 
4. 68⁰C for 15 minutes  
5. Repeat steps 2-4 for 19 cycles 
6. 68⁰C for 30 minutes  
7. Hold at 4⁰C 
Following the completion of PCR amplification, 5 µL of reaction was removed for 
control purposes.  1 µL of DpnI restriction enzyme (NEB) was added to the PCR 
product reaction, and mixed.  The digestion was incubated at 37⁰C for 2 hours to 
cleave methylated bacterial DNA (the template).  After digestion the DpnI enzyme 
was heat-inactivated at 65⁰C for 10 minutes.  2µL of the digested product (and 
control undigested product) was transformed into E. coli DH5α cells and plated on 
LB-agar plates supplemented with appropriate selective antibiotic.  Several colonies 
(3-5) were isolated, grown in 5 mL of LB and subject to MiniPrep DNA purification.  
Successful mutagenesis was confirmed by plasmid sequencing.  
 
2.5 Tissue Culture Procedures 
 
2.5.1 Cell lines and culture 
Cell lines were incubated at 37⁰C and 5% CO2 in a humidified incubator, with the 
exception of A375 cells which required a CO2 saturation of 10% for optimal growth.  
Required media, RPMI or DMEM (Gibco, Life Technologies), was supplemented 
with 10% (v/v) FBS (Biosera) and 1% (v/v) penicillin/streptomycin mix (Life 
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Technologies).  Table 2-4 lists the cell lines, their media requirement and AGR2 
status, used in this study. 
Table 2-4 Cell lines and tissue culture media requirements.  Media used were Dulbecco’s modified 
eagle medium (DMEM) and Roswell Park Memorial Institute (RPMI).  
Cell Line Cancer Type AGR2 Status Media 
A375 Human skin 
melanoma 
Negative DMEM 
MCF7 Human breast 
adenocarcinoma 
Positive DMEM 
OE19 Human oesophageal 
adenocarcinoma 
Positive RPMI 
A549 Human lung 
adenocarcinoma 
Positive DMEM 
T47D Human ductal breast 
epithelial 
Positive RPMI 
   
2.5.2 Passaging of cells 
Cell lines were grown in sterile 100 mm tissue culture plates (Corning) until near 
100% confluence.  To propagate growth, tissue culture medium was aspirated, and 
discarded.  Cells attached to the substrate were washed twice with 10 mL sterile 
phosphate buffered saline pH 7.4 (PBS) prior to the addition of 3 mL trypsin-EDTA 
(Life Technologies) and incubation at 37⁰C in the incubator for approximately 5 
minutes.  Following incubation, cells could be observed detached from the culture 
vessel.  7 mL of fresh complete tissue culture media was added to the plate, and the 
suspension transferred to a 15 mL tube.  Cells were appropriately diluted and seeded 
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2.5.3 Storage of mammalian cell lines and recovery 
In order to maintain a low passage number of cells for reproducibility, cells could be 
prepared for long term liquid nitrogen storage.  Cells were seeded into tissue culture 
plates and allowed to grow to 100% confluency.  Following growth, media was 
discarded and the cells washed with PBS and trypsinised from the tissue culture 
substrate as previously.  Once cells were detached, fresh media was added and the 
cells transferred to a 15 mL Falcon tube.  The cells were centrifuged for 5 minutes at 
1000 rpm, allowing the cells to pellet and the media discarded.  Cells were 
resuspended in 5 mL of cell freezing solution (10% DMSO in FBS), and 1 mL 
aliquots prepared in cryovials.  Vials were then transferred to an isopropanol bath 
(Nalgene) and incubated at -80⁰C for 24 hours.  Once gradually frozen, the aliquots 
were moved to liquid nitrogen for permanent storage.   
To recover cells, vials were rapidly thawed at 37⁰C in a water bath.  Thawed cells 
were then plated into a tissue culture plate with 10 mL of fresh media and incubated 
in the tissue culture incubator. 24 hours later, the media was aspirated and exchanged 
to remove traces of DMSO.  The cells could then be grown to confluency prior to 
experimental seeding. 
 
2.5.4 Transfection of plasmid DNA 
The cell line to be transfected was seeded in 100 mm tissue culture plates and 
allowed to grow to 75-90% confluence.  Media was discarded and fresh added prior 
to transfection.  The transfection mixture was prepared, as below, incubated for 15 
minutes at room temperature then added to cells drop wise.  The cells were incubated 
for 24-48 hours prior to harvesting.  The reaction could be scaled for tissue culture 
vessels of smaller surface area.  For control purposes, additional cells were 
transfected with the specified plasmid lacking the gene of interest.  Plasmids used for 
transfection are highlighted in Table 2-5. 
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Plasmid Transfection Preparation 
 0-10 µg Plasmid DNA 
15 µL Attractene (Qiagen) 
Made up to a final volume of 300 µL with serum free media. 
Table 2-5 List of plasmids used for cell transfection 
Plasmid Source 
wtAGR2-pEF5/FRT/V5-DEST Cloned in-house 
AGR2-KDEL-pEF5/FRT/V5-DEST Cloned in-house 
AGR2-ΔC-pEF5/FRT/V5-DEST Cloned in-house 
TSG101-pCMV-XL5 Origene 
 
2.5.5 Hygromycin B selection of stably transfected cells 
In order to stably transfect A375 (AGR2-null) cells with the single gene insert of the 
AGR2, the Flp-In system (Life Technologies) was utilised.  Briefly, cells were co-
transfected with the required plasmid and pOG44 plasmid at a ratio of 1:9 (0.5 µg + 
4.5 µg or 1 µg + 9 µg, respectively) and Attractene, as Section 2.5.4.  As a control, 
one condition was prepared with pOG44 only.  24 hour post-transfection, media was 
removed and replaced with fresh media supplemented with 50 mg/mL hygromycin B 
(Sigma).  Hygromycin supplemented media was exchanged every 2-3 days for 
approximately 2 weeks, until the control transfected cells (lacking the gene of 
interest and hygromycin resistance gene) had died and colonies were evident in the 
experimental plates.  Colonies were trypsinised from the plate, transferred to new 
tissue culture vessels and grown to confluency.  
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2.5.6 Transient silencing of gene expression using siRNA 
Cells were seeded in 6-well plates and grown to 40-60% confluence for siRNA-
induced gene silencing.  siRNA against AGR2 (ON-TARGETplus, Thermo 
Scientific) and TSG101 (siGENOME SMARTpool, Thermo Scientific) was used at a 
final concentration of 50 nM.  For each well, 5 µL of 20 µM siRNA stock was 
diluted using serum free, and antibiotic free media, to a final volume of 200 µL, 
concurrently, 4 µL of DharmaFECT I reagent was diluted with 196 µL of serum and 
antibiotic free medium.  Each mixture was prepared and incubated at room 
temperature for 5 minutes, prior to the diluted siRNA and DharmaFECT reagents 
being combined and incubated for a further 20 minutes.  During the incubation, 
tissue culture media was aspirated from the cells in culture, and replaced with 1.6 mL 
of fresh media.  Subsequently, the entire 400 µL siRNA-DharmaFECT reaction was 
added to the cells and incubated for 24-48 hours in the tissue culture incubator.  Cells 
were then harvested or treated as per figure legends. 
 
2.5.7 Drug treatment 
Drug compounds were used to analyse the response of experimental cells.  Cells 
were seeded in 6 well or 100 mm tissue culture plates prior to the dilution of drug to 
appropriate concentration (Table 2-6). 
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Table 2-6 Drug compounds used and details of treatment 
Drug Compound Final 
Concentration 
Function Incubation Supplier 
Cisplatin 20 µM DNA 
damaging 
agent 
1-24 hours Sigma 
Polyinosinic:polycytidylic acid  
(poly I:C) 
25 µg/mL TLR3 
activation 
1-6 hours Source 
Bioscience 
Tunicamycin 1 µg/mL ER stress 
induction  
1-4 hours Sigma 
MG132 10 µM Inhibition of 
proteosomal 
recycling 
3 hours VWR 
 
  
2.5.8 Harvesting cells 
Tissue cultures were placed on ice in preparation for harvesting.  Growth media was 
discarded prior to cells being washed twice with ice cold PBS.  Cells were scraped 
into ice cold PBS (1 mL for 100 mm plate, 400 µL for 6 well plate) using a cell 
scraper, before transferring to a pre-chilled microcentrifuge tube.  Cells were pelleted 
by centrifugation at 5000 rpm for 5 minutes at 4⁰C.  The supernatant was aspirated, 
and the cells snap frozen in liquid nitrogen.  Cells could then be stored at -80⁰C for 
later analysis or resuspended directly in lysis buffer for analysis. 
 
2.5.9 Cell lysis 
Pelleted cells were thawed on ice, before resuspension in approximately 3× pellet 
volume of RIPA cell lysis buffer.  Lysis was carried out for 20 minutes on ice with 
periodic vortexing.  The lysate was then centrifuged at 13200 rpm for 12 minutes at 
4⁰C to pellet insoluble material.  The supernatant was collected, transferred to a fresh 
microfuge tube and protein concentration assessed by Bradford assay.  The lysate 
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could be immediately used for downstream analysis or snap frozen in liquid nitrogen 
for -80⁰C storage.     
RIPA lysis buffer 
1% Triton-X100 
1% Sodium deoxycholate 
0.1% SDS 
0.15 M NaCl 
0.01M Sodium phosphate pH7.2 
1× Protease inhibitor (Roche) 
 
2.5.10 Bradford Assay 
Bovine serum albumin (BSA) standards (0.125-4 mg/mL) were prepared in RIPA 
buffer.  1 μL of standards or cell lysate were diluted into 200 μL of Bradford reagent 
and vortexed to mix.  50 μL aliquots were placed in a 96 well plate in triplicate.  The 
absorbance was read at 595 nm using Victor
3
 1420 multi-label plate reader.  A 
standard curve was calibrated using the absorbance of the BSA standards and sample 
concentrations calculated from the standard fit.    
Bradford Reagent 
0.01% (w/v) Coomassie blue G250 
4.25% (v/v) Ethanol 
8.5% (v/v) Phosphoric acid 
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2.5.11 Cell growth and invasion assays 
2.5.11.1 Scratch assay 
A375 FRT- (parental) and FRT-wtAGR2 engineered cells were plated in 100 mm 
tissue culture plates and allowed to grow to confluency.  A wound was simulated 
using a 10 µL pipette tip to make a straight scratch.  Microscopy images were 
collected at 4 hour intervals and analysed using TScratch software package.   
 
2.5.11.2 xCELLigence cell proliferation assay  
Cells to be investigated were trypsinised when 80% confluent (still in logarithmic 
growth), before counting using a haemocytometer.  5000 cells of each cell type were 
seeded into wells of an E-plate-view (Roche) in quadruplicate and incubated in 
cradles of xCELLigence RTCA DP instrument (Roche) at 37⁰C, 10% CO2 for 96 
hours.  The xCELLigence assay measures cell growth in real time as a measurement 
of electrical impedance across interdigitated electrodes on the base of the tissue 
culture plate.  The software program was written such that cell impedance readings 
were taken every 15 minutes over the complete incubation (96 hours and until cells 
were confluent).  Using Real-Time Cell Analyzer software package (Roche) data was 
analysed, averaged and plotted as changes in growth over time.  
 
2.6 Molecular Biology Techniques 
 
2.6.1 SDS-PAGE separation of proteins 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) allows 
separation of complex mixtures of proteins based on their electrophoretic mobility (a 
function of the length of the polypeptide and its charge) (277;278).  SDS is an 
anionic detergent which linearises proteins and imparts a negative charge to the 
linearised protein.  Thus the proteins will be separated as an approximation of their 
size.   Using the Mini-Protean kit (BioRad), the 0.75 mm resolving gel was first 
prepared, as per Table 2-7, and overlaid with water to maintain a clean, straight 
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interface on the surface of the gel.  Following polymerisation, the water was removed 
and the stacking gel was overlaid, directly on top of the resolving gel, and a 10- or 
15-well comb added.  Once the stacking gel has polymerised, the combs were 
removed, the gels loaded into the Mini-Protean tank and filled with ~ 1 L of 1× 
running buffer.  Normalised protein samples were prepared (20 µg of protein unless 
otherwise stated) was concurrently mixed with 4× sample buffer to a final 1× 
concentration and denatured by heating at 95⁰C for 5 minutes.  Proteins were then 
loaded to individual wells in the gel, along with pre-stained protein standards 
(Fermantas) as protein size markers.  Electrophoresis was carried out at 200V for 
~50 minutes, or until the bromophenol blue dye front of the sample buffer reached 
the bottom of the gel. 
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Table 2-7 Final concentrations of reagents required for resolving and stacking gels for SDS-
PAGE separation of proteins. 






30% Acrylamide mix 
(30% acrylamide, 
0.8% bis-acrylamide) 
12 % 13.5 % 5% 
1.5M Tris pH 8.8 0.39 M 0.39 M N/A 
1.0 M Tris pH 6.8 N/A N/A 0.13M 
10% (w/v) SDS 0.1% 0.1% 0.1% 
10% (w/v) APS 0.1% 0.1% 0.1% 
TEMED  0.04% 0.04% 0.1% 
Water As required 
 
1× Running Buffer 4× Sample Buffer 
192 mM Glycine 4 % (w/v) SDS 
25 mM Tris 200 mM Tris-HCl pH6.8 
0.1% (w/v) SDS 20% (v/v) Glycerol 
 10 mM EDTA pH 8.0 
 Bromophenol blue 
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2.6.2 Protein staining in gels  
Following SDS-PAGE, separated proteins could visualised in a number of ways.  
Firstly, Coomassie Blue staining (see below) was used, whereby the gel is incubated 
in Coomassie stain for 30 minutes, with constant agitation.  Once bands are evident, 
the gel was destained overnight in destain solution, followed by storage in deionised 
water.  Alternatively, proteins could be rapidly stained using InstantBlue stain 
(Expedeon), which required only 15 minute incubation with the staining reagent for 
visualisation of protein bands.  When greater sensitivity was required, gels were 
stained using a silver staining protocol (SilverQuest, Life Technologies) as per 
manufacturer’s instruction.   Gels could then be dried onto chromatography paper 
using a heated vacuum drier (Gel Master Model 1426, Welch Rietschle Thomas). 
Coomassie Stain Destain 
5% (v/v) Coomassie blue R-450 (Sigma) 7.5% (v/v) methanol 
50% (v/v) methanol 10% (v/v) acetic acid 
10% (v/v) acetic acid  
 
2.6.3 Immunoblotting 
Immunoblotting for specific protein of interest could be carried out following SDS-
PAGE if required.  Proteins were transferred from the polyacrylamide gel onto 0.2 
µm Hybond-C nitrocellulose membranes (GE Healthcare) in 1× transfer buffer, 
cooled with an ice pack at a constant current of 300 mA for 60 minutes.  The 
membranes were then ink, or Ponceau S (Sigma), stained to confirm transfer of 
protein and to assess loading.  Prior to immunoblotting, non-specific binding sites 
were blocked using 3% (w/v) dried skimmed milk powder (Marvel) in PBS-0.05% 
Tween (PBST), for one hour at room temperature with constant agitation.  
Subsequently, membranes were probed with primary antibody, at appropriate 
concentration in 3% milk-PBST, for one hour at room temperature, or overnight at 
4⁰C.  The probed membranes were then washed thrice with PBST to remove weak 
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and non-specific interactions, prior to incubation with a horseradish peroxidase 
(HRP) conjugated secondary antibody (DakoCytomation) for one hour at room 
temperature.  Membranes were again thrice washed with PBST and prepared on a 
glass plate for ECL detection.  The bound secondary antibody signal was detected 
using a 1:1 mixture of ECL1:ECL2 solutions, mixed and incubated for 30 seconds 
before application to the membrane.  The membrane was exposed to X-ray film then 
developed using a Konica Medical Film Processor.  Antibodies used are listed in 
Table 2-8. 
1× Transfer buffer 
0.192M Glycine 
25 mM Tris 
20% (v/v) Methanol 
ECL Solution I ECL Solution II 
100 mM Tris, pH 8.5 100 mM Tris, pH 8.5 
2.5 mM Luminol 0.02% (v/v) H2O2 
0.4 mM p-Coumaric acid  
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Description Supplier Dilution 





AGR2 19 Mouse 
Monoclonal 
Abnova 1:1000 





p21 21 Mouse 
Monoclonal 
Merck/Calbiochem 1:500 – 1:1000 
β-actin 42 Mouse 
Monoclonal 
Sigma 1:5000 – 1:10 000 
IRF-1 48 Mouse 
Monoclonal 





Santa Cruz 1:1000 
































2.6.4 Confocal immunofluorescence microscopy 
Cells were plated on coverslips at 2 × 10
5
 cells per well (40% confluency) in the base 
of 12-well tissue culture dishes, and incubated at 37⁰C for 16 hours.  Following 
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incubation, media was removed from wells and cells rinsed with 1 mL of Tris-
buffered saline (TBS), followed by fixation in Fixing solution for 10 minutes at room 
temperature. After fixing, the formaldehyde containing solution was removed, 
coverslips were retrieved from wells and cells washed twice with TBS-0.1% Triton 
X-100 (TBS-Triton), prior to permeabilisation and blocking for 1 hour at room 
temperature with 3% BSA in TBS-Triton.  Cells were incubated in a humid 
environment overnight at 4⁰C with primary antibodies diluted in blocking solution 
(1:500 anti-AGR2, Abnova and 1:250 anti-PDI, Enzo Life Sciences).  Coverslips 
were subsequently washed 3 × 5 minutes in TBS-Triton and incubated with 
appropriate secondary antibodies (Alexa Flurophore conjugated goat anti-mouse 488, 
or  Alexa Fluorophore conjugated donkey anti-rabbit 594) diluted 1:200 in blocking 
buffer for 30 minutes at room temperature in dark conditions.  Cells were subjected 
to a further 3 washes with TBS-Triton, prior to nuclear counter stain with 100 μL of 
1:1000  TO-PRO-3 nuclear stain diluted in TBS.  These coverslips were washed a 
further thrice with TBS-Triton before mounting on glass slides (Superfrost) with 
mounting fluid for fluorescent analysis (DakoCytomation).  Cells were analysed sing 
an Olympus FV1000 confocal microscope with a 60 × oil immersion objective and 
FV10-ASW software (Olympus). 
Immunofluorescence fixing solution 
3.7% Formaldehyde 
10 mM EGTA pH8.0 
100 mM Pipes pH 6.8 
1 mM MgCl2 
0.2 % (v/v) Triton X-100  
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2.6.5 Detection of secreted proteins in tissue culture media 
Cells were plated at constant number across experimental conditions, and allowed to 
grow to confluency over 72 hours.  Cells were washed twice with PBS and incubated 
for 24 hours in serum free media.  Media was subsequently concentrated 50× using 
10 kDa molecular weight cut off spin column filters (Millipore).  Protein 
concentration of media was quantified by NanoDrop, and standardised (if necessary) 
to 0.5 mg/mL, prior to boiling with SDS sample buffer, loading onto an SDS-PAGE 
gel.  Gels could be silver stained for whole secretome visualisation or immunoblotted 
for the protein of interest.  Alternatively 
35
S-methionine labelled proteins were 
detected using a phosphoimager. 
 
2.6.6 FACS analysis of protein expression 
Fluorescence activated cell sorting (FACS) was used to quantify the proportion of 
cells expressing a protein of interest.  Experimental cells were trypsinised, counted 
using a haemocytometer and diluted to 5 × 10
6 
cells/mL in ice cold PBS 
supplemented with 10% FBS and 1% NaN3.  100 μL of each dilution was required 
per experimental staining condition.  Cells were pelleted and fixed in 100 μL of 
0.01% formaldehyde for 15 minutes at room temperature prior to permeabilisation.  
Cells were permeabilised by incubation in 100 μL PBS supplemented with 0.1% 
Triton X-100 for a further 15 minutes at room temperature.  The FITC-conjugated 
antibody (Anti-Ki67, eBioscience) was prepared in a series dilution (1:20, 1:50 and 
1:100), along with negative controls, in the permeabilisation buffer.  Following 
permeabilisation, Cells were incubated with antibody reagent for 30 minutes, in 
darkened environment at room temperature to allow interaction.  After staining, cells 
were washed thrice by centrifugation at 400g for 5 minutes and resuspension in ice 
cold PBS with 3% BSA and 1% NaN3 prior to analysis.  Data from 1000-2000 cell 
events were detected using a FACSAriaII flow cytometer (BD Biosciences), with 
FITC detected in the green fluorescence channel, and data analysed using FACSDiva 
software (BD Biosciences).    
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2.6.7 Quantitative real-time PCR (qPCR) 
2.6.7.1 RNA extraction 
Cells were seeded in 6-well plates and allowed to grow to near confluency.  Cells 
were harvested as 2.5.8, prior to RNA extraction using RNeasy kit (Qiagen) in 
accordance with manufacturer’s instructions.  Samples were homogenised using 
QIAshredder (Qiagen) columns and RNA eluted using RNase free water.  During the 
procedure careful measures were taken to avoid contamination of RNA.  Once 
isolated, RNA was used immediately to synthesise cDNA.  
 
2.6.7.2 cDNA synthesis by reverse transcription PCR 
0.5 μg of RNA was diluted in 7 μL of RNase free water and incubated at 65⁰C for 5 
minutes.  RNA was then cooled and combined with 13 μL of the reverse 
transcription (RT) mastermix.  The mixture was incubated for 1 hour at 37⁰C.  
Following cDNA synthesis, cDNA could be stably stored at -20⁰C 
Reverse-transcription mastermix 
2 μL RT Buffer  
2 μL 5 mM dNTP 
0.2 μL 0.5 mg/mL oligo DT primers 
0.25 μL 40U/μL RNase inhibitor   
2 μL 100 mM DTT 
1 μL Omniscript Reverse transcriptase (Qiagen) 
5.6 μL nuclease free water. 
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2.6.7.3 qPCR Reaction 
qPCR was carried out using reagents from the Solaris kit (Dharmacon). The reaction 
mixture was prepared as indicated in white qPCR tubes with clear optical caps.  Each 
condition was carried out in quadruplicate.  The reaction was monitored on the PTC-
200 Peltier Thermal cycler using the indicated cycling program.  Once complete, Ct 
(cycle threshold, the number of cycles to reach an empirical reading of the label) 
values were obtained, and relative change calculated using the 2
-ΔΔCt
 method (279).  
ΔCt calculates the difference between the average Ct for the gene of interest and the 
control gene (e.g. GAPDH).  ΔΔCt indicates the difference between ΔCt for the 
experimental condition compared to control condition.  
qPCR Reaction Mix Thermocycling Program 
12.5 μL Solaris Mastermix 1. 95⁰C for 15 minutes 
1.25 μL Solaris Primer/Probe set 2. 95⁰C for 15 seconds 
500 ng cDNA 3. 60⁰C for 1 minute – read plate 
Adjusted to final volume of 25 μL with water Cycle to step 2-3 40 times 
 
2.7 Gene expression analysis by microarray 
 
RNA was extracted, as previously, using the RNeasy RNA extraction kit coupled to 
the QIAshredder.  RNA quality and quantity was assessed with NanoDrop and RNA 
integrity number (RIN) calculated using Agilent 2100 Bioanalyzer (Agilent 
Technologies).  Purified RNA (0.5 μg) was biotin labelled using the Illumina 
TotalPrep RNA amplification kit (Ambion) according to the manufacturer’s 
instructions.  Labelled cRNA was hybridised to Illumina HT-12 v3 BeadChips and 
scanned at the Wellcome Trust Clinical Research Facility, Edinburgh.  Gene 
expression analysis was performed using the open source statistical programming 
language, R (280), and associated Bioconductor packages (281).  Probe bead 
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summary data was quantile-normalised using the Lumi package (282).  Differential 
expression was determined using Rank Products analysis (283) with 5% false 
discovery rate.  Clustering and heat maps were performed and generated using the 
Cluster and TreeView programs (284).  The online Database for Annotation, 
Visualisation and Integrated Discovery (DAVID) program (285) was used to identify 
over-represented KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways 
from lists of differentially expressed genes. Statistical analysis was carried out in 
collaboration with Dr A. Sims, Applied Bioinformatics of Cancer, Edinburgh Cancer 
Research Centre. 
 
2.8 Expression and Purification of Recombinant 
protein from E. coli 
 
2.8.1 AGR2 protein expression from E. coli 
Hexa-histidine tag protein expression vectors (pEHISTEV (286)) cloned with wild-
type or mutant AGR221-175 or AGR3 genes were heatshock transformed into E. coli 
BL21-DE3 cells and selected on LB-agar supplemented with 50 µg/mL kanamycin.  
A single colony was isolated, and inoculated into 50 mL of LB (+ 50 µg/mL 
kanamycin) and incubated at 37⁰C with constant shaking (220 rpm) overnight.  This 
starter culture was diluted 1:20 into 500 mL LB containing selective antibiotic, and 
returned to the incubator until an OD600 nm of 0.6 was achieved.  Protein expression 
was subsequently induced with the addition of 1 mM IPTG.  The culture was 
incubated for a further 3 hours at 37⁰C with constant shaking.  Following induction, 
cells were centrifuged for 20 minutes at 6000 rpm at 4⁰C to pellet.  Pellets could be 
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2.8.2 Purification of His-tagged AGR2 
Two methods of His-tag purification were carried out.  For small scale purifications, 
bacterial pellets were resuspended in 10 mL of Lysis buffer and incubated on ice for 
30 minutes.  Cells were further lysed by sonication, in an ice bath, in three bursts of 
15 seconds with 30 seconds gap between steps.  Lysate was then cleared of insoluble 
material by centrifugation at maximum speed for 30 minutes at 4⁰C.  The supernatant 
was transferred to a tube containing 1 mL of Ni
2+
-NTA agarose beads (Qiagen), 
which had been pre-washed with 5 mL of lysis buffer.  The supernatant and beads 
were incubated at 4⁰C on a rotating table for 1 hour.  The mixture was transferred to 
a disposable purification column and allowed to flow through by gravitation force.  
The beads retained in the column were washed 2× 5 mL with lysis buffer and 2× 5 
mL with Wash buffer.  Following washes, bound His-tagged protein was eluted in 15 
elution steps of 500 μL of high imidazole Elution buffer.  Fractions were collected 
and analysed by SDS-PAGE and colloidal staining, and protein containing fractions 
pooled for immediate use or storage at -80⁰C.  To remove the His-tag leaving a 4 
amino acid overhang, protein was prepared in buffer containing 0.1M DTT and 330 
U AcTEV enzyme (Life Technologies).  A time course (1-24 hours) of recombinant 
tobacco etch virus (TEV) mediated cleavage was carried out to assess the rate of 
cleavage.  The digested protein was dialysed against Lysis buffer, or buffer 
exchanged using Zeba desalting columns (Thermo Scientific), to reduce high 
imidazole content before being purified over nickel-agarose beads to remove cleaved 
His-tag, and His-tagged protease. 
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Lysis Buffer Wash Buffer Elution Buffer 
50 mM NaH2PO4 As Lysis Buffer except with 
30 mM imidazole 
As Lysis buffer except with 
300 mM imidazole 
400 mM NaCl   
10 mM imidazole   




Alternatively, for larger scale purifications, bacterial pellets were resuspended in 30 
mL of Lysis buffer on ice and vortexed.  Lysis was achieved by high pressure cell 
disruption at 25k PSI using a 1.1 kW TS cell disruptor (Constant Systems), followed 
by centrifugation at 40,000 × g for 50 minutes to isolate the soluble fraction.  The 
supernatant was applied to a nickel-charged HisTrap FF 5-mL column (GE Life 
Sciences), pre-equilibrated with lysis buffer in an AKTA chilling cabinet (Edinburgh 
Protein Production Facility).  The immobilised protein was washed with 20 column 
volumes of wash buffer, followed by 10 column volumes of wash buffer 
supplemented with 30 mM imidazole, before final elution using 300 mM imidazole 
for 20 column volumes.  The eluted protein was pooled and cleaved with TEV 
protease overnight at 20⁰C.  The resultant solution was desalted into lysis buffer with 
a HiPrep desalt 26/10 column (GE Life Science) before reloading onto the IMAC to 
remove protease and uncleaved protein.  The protein was collected as flow through 
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2.8.3 Size-exclusion chromatography of purified AGR2 
Purified protein was analysed by gel-filtration size exclusion chromatography on an 
analytical Superdex PC75 3.2/30 column with a flow rate of 0.5 mL/minute at 
titrated concentrations ranging from 2.5 mg/mL to 5 μg/mL.  Detection was by 
absorption at 214 nm.  The column was previously calibrated with known protein 
standards (GE Life Sciences). 
 
2.8.4 Purification of GST-tagged Reptin 
Reptin-GST tagged vectors for protein expression (a kind gift from Dr M. Maslon) 
were transformed into BL21-AI cells.  These were cultured as 2.8.1, but induced with 
0.2% arabinose at room temperature for 3 hours.  Following induction cells were 
pelleted as previously.  The cell pellet was resuspended in 10 mL of Lysis buffer and 
incubated on ice for 30 minutes.  Cells were then further lysed by sonication in 3 × 
15 second bursts.  The lysate was centrifuged for 30 minutes at 4⁰C at maximum 
speed.  The supernatant was transferred to a fresh tube containing 500 μL of 
glutathione-sepharose 4B beads (Amersham), pre-equilibrated with 5 mL lysis 
buffer.  Beads and lysate were incubated for 1 hour at 4⁰C with constant agitation.  
The beads were subsequently washed twice with 5 mL high salt wash buffer, twice 
with 5 mL low salt wash buffer, prior to the addition of 5 mL of elution buffer.  
Elution buffer was incubated with the beads for 30 minutes at 4⁰C, and eluted protein 
collected as flow through. 
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Lysis Buffer High Salt Wash 
10% Sucrose 20 mM Hepes pH 7.5 
50 mM Tris pH 8.0 1 M NaCl 
400 mM NaCl 1 mM DTT 
0.5 mg/mL Lysosyme 1 mM benzamidine 
0.5% Triton X-100  
1 mM DTT  
1 mM benzamidine  
1 × protease inhibitor cocktail  
  
Low Salt Wash Elution Buffer 
20 mM Hepes pH 7.5 100 mM Tris pH 8.0 
50 mM NaCl 120 mM NaCl 
1 mM DTT 40 mM reduced glutathione. 
1 mM benzamidine  
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2.9 Quantitation of protein expression levels using 
SILAC mass spectrometry. 
 
2.9.1 Metabolic labelling of cellular proteins and preparation 
of cell lysate 
Experimental engineered A375-FRT cells containing the required gene 
recombination were incubated with isotope labelling media as described in the figure 
legends.  Briefly, media (Dundee Cell Products) containing normal isotope labelled 
lysine and arginine amino acids (R0K0, ‘light’), or heavy isotopes, 
13
C labelled Arg 
and 
2









labelled Lys (R10K8, ‘heavy’), supplemented with 10% dialysed FBS (Dundee Cell 
Products) was prepared.  Cells were propagated for >6 cell doublings to ensure 
incorporation of the isotope labelled amino acids (287).  A near-confluent (95%) 100 
mm tissue culture plate of the desired experimental condition was harvested and 
lysed with RIPA cell lysis buffer, as 2.5.9.  Protein concentration was determined by 
Bradford assay and samples mixed in a 1:1:1 ratio.  The mixed sample reduced in 
SDS-PAGE loading buffer containing 10 mM DTT, and alkylated in 50 mM 
iodoacetamide prior to boiling and separation by one-dimensional SDS-PAGE (using 
pre-cast 4-12% Bis-Tris Novex mini-gel, Life Technologies), and visualised by 
colloidal Coomassie staining.  The entire protein gel lane was excised and cut into 10 
gel slices.  Each gel slice was subject to in-gel digestion with trypsin (288).  The 
resultant tryptic peptides were extracted with 1% formic acid, lyophilised in a 
Speedvac (Helena Biosciences), and resuspended in 1% formic acid.  
 
2.9.2 Mass spectrometry methods 
Trypsinised peptides were separated using an Ultimate U3000 (Dionex Corporation) 
nanoflow liquid chromatography (LC)-system.  2 mg of digested peptides were 
loaded with a constant flow of 20 mL/minute onto a PepMap C18 trap column (0.3 
mm id × 5 mm, Dionex Corporation) for reverse phase chromatography.  After trap 
enrichment, peptides were eluted onto a PepMap C18 nano column (75 mm × 150 
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mm) with a linear gradient of 5-35% solvent B (90% acetonitrile, 0.1% formic acid).  
The HPLC system was coupled to an LTQ Orbitrap velos (Thermo Scientific) via a 
nano ES ion source (Proxeon Biosystems).  Full scan MS survey spectra (m/z 335-
1800) in profile mode were acquired in the Orbitrap, with a resolution of 60, 000 
after accumulation of 500,000 ions.  The five most intense peptides ions from the 
preview scan were fragmented by collision-induced dissociation (CID) for MS/MS 
sequencing.  Data were acquired using the Xcalibur software (Thermo Scientific).  
Mass spectrometric analysis was carried out by Dundee Cell Proteomics, Dundee. 
 
2.9.3 Relative Quantification and Bioinformatics analysis 
Quantification was performed using MaxQuant version 1.0.7.4 (289), by Dundee 
Cell Proteomics.  To minimise the effect of outliers, protein ratios were calculated as 
the median of all SILAC pair ratios that belonged to peptides contained in the 
protein.  The generation of peak list, SILAC quantitation, calculated posterior error 
probability (PEP), false discovery rate, peptide to protein group assembly, and data 
filtration was carried out using MaxQuant.  The derived peak list was searched with 
Mascot search engine (Matrix Science) against a concatenated database from 
International Protein Index (IPI) human protein database version 3.6 (forward 
database), and reversed sequences of all proteins.  Parameters allowed up to three 
missed trypsin cleavages and three labelled arginine and lysine amino acid residues.  
Initial mass deviation of precursor ion and fragment ions were up to 7 ppm and 0.5 
Da, respectively.  The minimum required peptide length was 6 amino acids.  For 
statistical evaluation, PEP for peptide identification should be below or equal to 0.1, 
and the false positive rate was set to 5% at the peptide level.  Proteins were 
quantified based on the presence if at least one MaxQuant-quantifiable SILAC pair 
was evident.  Enzyme specificity was set to trypsin allowing for cleavage of N-
terminal to proline and between aspartic acid and proline.  Carbamidomethylation of 
cysteine was searched as a fixed modification, and N-acetyl protein and oxidation of 
methionine were searched as variable modifications. 
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Data was mined as described in results and figure legends.  SILAC quantified 
relative expression ratios requiring a minimum fold change of 20% were empirically 
defined.  Expression changes ±20% with a minimum of 3 peptides used for 
quantitation were identified and submitted to Ingenuity Pathway Analysis (Ingenuity, 
Dr. J Nicholson, Australian Proteomics Facility, Sydney), allowing the identification 
of over-represented factors and comparison to a curated library of expression 
changes on biochemical function.  In addition, data-driven analysis was carried out 
through comparison of proteins of greatest change in relative expression levels with 
literature review, and thorough biochemical validation of results.  Biochemical 
validation required immunoblot studies, coupled with gene over-expression and 




2.10.1 Peptide ELISA 
White 96-well well microtitre plates (Costar) were coated with 1 μg per well in 50 
μL PBS streptavidin (Cambridge Bioscience) and incubated at 37⁰C overnight. Wells 
were subsequently washed 4× 200 μL with PBST, to remove excess streptavidin 
protein.  0.5 μg of biotinylated peptide per well in 50 μL of water was added and 
incubated for one hour at room temperature on a rotating table.  Following peptide 
addition, the plate was washed 6× with 200 μL PBST, before blocking with 200 µL 
of 3% BSA in PBST and incubated for one hour at room temperature with shaking.  
Subsequently the protein of interest, as indicated in the figure legend, was diluted as 
required in 50 μL of 3% BSA in PBST and added to the wells for one hour at room 
temperature.  The wells were washed 6× with PBST, as previously, and 1:1000 
dilution of the appropriate primary antibody in 50 μL of 3% BSA in PBST was 
applied to the wells and incubated for a further one hour at room temperature.  
Following a further 6 washes with PBST, before incubation with the appropriate 
HRP conjugated secondary antibody (diluted 1:1000 in 50 μL of 3% BSA in PBST) 
and incubated for 1 hour at room temperature.  A final 6 washes with PBST were 
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carried out, ECL reagents were mixed, and 50 μL applied to the well.  Luminescence 
was read using a plate reader (Fluoroskan Accent).  All experiments were carried out 
at least in triplicate, and representative of 2 experiments 
For epitope mapping experiments, diluted antibody of interest (in 3% BSA in PBST) 
was applied immediately following peptide incubation and subsequent washes.  
Incubation was carried out for one hour at room temperature before detection using 
secondary antibody and ECL as previously.  
 
2.10.2 Protein ELISA 
96-well microtitre plate was coated with 100 ng of protein (as per legend) in 50 μL of 
ELISA coating buffer (100 mM NaHCO3, pH 8.6) at 4⁰C overnight.  Subsequently, 
wells were washed with 6× 200 μL of PBST and non-specific interaction sites 
blocked by one hour incubation with 3% BSA in PBST on a shaking table.  A 
titration of the interacting protein (as per legend) was prepared with a final volume of 
50 μL in 3% BSA in PBST, and applied to well.  Protein incubation was carried out 
for one hour at room temperature with gentle agitation.  Following this, wells were 
washed with 6 × 200 μL PBST.  An appropriate primary antibody was added to wells 
(1:1000 dilution in 3% BSA in PBST), and incubated for one hour at room 
temperature.  Another round of 6 washes with PBST was carried out, and a 1:1000 
dilution of HRP-conjugated secondary antibody (50 μL) applied.  After a final 6 
washes with PBST, interaction was detected and quantified with ECL and 
luminescence detection.  All experiments were carried out at least in triplicate, and 
representative of at least 2 experiments 
 
2.10.3 Two-site sandwich microtitre assay (2SMTA)  
2.10.3.1 DyLight800 Fluorophore labelling of antibody 
MAB3.4 monoclonal antibody was conjugated to DyLight800 (DyL800) fluorophore 
(excitation at 770 nm and emission at 794 mm) using DyLight800 Microscale 
Antibody Labelling kit (Thermo Scientific) according to manufacturer’s instructions.  
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Briefly, 50 μL of MAB3.4 (1.3 mg/mL) was diluted to a final volume of 100 μL with 
5 mM Borate buffer and the protein added to a vial of DyLight800 reagent to initiate 
coupling and the reaction incubated in darkness for 60 minutes at room temperature.  
The labelled protein was applied to a spin column in microfuge format, and the 
labelled antibody separated from unreacted label by collecting the eluate after 
centrifugation.  The solution of MAB3.4-DyL800 was stored at 4⁰C for up to four 
weeks.  
 
2.10.3.2 2SMTA detection of AGR2 protein oligomerisation 
Capture immunoglobulins (unlabelled MAB3.4, 100 ng/50 μL) in the solid phase 
were adsorbed onto 96-well black walled, clear bottomed 96-well plates (Costar), 
diluted in 100 mM NaHCO3, pH 8.6 and incubated at 4⁰C, with agitation for 14-16 
hours.  Wells were subsequently washed 3-5 times with PBST, prior to non-specific 
site blocking with 200 μL of 3% BSA in PBST per well for 1 hour at room 
temperature.  Concurrently 100 ng (5.5 pmoles) of purified AGR2 protein was 
diluted to 50 μL per well in 3% BSA in PBST and incubated with the relevant 
screening condition (overlapping peptides of AGR2 or Strathclyde Institute for Drug 
Research (SIDR) library compounds) for one hour.  The blocking solution was 
removed from the plate, and replaced with the protein-condition mix solution and 
incubated on the plate for 1 hour at room temperature.  Protein was then aspirated 
and the plate washed 3-5× with PBST prior to antibody detection.  Detection 
antibodies, MAB3.4-DyL800 were diluted to 150 ng per well in 3% BSA in PBST 
and 50 μL per well incubated on the wells for 1 hour at room temperature.  Plates 
were washed a final 3-5× with PBST prior to detection.  DyL800 fluorophore was 
directly detected on the Licor Odyssey with 750 nm laser excitation and emission at 
800 nm.  Images were analysed and quantified with the Odyssey Sa software (Licor). 
Alternatively, to measure the oligomerisation status of mutant AGR2 proteins, 500 
mL pellets of bacteria induced to express the protein of interest, prior to lysis and 
sonication.  The lysed bacteria were centrifuged to isolate the soluble fraction.  10 μL 
fractions of each mutant crude lysate was separated by SDS-PAGE, 
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electrophoretically transferred to nitrocellulose membrane and probed with the 
DyL800-labelled MAB3.4 antibody.  Using the Licor Odyssey system, an 
immunoblot was used to relatively quantify and normalise AGR2 protein 
concentrations.  The 
2S
MTA was carried out as previously, and normalised AGR2 
protein applied in the mobile phase, prior to DyL800-MAB3.4 and near-IR detection. 
 
2.10.4 Oligomer cross-linking using DSS 
50 μL of normalised AGR2 induced crude bacterial lysates, or mutants thereof, were 
incubated with titrations of Disuccinimidyl suberate (DSS) from 5-1000 μM for one 
hour at room temperature.  The cross linking reaction was quenched following this 
incubation by the addition of 2.5 μL 1 M Tris pH 8.0.  Next, SDS-PAGE sample 
buffer was added, and samples heated for 5 minutes at 95⁰C, prior to SDS-PAGE and 
subsequent immunoblotting to detect quaternary structure.   
 
2.11 Protein crystallisation methods 
 
Screens were prepared in 24-well or 96-well plates (Linbro).  Mother liquor well 
solutions were empirically defined, or pre-prepared from commercial crystallisation 
screens as described (Molecular Dimensions).  Purified protein was concentrated 
using spin columns with a molecular weight cut off of 5 kDa, to the required 
concentration.  Droplets were prepared consisting of 50% purified protein and 50% 
well solution either by hand or using the Oryx 8 robot (Douglas Instruments).  
Crystal presence and phase separation were first analysed by the operator, or 
alternatively for high throughput using CrysCam X-Y stage coupled with CrysScore 
software (Art Robbins Instruments).  Crystallisation conditions were incubated at 
18⁰C.  Seeding solutions could be used to initiate protein nucleation, using a 
condition which shows small protein micro-crystals diluted 1:10 in protein buffer 
than supplemented to the drop at 10% of final volume prior to incubation.  Following 
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incubation, crystals were dipped in a 40% PEG freezing solution prior to immersion 
in liquid nitrogen.  Crystals were exposed to X-ray at Diamond Light Source. 
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Chapter 3: Generation and Characterisation of 
an Isogenic Stable Cell Panel for the 




The efforts of the Human Genome project, and other studies to map the genome 
sequence of other organisms, have provided us with data of the existence of tens of 
thousands of genes and their potential expressed products.  The human genome is 
estimated to consist of 20,000 – 25,000 unique genes (290) rather than the ~100,000 
originally estimated (291).  The biological machinery of the cell is diversified by the 
numerous post-translational modifications, secondary promoters, alternative splice 
sites and differential transcription termination, resulting in an estimated total number 
of proteins to be over one million (292-294).  Despite this plethora of information, 
the understanding of essential processes is staggeringly limited, such that thousands 
of known proteins remain functionally lacking description, almost ten years since 
their first elucidation.  Understanding the specific function of a protein in a signalling 
system might provide an insight into a physiological process, and the understanding 
of therapeutic strategies for a protein prognostic of a disease outcome.  The network 
of regulatory systems, and resultant signalling cascades, mediated through protein-
protein interactions can provide a comprehensive picture of derived protein function.  
Previously described functions of Anterior Gradient-2 include roles in development 
(149;151;159;207;244;295), endoplasmic reticulum stress response (165;179), 
protein maturation (165;233) and cell growth (150;164;244;249;270), coupled to 
this; complexities in the sub-cellular distribution of the gene product (187;188), 
present an intricate network of interplay which describes the diversity of AGR2-
associtated pathways.  The identification of AGR2 as an over-expressed feature in a 
vast range of human cancers, its discovery as an inhibitor of p53 (150), and the 
perturbation of the EGF receptor cascades (194) has driven efforts to deconvolute the 
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signal transduction pathways influencing pro-oncogenic functions to assess AGR2 as 
a possible therapeutic target for novel anti-cancer drugs.  Upstream induction by 
chemical agents promoting endoplasmic reticulum stress has been thoroughly 
characterised (179).  Additionally, the transcriptional induction of the agr2 gene by 
oestrogen (175;176) and anti-oestrogen drug compound, tamoxifen (174;272), as 
well as serum independent signals (178) have been well described.  Conversely, agr2 
suppression by the SMAD4-TGFβ signalling axis highlight an oestrogen 
independence to cell signalling (180). These build on the fields understanding of 
AGR2 induction and purpose in the stress response, while addressing the subsequent 
molecular effect of this induction remains elusive. 
The majority of studies interrogating downstream AGR2 effects have focussed on the 
direct interaction between AGR2 and protein interaction partners, to build an 
interactomic network which describes the interplay between molecules resulting in 
the global AGR2-dependent output (Table 1-2).  For example, the identification of 
AGR2 co-immunoprecipitation with MUC2 (165) has been used to characterise the 
function of AGR2 as an ER chaperone protein, assisting in the maturation of cysteine 
rich nascent peptide derivatives.  The yeast-2-hybrid approach has identified C4.4A 
and α-dystroglycan (172), as potential co-factors involved in the metastatic nature 
associated with AGR2; however these interactions have not been thoroughly 
biologically validated as bona fide protein-protein interaction partners in human cells 
(199).  Due to the false positive prone nature of yeast-2-hybrid studies, thorough 
validation of partners is necessary to demonstrate biological significance (296).  
Subsequently, the ATP binding protein Reptin has been identified by yeast-2-hybrid 
followed by thorough validation providing the first comprehensively confirmed 
AGR2 binding protein (199); such that the interface of AGR2 binding to Reptin has 
been mapped to a specific domain, amino acid residues 104-110, representing a 
divergent loop shared with ERP18.  Accordingly, AGR2 is thought to have some 
regulatory effects on the many functions of Reptin (ATPase activity, ATP binding, 
helicase functions, telomerase/Pontin binding, APPL1/2 binding, TIP60 interactions 
among others).  Ongoing cellular studies will determine whether Reptin forms a key 
determinant in the cell signalling pathways modulated by AGR2 expression. 
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An alternative approach to defining the AGR2 interactome sought the use of a 
combinatorial phage-peptide library to search for a high affinity peptide motif 
binding to AGR2 (275).  AGR2 was shown to have peptide binding activity by 
ELISA and complementary Western blot assays to the peptide motif (S/T)xIhh 
(where x represents any amino acid, and h is an amino acid with a hydrophobic side 
chain).  Proteins containing these motifs could diversify the AGR2 interactome 
landscape.  The (S/T)xIhh peptide expressed in a GFP-fusion vector could increase 
AGR2 protein levels and induce p53 activity (187).  Indeed several proteins have 
been identified containing these motifs and are subject to ongoing study (Table 3-1.  
Personal discussion E. Murray, M. Maslon, J. Nicholson, M. Lawrence and T.Hupp).  
In addition, two groups concurrently utilised a protein crosslinking approach to 
identify interacting partners of AGR2 in close proximity using cell permeable 
covalent crosslinking agents, prior to immunoprecipitation and identification by mass 
spectrometry (202;203). Despite observing high molecular weight cross-linked 
complexes, the dominant crosslinked partner protein in these studies was identified 
as AGR2 itself, signifying that AGR2 appeared to form homodimeric complexes in 
vivo and in vitro. 
Table 3-1 Proteins containing the (S/T)xIhh motif for further study of AGR2 interactome 
Protein Motif Role 
TMEM67/Meckelin PTPIFY Transmembrane protein 
involved in cilia formation 
SMG-7 LPTLIYY Non-sense mediated decay 
factor 
HECTD1 STIFY E3 ligase 
TMEM63B PTIVYY Transmembrane protein 
HERC2 LTTEFG E3 ligase 
 
To date few studies have begun to try to disentangle the molecular effect of AGR2 
expression in cancer pathways.  Dong et al. (194) describes AREG as an effector 
molecule of AGR2, implicating the Hippo signalling pathway co-activator, Yap-1.  
AGR2 induces the nuclear localisation of Yap-1, thought to be a dephosphorylation 
effect, and resultant expression of Yap-1 transcriptional targets, including AREG.  
The resultant elevation of RNA and protein expression of AREG, but not that of 
other EGFR ligands, is the major stimulatory factor of the EGFR signalling pathway, 
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and could explain the increased cell proliferation and anchorage-independent growth 
observed in previous studies (164;218).  This insightful study begins to develop the 
molecular mechanisms whereby AGR2 achieves cellular effects, but does not look 
broadly at the cell-wide effect of AGR2 up-regulation.   
The difficulty of interrogating the downstream effect of AGR2 expression lies in the 
development of appropriate models.  In vitro transient transfections and RNAi based 
methodologies present a rather crude mechanism to measure AGR2 output since 
there is a lack of acute control of the level of gene expression exogenously induced 
or silenced.  As such, detected outputs may be as a result of stress mechanisms 
induced in the cells following modified protein synthesis machinery, or stress 
pathways induced by the transfection reagent itself.  In this study, I present a 
methodology to prepare a stable cell line, constitutively expressing AGR2 for use in 
a systems biology approach to begin to understand the function of AGR2 
overexpression in multiple pathologies.  I also present data on the engineering of a 
stable cell line, and characterisation therein of a novel tool for the interrogation of 
AGR2 signal transduction. 
 
3.2 Results  
 
3.2.1 Preparation of a cell line incorporating the Flippase 
recombination target site into the genome 
The AGR2-negative A375 human melanoma cell line was chosen as the model 
system to define the ability of the artificially-recombined AGR2 allele to alter 
proteostasis and reprogramme a cell into a pro-oncogenic mode.  The cell model 
exhibits a well profiled wild-type p53 pathway responsiveness (297), toll-like 
receptor 3 (TLR3) interferon system signalling (298), cell cycle checkpoint pathway 
and DNA damage responsive network that provides a template from which the 
introduction of the AGR2 gene product can be evaluated through alterations in 
homeostatic growth control, and link to the p53 pathway.  We sought to use a cell 
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line which stably integrated a single gene allele, using a promoter system that 
expressed relatively modest levels of the target gene to determine how low level 
introduction of an onco-protein can alter cell signalling pathways involved in the 
phenotypically described activities of AGR2.   
The initial stage of the Flp-In system requires the integration of a single Flippase 
recombination target (FRT) site into the genome of the host cell line (Figure 3-1A).  
A375 cells were first transfected with the pFRT/lacZeo plasmid prior to subculture 
into single clones for analysis of single site integration.  The pFRT/lacZeo contains a 
single 34 base pair FRT sequence which serves as the target for Flp recombinase 
(299-301), and a lacZ-Zeocin fusion gene under the control of an SV40 promoter 
which codes for Zeocin antibiotic resistance (Figure 3-1B).  Successful integration 
permits the isolation and proliferation of zeocin-resistant foci.  Resistant foci were 
isolated (24 in total), genomic DNA extracted and screened by Southern blot 
(protocol devised and carried out by Dr. Khaldoon Al-Sammam, University of 
Edinburgh).  Genomic DNA was digested with Hind III which digests at a single site 
within the minimal FRT site (but not within the lacZ gene) of the pFRT/lacZeo, 
before being probed with a 
32
P radio-labelled probe specific for the lacZ gene.  Due 
to the random nature of genetic transfection, the pFRT/lacZeo plasmid may integrate 
numerous times into the genome of the host cell line, and it is imperative at this stage 
to identify and discard clones which contain more than one FRT site.  Multiple FRT 
sites may result in increased chromosomal rearrangements or unexpected 
recombination events as a result of complementary FRT sites being in near 
proximity.  Successful integration is confirmed by the appearance of a single band in 
the Southern blot, corresponding to the 400 base pairs of the lacZ gene.  Mammalian 
cells do not endogenously contain a lacZ gene; therefore clones containing 
pFRT/lacZeo could be easily identified.  The Southern blot band varies depending on 
the location within the genome and the different sizes of the Hind III fragments.  
Selected results (Figure 3-1C) indicate clones with single FRT site integration (clone 
1), no integration (clone 2, possible error with restriction digest and/or probe 
hybridisation) and multiple FRT site integration (clone 3) which demonstrate distinct 
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location within the genome of the host cell line.  In this representation, only clone 1 
can be progressed for further analysis. 
 
Figure 3-1 Incorporation of the FRT site into the A375 host cell line genome  (A) Schematic 
illustrating the transfection of A375 cells with pFRT/lacZeo plasmid and the integration of the single 
FRT site into host cell genome.  The lacZ-Zeocin fusion gene incorporated into the vector allows 
selection for Zeocin-resistance.  (B) The minimal FRT site consisting of 34 bp sequence containing 
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the two imperfect 13 bp inverted repeats separated by an 8 bp spacer that includes an Xba I restriction 
enzyme digest site.  The Flp recombinase recognises this site and mediates recombination between 
two FRT sites of interacting DNA molecules, the cleavage sites are signified by the two asterisks (*). 
(C) Southern blot of A375 cells transfected with pFRT/lacZeo and cultured in medium containing 400 
μg/mL Zeocin for 14 days.  24 single surviving clones were isolated and repopulated.  The DNA of 
these clones were extracted and digested with Hind III (contains a single restriction digest site within 
the FRT site), followed by analysis using a 
32
P radioactive labelled probe specific for the lacZ gene.  
Results show 3 representative clones with a single FRT site integration (black arrows), which 
demonstrate a distinct location within the host cell lines.  In some Zeocin resistant cells, no 
identifiable FRT insertion, as in clone 2, was detected (possible error in digestion and probe 
hybridisation), and some incorporate more than one FRT site, as clone 3.  Only single integrants were 
progressed.  
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 3 – Generation and Characterisation of an Isogenic Stable Cell panel for the 
Investigation of AGR2 Function  94 
3.2.2 Validation of the normal functioning signalling 
pathways of the A375-FRT cell line 
Once single site integrants were confirmed, the clonal cell line was tested for normal 
functioning pathways (Figure 3-2).  It had be previously been shown that AGR2 
functions to promote cisplatin resistance in xenograft models (248), and the protein 
can be over expressed in cancers which are targeted for therapy using cisplatin.   
Host FRT-containing cell lines were challenged as to whether or not they retain the 
ability to activate the p53 tumour suppressor, and resultant p21 up-regulation in 
response to cisplatin-induced DNA cross-linking (Figure 3-2A).  In addition, the 
TLR3-responsive interferon system represents a second p53-dependent signal 
responder; the treatment of cells with poly-inosinic:poly-cytidylic acid (poly I:C) 
stabilises the IRF-1 protein (Figure 3-2B, data courtesy of Dr K. Al-Samman), 
indicating that the parental host cell line retains p53 signalling integrity (297;298).    
Poly I:C is a synthetic analogue of double stranded RNA, allowing simulation of 
viral infection, This is recognised by the TLR3-receptor pathway and subsequent 
induction of cytokines (302).   
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Figure 3-2 Evaluation of the integrity of the A375-FRT parental cells  (A) Evaluation of a 
functional wild-type p53 pathway was defined by the ability of p53 to be activated by incubating cells 
with 20 μM cisplatin over a 24 hour time course.  The induction of p53 protein results in a subsequent 
induction of p53 activity-dependent gene product p21.  Cells were lysed in 1% NP40 lysis buffer and 
20 μg of protein lysate was loaded onto a 13.5% polyacrylamide gel and probed for p53, p53-
dependent activity using p21-WAF1.  (B) Cells also demonstrate an intact IRF-1 response to 25 
μg/mL poly I:C treatment over a 6 hour timescale, β-actin is shown as a loading control.   
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3.2.3 Cloning of the AGR2 gene into the FRT-site containing 
expression vector and engineering of the constitutively 
expressing AGR2 experimental cell line.  
Concurrently, utilising the Gateway technology (Life Technologies, UK) the gene of 
interest can be PCR amplified from a template using prepared forward and reverse 
primers incorporating the attB sites (Figure 3-3).  The PCR product is then 
recombineered, using the BP clonase enzyme, into the empty pDONR221 backbone 
vector which has the complementary attP sites, prior to being transformed into E. coli 
and selected for kanamycin resistance.  This process removes the ccdB/CmR from 
the pDONR221, allowing the insertion of the gene of interest (GOI), and forms the 
attL sites important for the second step of the process.   Once positive clones were 
identified, isolated and DNA extracted, the second reaction, the LR reaction, was 
prepared.  This involves incubating the entry clone (pDONR221-containing GOI) 
with the destination vector, and the LR clonase enzyme which catalyses the 
recombination of gene of interest via the attL sites with the attR sites of the 
destination vector, in this case pEF5/FRT/V5-DEST.  The pEF5/FRT/V5-DEST 
vector contains key elements for the expression of the gene of interest. (i) The FRT 
site in the backbone is identical to that of the pFRT/lacZeo, and subsequently 
mediates the integration into the host cell (Figure 3.1B); (ii) the bovine growth 
hormone (BGH) poly-adenylation sequence allows the proper termination and 
processing of the recombinant plasmid and (iii) the hygromycin resistance gene, 
which lacks a promoter and an ATG initiation codon.  Once the host cell line is 
confirmed to only integrate one FRT site, and the gene of interest is cloned into the 
FRT-site containing vector then the reagents for the engineering of a stable cell line 
are prepared. 
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Figure 3-3 Schematic of the Gateway cloning technology  allowing the recombination of the gene 
of interest, in this case AGR2 or AGR3, into the Flippase Recombination Target-containing 
destination vector, pEF5/FRT/V5-DEST.  
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The A375-FRT host cell line was co-transfected with pEF5/FRT/V5-DEST 
containing the gene of interest, and pOG44 in a ratio of 1:9 (Figure 3-4).  pOG44 
vector expresses the Flp-recombinase enzyme which recognises the FRT sites 
integrated into the A375 cell genome and the protein expression vector, and catalyses 
the homologous recombination event.  This recombination event incorporates the 
gene of interest into the host cell genome, while bringing the SV40 promoter and 
ATG initiation codon into frame with the hygromycin resistance gene and inactivates 
the lacZ-Zeocin fusion gene.    The AGR2 gene is also placed under the control of 
the strong regulatory human cytomegalovirus (CMV) promoter from the pEF5/FRT 
backbone.  This is a key requirement due to the presence of only a single allele of the 
AGR2, and as a result the expression of the gene product at an appropriate level for 
biochemical detection.    The recombination event is carried out for 24 hours at 32⁰C, 
the optimal temperature for the catalysis of the reaction.  Subsequently, media was 
then exchanged and challenged with hygromycin-supplemented media for selection 
of positively recombineered cells.  Following this step, all hygromycin resistant foci 
are isogenic, containing a single integrated copy of the gene of interest, and all 
exhibit this gene at the same location in the genome under the control of the same 
promoter. 
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Figure 3-4 Illustration of the engineering of stable cell lines stably expressing a gene of interest 
utilising Flp-In methodology.  A375 cells integrating the single FRT site are co-transfected with 
pEF5/FRT/V5-DEST expression construct containing the gene of interest and pOG44 plasmid 
expressing the Flp-recombinase enzyme, as indicated.  Following hygromycin antibiotic selection, 
isolated cells are assayed for the expression of the protein of interest.   
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3.2.4 Characterisation of the A375-FRT-AGR2 cell line 
Following the hygromycin selection of isogenic cells, cell lysates were then assayed 
for the expression of the protein of interest (Figure 3-5A) and Zeocin-sensitivity 
(data not shown).  As expected, the parental cell line expresses no AGR2 protein, 
while the cells engineered to express AGR2 exhibits distinct constitutive levels of 
expression.  Expression levels of AGR2 in the A375-FRT-AGR2 cell line were 
analysed relative to the expression levels of known endogenous AGR2-expressing 
cell lines (Figure 3-5B).  The breast cancer cell lines MCF7 and T47D, oesophageal 
cancer line OE19 and lung cancer cell line A549 are all commonly used in tumour 
cell studies and in vitro models of AGR2, all demonstrate expression levels >5-fold 
greater than that of the experimentally engineered cells.  This is an essential 
characteristic of these model cell lines such that, it is now obvious that AGR2 protein 
is not being expressed significantly above the physiological level that we might 
expect from a transient transfection methodology.  Rather, the relatively low level 
expression of AGR2 allows the interrogation of whether subtle expression of AGR2 
reprogrammes cell signalling and/or signal transduction pathways. 
Subsequently, the role of AGR2 following ER stress could then be assessed.  AGR2 
as an ER-resident PDI has previously been discussed (1.3.4.1), and ER stress 
response is published to impinge upon the function of AGR2 (179).  The report by 
Higa et al. suggests that RNAi silencing of AGR2 restricts the unfolded protein 
response (UPR) via a reduction in the expression of Bcl-2 suppressor protein CHOP 
(CCAAT/-enhancer-binding protein homologous protein).  In the synthetically 
engineered cell lines (Figure 3-5C) an enhanced CHOP response is apparent as a 
result of AGR2 expression relative to the AGR2-negative cells.  Accordingly, we 
suggest that these cells are mimicking authentic AGR2-expressing cells in respect to 
ER stress responsiveness, and that the single gene introduction of AGR2 is enough to 
recapitulate the in vivo ER chaperone function of AGR2.     
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Figure 3-5 Characterisation of the A375-FRT-AGR2 experimental cell line examining 
expression of AGR2 and the effects of tunicamycin treatment on CHOP levels.  (A) Immunoblot 
comparing the expression of AGR2 of the A375-FRT-AGR2 cell line, following engineering of stable 
expression in Figure 3-4, relative to the parental A375-FRT cells.  (B)  Comparison of the expression 
levels of the AGR2 isogenic cell population with authentic endogenous AGR2 expressing cell lines 
commonly used in vitro studies, MCF7, OE19, A549 and T47D.  10 μg of protein lysate from each 
cell line are shown, with an additional lane loaded with 50 µg of A375-FRT-AGR2 lysate. β-actin is 
shown as a loading control.  (C)  Measuring the integrity of the FRT-AGR2 by examining the effects 
of tunicamycin on the expression levels of CHOP.  Previous studies identified the first clear evidence 
of the role of AGR2 in response to ER stress (179).  A time course of tunicamycin at 1 μg/mL 
demonstrates that AGR2 presence elevates the expression of CHOP in response to stress (comparing 
lanes 7 and 8), consistent with the published reduction in CHOP levels induced by tunicamycin when 
AGR2 is silenced.  These data suggest that the artificial A375-FRT-AGR2 cell line faithfully 
recapitulates the ER stress response. 
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Having established that the FRT-FlpIn cell system allows authentic recapitulation of 
the p53 response to genotoxic stress and AGR2 ER stress responsiveness, effects of 
AGR2 expression on cell growth were next investigated.  The p53-suppressive nature 
of AGR2 (150) and effects of AGR2 overexpression on cell growth are broadly well 
documented (164;244), along with the influence of AGR2 on colony formation 
(175).  It was therefore necessary to elucidate whether our isogenic, AGR2 over 
expressing cells could influence cell proliferation and invasion.  A scratch assay 
(Figure 3-6) was applied (protocol devised and carried out by Dr. R. Hrstka, Masaryk 
Memorial Cancer Institute, Brno), in which a 100% confluent monolayer of the 
control and AGR2-expressing cells are scratched, and at regular intervals analysed to 
quantify the rate of wound healing (303).  The data suggest that even subtle 
expression of AGR2 increases the rate of proliferation and migration compared to the 
AGR2-null cell line.  Over the course of the 4 and 8 hour time points, AGR2-
expressing cell migrate and proliferate into the wound significantly more readily than 
the non-expressing cell line, such that the wound is completely healed by 8 hours of 
growth of the AGR2-cells and this is not evident until 4 hours later in the parental 
cells.   
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Figure 3-6 Analysis of A375-FRT-AGR2 cell proliferation and migration compared to the 
AGR2-null cell line, using a wound healing assay.  A confluent monolayer of each cell line was 
scratched with a 10 μL pipette tip at zero time point.  Images were then recorded at four hour time 
points for the duration of the study.  Recorded images were then analysed by TScratch software 
(ETH) (304) to quantify proliferation.  
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3.2.5 The development of a panel of engineered cell models 
to define the extent to which AGR2 can alter 
proteostasis. 
Having characterised the experimental engineered cell line in terms of p53 response, 
AGR2 responsiveness to ER stress, and cell proliferation/migration, we next set out 
to determine how a key domain of AGR2 can impact on cell signalling (Figure 3-7 
and 3-8).  As the only known domain of AGR2 that regulates localisation is the C-
terminal ER-retention motif (187;188), we proceeded to engineer a panel of cell lines 
that either integrated the C-terminal ER-retention optimised AGR2-KDEL mutant 
(187;188), or the C-terminal deletion mutant, AGR2-ΔC, containing a four amino 
acid deletion of the wild-type ER retention motif (188) instead of the wild type non-
optimal KTEL motif.  Quantitative real-time PCR (qPCR) was employed in order to 
validate the presence (or absence, in the case of the control cell line) of the AGR2 
isotype (Figure 3-7).  These data demonstrate that in all of the experimental cases, 
the AGR2 gene is present (Figure 3-7A) compared to the FRT- parental cell (black 
line).  Using the 
ΔΔ
Ct method of normalisation to GAPDH gene (Figure 3-7B), we 
can see that relatively similar levels of AGR2 and mutant mRNA are present in the 
engineered cells (Figure 3-7C), and that the AGR2 gene is absent from A375-FRT 
parental cells thus no mRNA is detected.  Due to the isogenic nature of the cell lines, 
and the fact that all AGR2 constructs were recombined into the same A375-FRT 
clone, variation in mRNA levels may be as a result of a variety of factors including 
RNA degradation during extraction, mRNA decay, and hybridsation effects during 
PCR cycles. 
Additionally, the C-terminal mutant panels were assayed for protein expression and 
localisation (Figure 3-8).  Using confocal immunofluorescence microscopy to 
describe subcellular protein distribution, it was possible to identify populations of 
wild-type AGR2 protein (Figure 3-8A, top panel, [i]) frequently co-localised with the 
endoplasmic reticulum marker (protein disulphide isomerase, PDI) in a perinuclear 
location (Figure 3-8B, top panel).  However, wt-AGR2 does not appear to always co-
localise with PDI, characterised by some regions of red (488 nm) staining but lacking 
the green (594 nm) staining of the ER marker.  AGR2-ΔC (Figure 3-8A, [ii] and 3-
8B, middle panel) is minimally detectable within the cell, possibly only indicating 
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newly synthesised protein, as it is expected that the majority of the protein will be 
secreted into the extracellular milieu (188).  Conversely, AGR2-KDEL mutant 
(Figure 3-8A, [iii] and 3-8B), exhibits a more prominent intracellular localisation and 
shows significant, almost complete, co-localisation with PDI.  This indicates, as 
expected, that mutating the wild-type KTEL to the canonical KDEL motif locks the 
protein into the ER compartment.  Finally, to ensure that AGR2-ΔC was in fact being 
trafficked out of the cell, and not rapidly degraded by cellular machinery, whole cell 
lysate and concentrated conditioned tissue culture media from wt-AGR2 and 
AGR2ΔC expressing cells were separated on a 12% polyacrylamide gel and 
immunoblotted for AGR2 using short and long exposure times (Figure 3-8C).  These 
data confirm that a small proportion of AGR2-ΔC is present intracellularly, while the 
majority of protein is trafficked to the extracellular environment.  Wild-type AGR2 is 
clearly apparent within the cell, and only a very small amount evident in the 
conditioned media.  The latter data are consistent with a previous report that AGR2-
ΔC is secreted (188) and further suggests that this engineered A375-FRT cell model 
reconstitutes an authentic AGR2 trafficking response .    
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Figure 3-7 qPCR of C-terminal mutants of AGR2 compared to the AGR-null parental cell line.   
RNA was isolated from the four cell panels and the extent of (A) agr2 and (B) gapdh mRNA 
evaluated.  The data are plotted as the hybridisation signal as a function of PCR cycle number and an 
average of three experiments.  (C) Using the 
ΔΔ
CT method of qPCR data normalisation, an estimate of 
AGR2 mRNA for each cell line was estimated as a percentage of wtAGR2.  
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Figure 3-8 Localised subcellular distribution of wt-AGR2, AGR2-ΔC and AGR2-KDEL mutant 
proteins using confocal microscopy and conditioned concentrated tissue culture media.  (A&B) 
Cell lines were grown to ~70-80% confluency on glass cover slips before fixing and permeabilisation 
as per Methods.  AGR2 mouse monoclonal antibody was used to probe for AGR2 proteins, and 
detected by goat anti-mouse secondary antibody conjugated to a 488 nm fluorophore.  A rabbit 
polyclonal antibody protein disulphide isomerase (PDI, Enzo) detected by a 594 nm conjugated 
donkey anti-rabbit secondary provided an endoplasmic reticulum marker.  The nucleus was stained 
using TOPRO-3 (Life Technologies).  Microscopy was carried out using an Olympus FV1000 
confocal microscope with a 60 × oil immersion objective lens and LAS-AF software.  (C) 
Immunoblot of parental FRT, wt-AGR2 and AGR2-ΔC expressing cells demonstrate that, in lanes 1-
3, wt-AGR2 is more easily detectable than AGR2-ΔC, which is minimally detected, within the cell 
lysate.  By contrast, in lanes 4-6, when conditioned media from tissue culture was collected and 
concentrated 50-fold using 10 kDa molecular weight cut off filters, and loaded to a 12% 
polyacrylamide gel followed by AGR2 detection using an AGR2 monoclonal antibody the majority of 
AGR2-ΔC was evident secreted into extracellular milieu, compared to wt-AGR2 were only a very 
small amount was detected extracellularly.  
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Further characterisation of the wt-AGR2 and C-terminal mutant expressing cell lines 
employed the use of a novel cell growth assay to measure real-time changes in 
proliferation and cell doubling rate of engineered cells compared to the AGR2-null 
cell line (Figure 3-8A).  The xCELLigence system (Roche), allows real-time label-
free monitoring of cell growth by non-invasively measuring electrical impedance of 
cells cultured on gold micro-electrodes (305).  As cell number increases, the 
resistance of the circuit correlates, resulting in a calculated quantitation of 
proliferation as cell index.   Cells are seeded into microtiter plates, incorporating gold 
micro-electrodes, in equal number and in quadruplicate, over a period up to 96 hours 
(or until confluency has been achieved).  Figure 3-8A[i] presents raw cell growth 
data of wild-type AGR2, AGR2- ΔC and AGR2-KDEL indicating that regardless of 
the subcellular localisation of AGR2, a cell growth benefit is achieved just through 
expression of this gene.  Comparing wt-AGR2, AGR2-ΔC and AGR2-KDEL 
expressing cells with the AGR2-null cell line, all have an increased rate of cell 
proliferation [ii] and a reduced cell doubling time [iii].  For clarification that the 
process of stable cell engineering does not select for cells with increased 
proliferation rate, a further cell model is described (Figure 3-8B).  The FRT-STOP 
cell line in this case expresses the N-terminal residues of AGR2, before truncating 
the gene product after only four amino acid residues (MEKI-STOP).  This allowed 
an alternative control cell line which exhibits the integration of a gene, and selection 
agent resistance, without the gene product effect of gene expression.  In this case, the 
FRT-STOP cell line did not provide any proliferative benefit to the cell line ([ii] and 
[iii]) compared to the wt-AGR2 expressing cells, and mimicked cell growth 
characteristics of the parental cell line.  Collectively, these data indicate that the 
specific introduction of the AGR2 gene, irrespective of the subsequent subcellular 
localisation, promotes a proliferative nature of the cell line characteristic of an 
oncogene. The data observed are in agreement with previous studies highlighting the 
detection of AGR2 in multiple subcellular compartments in tumours, as regardless of 
location AGR2 appears to be promoting an increase in cell growth.  However, it also 
conflicts with previous data suggesting that the C-terminal motif is essential for 
AGR2 function (188).  
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Figure 3-9 Analysis of the expression of the AGR2 protein, and its subcellular localisation, on 
cell growth using xCELLigence cell proliferation assay.  5000 cells were seeded into wells of a 
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microtiter plate with gold micro-electrodes (E-plate-VIEW, Roche) in quadruplicate and incubated at 
normal cell growth conditions (37⁰C, 10% CO2) for up to 96 hours, or 100% confluency.  Electrical 
impedance was measured in real-time every 15 minutes, mean cell index values were calculated and 
plotted as a function of time. (A) (i) A375-FRT cell index was compared to isogenic cells 
incorporating the wt-AGR2, AGR2-ΔC and AGR2-KDEL gene.  Data analysis allows the calculation 
of (ii) cell proliferation (change in cell index as a function of time) and (iii) cell doubling time (the 
amount of time taken for the cell index to double).  Indicating that the expression of the AGR2 gene in 
all cases promotes an increase in cell growth, despite differences in subcellular distribution (as seen in 
Figure 3-7).  The asterisk (*) indicates significance p<0.05 in a two-tailed unpaired t-test.  The 
experiment was carried out in quadruplicate, and data is representative of twice replicated 
experiments.  (B)(i) Comparably, a FRT-STOP mutant expressing cell line was engineered to ensure 
that the selection of stably integrating cell lines was not biasing the proliferation of cells with 
increased growth rate.  FRT-STOP cells expressed a truncated wt-AGR2 motif but the premature 
integration of a stop codon after the first four amino acid codons.  This additional control cell line 
exhibited proliferation rate (i) and cell doubling (ii) characteristics similar to the AGR2-null parental 
cell line, and distinct from the wt-AGR2 expressing cell line.  The asterisk (*) indicates significance 
p<0.05 in a two-tailed unpaired t-test.  The experiment was carried out in quadruplicate, and data is 
representative of twice replicated experiments.  
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3.2.6 The effect of AGR2 expression on basal transcription of 
the cell 
In order to define the dominant pro-oncogenic pathways that are altered by AGR2 
expression, we first evaluated whether wt-AGR2 altered the basal transcription of the 
cell.  There is evidence, indeed, that forced expression of AGR2 by ectopic 
expression or RNAi silencing of the endogenous protein from AGR2-positive cells 
can regulate EGFR pathway activation (194).  This was achieved using an Illumina 
HT-12 BeadChips transcriptome microarray to screen the mRNA expression of > 
25,000 genes using 48,000 probes.  As controls for this experiment, cells expressing 
AGR2-ΔC, to control for extracellular effects (while also envisaging the use of data 
for the effect of secreted AGR2 as a mitogen affecting transcriptional pathways), or 
AGR3, to control for specificity, were engineered concurrently, using the same 
methodology and parental cell stock, with cells expressing wt-AGR2 (Figure 3-10).  
From each cell line, RNA was extracted and biotin-labelled in three independent 
studies to control for user bias and RNA degradation prior to hybridisation.  
Bioinformatic analysis deconvoluted complex data using Rank Product analysis with 
a 5% false discovery rate (Dr. Andrew Sims, University of Edinburgh).  All 
transcriptomics data is provided in Appendix 1.  Due to the reasoning that cell lines 
are isogenic, except for the expression of the exogenous experimental gene, only 
small specific changes in gene expression were expected. Broadly, the gene 
expression data (Figure 3-10A) demonstrate that the synthesis of wt-AGR2 has a 
negligible effect on global transcriptional homeostasis, presenting a very similar 
signature to the A375-FRT-parent cell and the AGR2-ΔC expressing cell, with only 
27 genes expression diverging from the non-AGR2 expressing cell line (Figure 3-
10B). Comparatively, the AGR3-expressing cell exhibits an almost 10-fold increase 
in gene transcription (229 genes) modulated in response to AGR3 presence.  Of the 
20 genes whose expression is altered following wt-AGR2 expression, all indicate 
significant up regulation, and one gene cluster  of closely related genes demonstrates 
significant over-representation, the GAGE genes (family members GAGE2B , 4 
(shared with AGR2-ΔC expressing cells), 5, 6, 12B,12C, 12F, 12G,12I and 12J).  
These are defined as cancer/testis genes, not expressed in normal tissues outwith the 
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highly tissue-restricted expression exhibited exclusively in normal testis and in a 
large proportion of tumours with varying histological origins (306). 
Gene expression analysis alone is not generally accepted as proof of transcriptional 
effect unless further validation is sought.  Due to the many steps and variations in 
microarray processing errors can be propagated due to background fluorescence, 
uneven hybridisation, fluorophore bleaching by light, temperature variation, 
hybridisation time and dye leaking (307).  Therefore, a qPCR methodology was 
undertaken to validate data prior to further study of the effect of wt-AGR2 
expression on the target genes (Figure 3-11).  Somewhat surprisingly, the small 
cluster of GAGE genes that exhibited significantly higher expression in the wt-
AGR2 expressing cells compared to the parental and AGR2-ΔC cells could not be 
reproduced by qPCR (Figure 3-11).   
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Figure 3-10 Analysis of transcriptional effects of AGR2 gene expression.   (A) Heat map of 
differential expression of genes and gene probes from Illumina HT-12 v3 BeadChip microarray 
indicating biotin labelled isolated transcribed mRNA from the four conditions of parental A375-FRT 
cells, A375-FRT-wtAGR2, A375-FRT-AGR2ΔC and A375-FRT-AGR3 cells, reproduced in 
triplicate.  Green indicates down regulation and red up regulation of hybridisation signal relative to the 
parental non-AGR expressing cell line mRNA.  (B) Venn diagram demonstrating the overlap and 
individual gene expression changes, relative to the parental cell line, of isogenic cells expressing wt-
AGR2, AGR2-ΔC and AGR3.  
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Figure 3-11 Normalised quantitative real-time PCR of selected genes identified from the 
Illumina HT-12 gene expression analysis   (Figure 3-10), whose expression is up regulated 
following wt-AGR2 expression in isogenic cells relative to AGR2-null cells.   
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3.3 Discussion 
 
The overexpression of AGR2 protein in a diverse range of tumour subtypes (205) 
makes it a compelling protein to begin to understand its role in cell growth, cell 
transformation and migration (164).  Pro-oncogenic properties of AGR2 whereby it 
can exhibit these functions are thought to include its chaperone function as a protein 
disulphide isomerase in the ER, and the ability to mediate induction of oncogenic 
signals like epidermal growth factor (EGF) and the suppression of the tumour 
suppressor gene, p53 (150;188;194).  However, mechanisms and co-factors 
employed to perform these roles are poorly understood.  The majority of studies 
interrogating molecular basis of AGR2 signalling comes primarily from protein-
protein interaction yeast-2-hybrid studies which have implicated C4.4A, α-DAG 
(172) and Reptin (199), and others requiring further validation (169).  At present, 
interactomic studies have highlighted the complexity of AGR2 function, with roles in 
the ER (179), other subcellular compartments (187), membrane bound (204) and the 
extracellular environment (172).  These studies, while informative and necessary, 
have not yet developed an understanding of the mechanisms of AGR2 protein 
overexpression in tumour cells and, mechanistically, how AGR2 influences the cell 
to exhibit pro-oncogenic characteristics.   
Studies to date analysing the pro-oncogenic signalling of AGR2 firstly elucidated the 
p53-suppressive nature of AGR2 through an increase in specific phosphorylation on 
the tumour suppressor (150) and the nuclear exclusion of a key transcription factor 
involved in cellular homeostasis (187).  The manner in which AGR2 performs these 
functions is not understood.  Subsequent signalling pathway studies highlighted the 
induction of the EGF receptor ligand AREG, a growth promoting signalling protein, 
which could recapitulate the transformed phenotype absent when AGR2 was silenced 
(194).  This study, by Dong et al., was the first to investigate and characterise the 
modulation of a tumour-associated signalling pathway by AGR2, implicating the 
nuclear localisation and dephosphorylation of the Hippo pathway co-activator, Yap-
1, as the transcriptional activator to functionally link the activity of AGR2 to AREG 
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expression (194).  However, the effect of AGR2 on AREG does not attribute for all 
the pro-oncogenic properties described by AGR2 overexpression.  Therefore, the 
study presented here undertook a methodology to engineer biological tools which 
could ultimately be used in the characterisation of AGR2 signalling pathways, and 
more widely be used in the understanding of AGR2 in normal and diseased cells.     
The engineering of a stable cell line, employing the Flp-In system, allows the 
creation of an isogenic cell panel, differing only in the single gene allele integration 
of the gene of interest.  Initially, any cell line can be engineered to include the FRT 
site required for stable cell line generation, so it was considered which cell line 
provides the most appropriate model for analysis of AGR2 function.  Although not 
essential, it was decided an AGR2-null cell line would be the most straightforward 
for downstream study, as any change in characteristic from the parental cell line 
could be attributed to the presence of AGR2.  Theoretically, an AGR2 expressing 
cell line may propose a better model as the AGR2-dependent signalling pathways are 
already functional; however this makes analysis rather more complex such that 
external mechanisms would influence endogenous AGR2 expression levels resulting 
in potentially erroneous conclusions.  It was also decided that the cell line should 
have a wild-type p53 background, due to the proposal of AGR2 as a p53-suppressor 
(150); this would give the greatest opportunity to study the role of AGR2 expression 
on one of the most aberrant homeostatic mechanisms prevalent in cancer studies.  
The A375 skin melanoma cell line met both these requirements, so provided the best 
model for AGR2 gene insertion study.  There is a risk in the synthesis of any stable 
cell line panel, that the expression of the exogenous gene drives a selective pressure 
driving mutations in the cell signalling pathways.  Such mutations could be 
propagated driving downstream detectable changes, which are then inaccurately 
attributed to AGR2 expression.  To some extent these selective pressures cannot be 
completely avoided since the experiment requires the expression of detectable levels 
of the protein of interest.  Therefore, in all circumstances where the A375-FRT cell 
model has been used in experimental protocols, passage numbers were restricted to a 
maximum of 10, and experiments comparing the expression of mutant or paralogous 
proteins were prepared from the same pool of A375-FRT parental cells.  
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Subsequently, control cells were always from this same pool also. The manner in 
which AGR2 drives selective pressure to promote potential oncogenic mutations 
over numerous cell doublings is a very interesting study in itself, however this was 
deemed outwith the scope of this study.     
The gene recombination is integrated into the same location, and under control of the 
same promoter system, in all experimental cell lines synthesised resulting in a useful 
experimental model for the analysis of gene function.  Alternative techniques rely on 
the transient transfection, and subsequent selection, of exogenous expression clones, 
or RNAi-based reagents to overexpress or silence the gene of interest.  In these cases, 
the number of genes inserted into, or the extent of silencing, the host cell genome 
cannot be controlled.  Therefore, these cell models may exhibit artefacts of 
over/under expression in protein folding, trafficking and ER stress.  By using the 
recombination-based FRT genetic motif, it is known that only one gene can be 
controllably inserted into the host DNA, thus in further studies of mutants and 
paralogous proteins, divergences from the control are clearly as a result of the 
controlled variable.  It must be noted that this technique is only of benefit if cells at 
each stage are appropriately characterised (as in Figures 3-1 and 3-2).  Due to the 
random integration of the pFRT/lacZeo gene into the host cell genome, some 
chromosomal location dependent effects on gene transcription and protein expression 
would be expected.  Therefore, it is essential to correctly identify that only one FRT 
site is integrated into the genome (otherwise resulting in excision of intervening 
DNA if FRT sites are directly repeated in the same DNA strand, DNA inversion if 
the sites are in opposing orientations and deletion of genomic sequences) and that 
this integration does not have a dysfunctional effect on genes and signalling 
pathways essential to the study of the gene of interest (in this case, the p53-response 
to DNA damage, and the TLR3 interferon signalling system). 
Following the recombination of the gene of interest into the host cell line (Figure 3-
4), cells were assayed for described AGR2 characteristics.  First of all, experimental 
cells express the AGR2 at the protein level in contrast with the parental cell line.  
This is an important outcome based on several factors: (i) The expression of AGR2 is 
not a lethal effect.  As with any gene which disrupts normal cellular homeostasis, in 
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particular cell growth, the mere expression of the introduced gene may perturb 
cellular dynamics such that mechanisms within the cell sense erroneous cell 
signalling and action a senescent or apoptotic response.  (ii) The gene expressed is 
translated into the gene product.  It is plausible to consider that transcription of an 
exogenous gene, not normally exhibited by this cell line, may be subject to 
degradative machinery prior to phenotypic expression.  This may occur at the mRNA 
level via salvage pathways, or during translation by proteosomal or lysosomal 
nutrient recycling systems. Fortunately, these engineered cells lack any apparent 
unstable characteristics, and exhibited the protein product at a level approximately 
1/5
th
 of the expression level identified in commonly used cancer cell lines (Figure 3-
5).  Significantly, wt-AGR2 expressing cells also demonstrated an increased 
response to ER stress induced by a tunicamycin treatment time course, through an 
induction of CHOP mechanism (Figure 3-5).  This supports the recently published 
RNAi silencing of AGR2 in vitro causing an increase in sensitivity to ER (179), 
suggesting that the artificially engineered FRT-wt-AGR2 cell line is faithfully 
recapitulating the ER-stress response observed in an endogenous AGR2 expressing 
HeLa cell line.   
Further, the growth/invasion enhancement observed in the wound healing assay 
reiterates previous studies indicating that AGR2 over expression provides a survival 
benefit in vitro (150;175) and in vivo (218;231).  There are apparent limitations to the 
wound healing assay, such that it is manual and subjective, and in the format used 
does not distinguish between cell proliferation and migration.  Yet it provides a 
straightforward, rapid and economical technique (303), and coupled to TScratch 
analysis software (304), provides first line estimation of AGR2 expression effect on 
cell growth.  These data were subsequently validated using a secondary 
xCELLigence real-time growth assay (Figure 3-9A).  The benefit of cloning C-
terminal mutant constructs of the AGR2 gene (Figure 3-7) was two-fold.  It provided 
evidence to suggest that the A375-FRT cells were transporting the expressed protein 
to the correct subcellular compartment as suggested by bioinformatic analysis and by 
previous publications (188), detectable by immunofluorescence studies (Figure 3-8).  
They also provided excellent control cell lines for downstream analysis of wt-AGR2 
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specific activity, with the ultimate aim of determining whether the function was 
restricted to the ER-localised, the extracellular pool, or specific to the multi-
compartment wild-type protein.  While the mutant genes also being transcribed at a 
relatively similar level to that of the wild-type protein (Figure 3-7).  Collectively, 
these data suggest that the isogenic cell panel described herein provides an 
appropriate model of AGR2 function in agreement with a range of publications of 
proposed AGR2 function.   
The C-terminal mutant AGR2 expressing cell lines also provided an insight into the 
growth promoting nature of AGR2 using the xCELLigence cell growth assay (Figure 
3-9A).  A previous publication has described the wild-type C-terminal motif of 
KTEL being an essential requirement for the EGFR-activating activity of AGR2 
(188;194).  The data from these cell models somewhat conflict this previous study 
indicating that subcellular location is not a restraint on the proliferative growth effect 
of AGR2 expression since all AGR2 expressing cell models exhibited some level of 
increased cell growth rate, and reduction in cell doubling time.  This raised the 
question as to whether the recombination of any gene was resulting in perturbation of 
normal cell growth.  Therefore, a further cell line, incorporating a premature stop 
codon in the AGR2 gene, resulting in the expression a four amino acid residue 
peptide product, was engineered to challenge this (Figure 3-9B).  As a result, since 
the A375-FRT-STOP cell line exhibited similar characteristics of the AGR2-null 
parental cell line, we can confidently conclude that the expression of AGR2 is the 
determining factor increasing the growth rate of these isogenic cell panels.  The 
continuous cell monitoring nature of the xCELLigence proliferation assay makes it a 
more reliable measure of cell growth than the scratch assay (with particular reference 
to replicate experiments carried out in quadruplicate and statistical analysis of 
variation), yet this is balanced by increased cost, and technical skill required to 
prepare and analyse the assay.   
The final characterisation of the wt-AGR2 expressing cell line was to analyse the 
effect of wt-AGR2 on the global basal gene expression of the cell (Figure 3-10).  In 
order to appropriately determine changes in the transcriptome of AGR2 expressing 
cells, two additional controls alongside the AGR2-null cell line were assayed.  The 
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AGR2-ΔC mutant as a control allows the identification of the reasoning behind the 
divergence of the C-terminal motif from KDEL (of ERP18) to the KTEL motif 
exhibited by wt-AGR2 which demonstrates reduced affinity for KDEL receptor 
proteins (192), and the properties shared between wt-AGR2 and secreted AGR2-ΔC. 
A375-FRT cells expressing the protein AGR3, with high levels of similarity, but less 
regularly identified as an oncoprotein in proteomic screens, is the final control as a 
control for specificity of AGR2 effects.  Additionally, data collected from this cell 
line can be retrospectively studied to analyse the potential role of AGR3 whose 
overexpression, and uncoupling form AGR2, has been implicated in several subtypes 
of ovarian cancer (248), among others.  Somewhat surprisingly, from a screen of 
40,000 gene probes of the Illumina HT-12 BeadChip, only 27 genes were identified 
as exhibiting significantly different gene expression as a result of wt-AGR2 
expression from those of the AGR2-null cell.  Of these all were identified as having 
upregulated expression and bioinformatic analysis identified the GAGE gene cluster 
as being over represented.  The GAGE gene family are a cluster of highly similar 
genes of repeated units which absent from normal tissue, except those of the testis, 
and highly expressed in cancerous tissue (308).  This cancer specific nature of the 
GAGE genes has made them a highly attractive target for cancer therapy (309).  The 
biological functions of GAGE genes are not yet clear, but emerging evidence 
suggests that they direct proliferation, differentiation and survival of human germs 
cells, and this may be recapitulated in cancer cells (310).  Selected members of this 
group of genes, and others highlighted from the microarray, whose expression was 
modulated by AGR2 expression were assayed by qPCR as a validation, yet these 
could not be reproduced (Figure 3-11). 
The inability of these gene expression experiments to reproduce the AGR2-
dependent induction of the EGFR pathway, previously published (194), may be due 
to the relatively low level protein expression in the engineered cells relative to the 
authentic AGR2 expression in cancer cell lines (Figure 3.5B). Other tumour 
associated pathways AGR2 has been linked with perturbing include c-myc, cyclin D1 
and survivin (231).  This study, by Vanderlaag et al., found that protein levels of 
these three proteins, involved in cell survival, had reduced protein expression in 
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response to AGR2 silencing.  Data presented herein indicate that overexpression of 
AGR2 in this A375 cell model does not affect transcriptional levels of these genes to 
a level of significance, and this can be justified by a number of reasonings: because 
AGR2 is not an endogenous protein in this system the signalling pathway to these 
proteins is not active or that AGR2 may indeed be affect the expression at the protein 
level as part of the function of an ER chaperone protein.  Therefore, if threshold of 
AGR2 levels are important, then a hierarchy of AGR2 function would first impact on 
CHOP-dependent ER-stress response processes, prior to transcriptional-dependent 
effects on the EGFR pathway and other cancer associated signalling systems.   
The engineering of the methodology and characterisation of these isogenic cell lines 
constitutively expressing AGR2, C-terminal mutants of AGR2 with distinct 
subcellular distribution and a closely related protein, AGR3, provides a novel, 
reliable and reproducible tool for the study of Anterior Gradient proteins.  The 
exhibition of described AGR2-dependent functions in the suppression of CHOP and 
increased cell growth validate these cells as exhibiting displaying key natures 
attributed to AGR2.  These tools therefore lend themselves to further interrogation, 
with particular respect to disease causing manifestations, of the functional roles of 
AGR2 in vivo with significance away from effects at the mRNA level. 
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Chapter 4: The Application of Quantitative 
Proteomic Methods to Identify AGR2 




Since the cataloguing of the DNA blueprint comprising the complement of genes in 
the human genome, we have begun to understand that this knowledge base is 
conceivably immeasurably complicated throughout the central dogma of molecular 
biology, to reach the phenotypic level (Figure 4-1A) (311).  That is the translated 
proteins that act as the functional effectors of the signalling pathways in response to 
changes in the cells’ external environment.  It was previously thought that these 
signalling pathways could be interrogated at the mRNA level, as signalling responses 
were thought to transcriptionally up- or down- regulate effector proteins.  It has 
subsequently been found that this is not as simple as originally assumed, such that 
transcribed RNA levels do not necessarily correlate with protein expression levels 
(312;313); transcribed mRNA is not always translated into protein, and that the 
amount of protein transcribed from a specific amount of mRNA into protein can vary 
(314;315).  The term ‘proteome’ was coined to describe the entire complement of 
proteins, incorporating modifications made, produced by an organism or system 
(316).  Proteomics, in contrast to genomics, is dynamic and complex, in response to a 
changing environment, and adaptation to these changes (317).  Proteins also lack the 
molecular capacity to be amplified, like DNA can be, as such no technology exists 
yet which can detect all proteins in the cell, so sequencing and identifying proteins 
requires a more challenging approach. 
As such, significant investment has been made into developing technologies for 
interrogating the protein landscape to identify expression changes in diseased cells 
representing potential novel biomarkers (318).  Undoubtedly, the impetus for 
progress in proteomics has been driven through revolutionary development in mass 
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spectrometry (MS) instruments, ‘soft’ ionisation methods and bioinformatical 
software packages (319).  However, only a fraction of the proteins in the cell can be 
quantified by mass spectrometry.  The detection of a peptide by MS is not reliant on 
abundance alone; rather the ionisation, chromatographic behaviour, solubility and 
interaction of the peptide ion with other compounds can all play a critical role.  In the 
current preferred method, protein samples are first enzymatically cleaved into 
peptides, prior to fractionation of the sample by a variety of means (gel-based SDS-
PAGE, subcellular compartment enrichment and strong cation exchange) before 
ionisation by techniques such as electrospray (320) or MALDI (matrix-associated 
laser desorption ionisation) (321).  Ionised samples are analysed in a primary MS 
step, and precursor, or parent, peaks are isolated (Figure 4-1B).  This provides a 
mass/charge (m/z) ratio for the whole peptide; however, this is insufficient for 
peptide/protein identification as several peptides will exhibit the same m/z ratio.  
Therefore, peaks are selected and the peptides are subjected to fragmentation, by 
collision with an inert gas, to identify the product or daughter ions.  This second MS 
step fragments the peptide via the peptide bond into y and b ions, allowing 
comparison with a database of predicted masses of peptide sequences and subsequent 
amino acid residue identification (322;323) (Figure 4-1C).  Thus, MS can identify 
the mass/charge ratio of the ionised peptide, and in a second MS step (tandem MS, or 
MS/MS), the peptide can be sequenced and, through the sequencing of multiple 
peptides, the protein identified through database searches (Figure 4-1B) (319). 
Advances in the use of MS to study proteins have driven the development of 
methodologies to quantify the expression levels of proteins in experimental or 
clinical conditions.  There are a range of quantitation methods available for the 
analysis of protein expression which utilise different technologies to differentiate 
between conditions giving information on the relative or absolute protein expression 
levels.  The technique utilised in this study was stable isotope labelling by amino 
acids in cell culture (SILAC) (324).  This methodology, pioneered by the lab of 
Matthias Mann  (Max Planck Institute of Biochemistry, Munich), requires 
experimental cell lines to be grown in specialised media containing non-radioactive 
stable isotope labelled amino acids for metabolic incorporation into newly 
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synthesised proteins (Figure 4-2).  Mammalian cells cannot synthesise a number of 
amino acids, therefore these essential amino acids must be provided in the tissue 
culture media, in this study we used the essential amino acid lysine, and the 








N lysine (R10K8, ‘heavy’) or 
13
C arginine and 
2
H lysine 
(R6K4, ‘medium’) or unlabelled (R0K0, ‘light’) and supplemented into the media as 
free amino acids to support growth, and in turn are incorporated into nascent protein 
chains during translation.  Controlled absence of any unlabelled specific amino acid 
is imperative, therefore cells must be cultured in media containing dialysed serum, 
and care must be taken to avoid enzymes regularly used in tissue culture, such as 
trypsin, which might provide a source of unlabelled amino acids.  Following a 
number of cell doublings, each occurrence of the specified amino acid will be 
replaced by its isotopically tagged analogue.  As there is no chemical difference 
between the natural and labelled amino acid (SILAC labelling has been tested in a 
range of cell lines and primary cultures with no detrimental effect on growth, 
morphology or biological activity (326)), the cell should act identically to a control 
cell line grown in media with natural amino acids.  
Therefore, labelled cells can be experimentally treated along with an untreated 
control, subsequently harvested, and because the label is encoded directly into the 
amino acid sequence of every protein, the extracts can be mixed, and processed 
(reduced and alkylated) concurrently removing additional potential sources of error 
(324).  Mixed lysates are then subject to enzymatic digestion, most commonly and in 
this study, with trypsin.  Due to the specificity of the trypsin enzyme, cleaving only 
when the carbonyl group is contributed by a lysine or arginine residue, every peptide, 
excluding the very C-terminal peptide, will therefore incorporate an isotopic tag 
(327).  In shotgun proteomics, the trypsinised peptides are then injected directly into 
a high performance liquid chromatography front-end, or alternatively to reduce 
sample complexity we fractionated the protein lysates off-line using gel 
electrophoresis (326) prior to sample introduction.  This additional fractionation aims 
to allow maximal identification of proteins within the sample, and also aid the 
identification of lower abundance peptides as the fractions will be less complex 
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(328;329).  Therefore, once tryptic peptides are injected to the MS, a mass shift 
between cells cultured in the distinct labelled amino acid containing conditions exists 
and can be detected in the first MS.  Following the MS/MS peptide identification and 
confirmation, the area under the MS1 spectra can be integrated and a calculation of 
peptide quantitation derived.  Using the quantitation of several unique peptides, a 
measure of protein expression level (and confidence in this expression) can be 
compared to the differentially labelled cell lines, resulting in relative quantitation of 
the protein.  The early combination of samples and metabolic labelling, results in 
SILAC being likely the most accurate quantitative MS method, and is particularly 
suitable for assessing comparatively small changes in protein levels (330). 
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Figure 4-1 Overview of mass spectrometry based study of proteomics.  (A)  The central dogma of 
molecular biology where static, unchanging DNA in the genome is transcribed to mRNA, before 
translation into the final gene product, the protein. (B) Illustration of mass spectrometry application in 
peptide, and subsequently protein identification.  (C) Fragmentation at the peptide bond, yielding 
different ion series  
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Figure 4-2 Stable isotope in amino acid cell culture (SILAC) protocol employed to interrogate 
how wtAGR2 expression affects the protein landscape.  
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Thus, SILAC can be appropriately utilised in the identification of expression changes 
induced by the expression of the gene of interest and can then be mined for over-
representation indicating the specific action of the experimental gene using a range 
of widely available bioinformatics packages (331).  The software package Ingenuity 
Pathway Analysis (IPA, Ingenuity Systems, www.ingenuity.com), allows the 
identification of biological mechanisms, pathways and functions most relevant to a 
high-throughput proteomic data set to allow interpretation of the biological 
significance and meaning of variation in expression levels.  IPA incorporates a 
curated distinct knowledgebase collating literature of biological and chemical 
knowledge from published peer-reviewed journals and biomedical databases to allow 
computational disentangling of complex data to identify key modulated biomolecular 
events. 
These techniques, coupled to the engineered isogenic stable cell lines, described and 
characterised in Chapter 3, allowed the interrogation of the cell signalling pathways 
disrupted or reprogrammed by the low level expression of the AGR2 gene.  The 
coupling of novel quantitative mass spectrometry techniques with isogenic cells lines 
is a somewhat new application for SILAC in the understanding of protein function 
and signalling, with relatively few publications to date (332;333).  As AGR2 is 
fundamentally an ER resident PDI (179), perhaps its chaperone function has a 
primary effect on cell signalling.  As such, we can evaluate whether the addition of 
the single AGR2 expressing allele can reprogramme the cellular steady state 
proteome under conditions which the transcriptome changes were negligible (Figure 
3-10). 
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4.2 Results 
 
4.2.1 SILAC quantitation of the protein landscapes of 
isogenic cell lines incorporating the AGR2 gene 
The SILAC methodology allows a degree of multiplexing of the experiment design, 
to incorporate relevant controls for the analysis of function of the AGR2 gene of 
interest.  We employed the triple-SILAC technique  (Figure 4-2), allowing the 
relative expression of three isogenic cell lines to be compared, to compare the A375-
FRT (AGR2-null) parental cell, A375-FRT-wtAGR2 incorporating the wild-type 
AGR2 gene, and the A375-FRT-AGR2ΔC which recombined the mis-localised 
mutant   AGR2 (Figure 3-8) protein as a control for specificity.  Due to the cells 
being isogenic, any modification from the parental cell line suggests a potential role 
of the introduced gene in the reprogramming of the cell.  Control AGR2-null cells 
were cultured in media containing unlabelled lysine and arginine residues (‘light’ 
condition), wild-type AGR2 expressing cells incorporated the 10 Da labelled 
arginine (‘heavy’ condition), and 8 Da lysine, while AGR2-ΔC expressing cells the 6 
Da arginine and 4 Da lysine (‘medium’ condition) prior to gel-based separation and 
MS processing, thus peptides detected from each condition can be distinguished 
(Figure 4-2).  Figure 4-3A presents an illustration of the distinct MS1 spectra 
expected of peptides derived from the three conditions and the mass/charge shift 
expected from lysine or arginine containing peptides.  Raw mass spectral data 
(Figure 4-3B) presents an example of MS1 data of a peptide identified in two of the 
conditions, light and medium labelled, of a lysine containing peptide whose product 
ion is separated by a 4 Da m/z shift.  From MS1 spectra, it can be identified that the 
peptide must contain a C-terminal lysine (due to the 4 Da shift) and that there is a 
small variation in the detection of the peptide with less peptide abundance in the 
medium labelled condition.  The product ions of both conditions were isolated and 
fragmented, allowing sequencing of the peptide as DSYVGDEAQSK.  Submission 
to bioinformatical databases allowed this peptide to be identified as unique to the 
cytoskeletal protein, actin (IPI00021440, ACTG1), and, together with a number of 
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other peptides, allowed statistical quantitation of the protein expression levels in the 
two conditions and a relative expression level derived. 
MaxQuant quantitation (289) utilises the generated peak list, SILAC label and 
extracted ion current-based quantitation to calculate a posterior error probability 
(PEP), and false discovery rate based on the search engine (Mascot) results, peptide 
to protein group assembly allowing filtration and presentation of data.  29044 
peptides were sequenced in the experiment allowing quantitation of 2877 proteins, 
and of these 2425 proteins were present in all 3 conditions, and thus used for relative 
quantitation (Appendix 2).  Data were then imported to Microsoft Excel for further 
analysis.  Due to the cell lines being isogenic, except for the recombination of the 
experimental gene, few significant changes from the expression of the control 
AGR2-null cell line were anticipated.  Indeed the expression ratio of most proteins 
remains unchanged (Figure 4-4A) and by plotting natural logarithm ratios of protein 
expression changes when wt-AGR2 is expressed compared to the AGR2-null cell, 
against the –log10 PEP (Figure 4-4B), the majority of protein expression levels 
quantified across all three conditions were not significantly altered more or less than 
the empirically derived 20% change cut off, from the AGR2-null cell line.  This 
suggests that AGR2 is not completely abrogating functional signalling pathways and 
that the pro-oncogenic, pro-growth reprogramming of the cell by AGR2 is much 
more specific.  The expression of wildtype-AGR2 resulted in the change of 
expression of 735 proteins (333 up-regulated and 402 down-regulated) by >20% 
(Figure 4-4C). By comparing the perturbed expression of proteins when wt-AGR2 is 
expressed, to expression levels of proteins from the secreted AGR2-ΔC expressing 
cells (Figure 4-4C), we can distinguish that wt-AGR2 is acting specifically within the 
cell to perturb signalling pathways, as there is only a small proportion of overlap 
between the proteins whose expression changes as the gene is exhibited.  Further, 
these overlapping data of the 226 proteins whose expression is linked to both wt-
AGR2 and AGR2-ΔC (91 upregulated and 135 downregulated) may subsequently be 
useful in identifying the extracellular function of AGR2. 
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Figure 4-3 Example of SILAC Quantitation.  (A) Illustration of the stable isotope labels used in the 
labelling of conditions and the m/z shift expected from the incorporation of the distinct tags on lysine 
and arginine residues.  (B) Simplified mass spectra of the peptide DSYVGDEAQSK from the protein 
Actin (IPI00021440, ACTG1) present in A375-FRT and A375-FRT-AGR2ΔC exhibiting a 4 Da m/z 
shift and variation in peptide detection.   
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Figure 4-4 Quantitative mass spectral data indicates that wt-AGR2 expression subtly 
reprogrammes the proteome of the cell.  (A) Log2 of the expression ratios of the 2425 SILAC 
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quantified proteins of wt-AGR2 expressing cells compared to isogenic AGR2-null cell line, 
demonstrating the majority of expression is clustered near the x-axis indicating no significant change.  
(Red lines indicated a 20% expression change gate).  (B) Plot of Log2 ratios of protein expression 
changes induced by wt-AGR2 relative to AGR2-null cells plotted against log10 of the posterior error 
probability.  The red lines indicate the threshold for change in expression set at ±20%.  (C) Venn 
diagram indicating the number of proteins up- and down-regulated (>20%) as a result of wt-AGR2 or 
AGR2-ΔC gene recombination relative to the parental cell line lacking any AGR2 gene, and the 
overlap of shared expression profiles.  
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4.2.2 Functional analysis of SILAC proteomic data 
As is the case with all OMICs technologies, the value of the data lies in the 
functional interpretation of the results to drive a phenotype or disease pathway.  
Also, proteomic data is inherently complex as each of the numerous detected proteins 
may be a member of several pathways, connected by multiple protein interactions 
and regulated by a variety of remote regulators.  Knowledge based approaches deal 
with this complexity by creating a structured database of protein interactions, 
pathways and protein-disease associations from experimental literature and a set of 
statistical tools to compare the proteomic profiles with this rich source of 
accumulated knowledge (334).  The knowledge database incorporated into Ingenuity 
Pathway Analysis avoids operator bias and blindly assumes no previous knowledge 
of the experiment, allowing visualisation of high throughput data in the context of 
biological networks.  Submission of protein expression ratios for wt-AGR2-
expressing cells versus AGR2-null parental cells which were quantified using at least 
three peptides (to increase reliability of data set (324)), and exhibited expression 
changes of at least 20% were submitted to IPA for evaluation (data processing 
carried out by Dr. Judith Nicholson, Australian Proteome Analysis Facility, 
Macquarie University, Sydney).  This bioinformatic analysis identified TP53 
transcription factor activity as the most perturbed (p-value = 1.42 × 10
-4
), through the 
aberration of 39 different proteins whose expression is linked to p53 signalling, and 
that this transcriptional pathway was in a state of inhibition (Table 4-1 and Figure 4-
5).  TFEB (p-value = 1.16 × 10
-3
) and E2F1 (p-value = 2.20 × 10
-4
) pathways were 
also identified as being significantly inhibited and activated, respectively.  This result 
links to the increased growth of wt-AGR2 expressing cells (Figure 3-6 and 3-9), yet 
the misregulation of these pathways were not previously highlighted by the whole 
genome gene expression profile (Figure 3-10).  Comparatively, expression changes 
as a result of AGR2-ΔC gene insertion did not show any significant effect on p53, or 
significant modulation of any other transcriptional pathway (Table 4-2).     
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Table 4-1 Pathway annotation using Ingenuity Pathway Analysis highlighted the dominant 
pathway suppressed by wt-AGR2 expression was TP53 transcriptional regulator. 











HNF4A 93 1.70 × 10-5   
TP53 39 1.42 × 10-4 Inhibited -2.747 
E2F1 21 2.20 × 10-4 Activated 2.204 
E2F2 7 6.73 × 10-4   
TFEB 5 1.16 × 10-3 Inhibited -2.201 
 
Table 4-2 Transcriptional regulator pathways are not affected by the expression of AGR2-ΔC 











HNF4A 126 6.18 × 10-8   
SREBF1 13 3.81 × 10-5  -1.517 
MCYN 21 6.90 × 10-5  1.678 
IRF2 6 1.04 × 10-3  -0.044 
MYC 19 1.71 × 10-3   
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Figure 4-5 Ingenuity network map of TP53 signalling axis.  Nodes highlighted with grey shading 
are significantly changed following the overexpression of wt-AGR2 in A375-FRT cells, and thus 
included in the submitted dataset   
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4.2.3 Validation of p53-dependent activity repression in 
wtAGR2-expressing A375-FRT cells 
The bioinformatic elucidation of suppression of the p53-signalling axis in wt-AGR2 
expressing cells was a stimulating result when compared to available literature 
demonstrating previous reporting of the p53-suppressive nature of AGR2 (150;187).  
However, due to the nature of in silico techniques and lack of appropriate replicates, 
biological validation of the hypothesis was sought for assurance.  We had previously 
used the platinum containing, DNA-crosslinking cancer therapeutic cisplatin to 
demonstrate that the integration of the recombination target into the host cell line had 
not disrupted the functional DNA damage response pathways in line with previous 
publications (297) (Figure 3-2).    This demonstrated that p53 was induced, following 
DNA damage, promoting cell repair or a pro-apoptotic response.  AGR2 is also 
described as mediating cisplatin resistance in xenografts (248).  Accordingly, the 
panel of AGR2-null isogenic cells, and cells expressing wild-type, KDEL or ΔC 
mutants of AGR2, were challenged with cisplatin over a 24 hour time course.  Thus 
allowing for evaluation of whether or not AGR2 expression indeed had any effect on 
the p53-response to DNA damage, to recapitulate the SILAC-IPA coupled data 
analysis (Table 4-1).  Additionally, the C-terminal mutant cells might suggest 
whether any deviation was as a result of the ER localisation of AGR2 (KDEL, 
untested) or extracellular secreted (ΔC, SILAC analysis had not highlighted p53-
signalling to be perturbed, so the hypothesis expected this not to be the case). 
Western-blot analysis of the p53-response to cisplatin-induced DNA damage in the 
isogenic cell panel, followed by densitometry measurements of protein bands 
highlighted, in the first instance, that wild-type AGR2 expression was indeed 
suppressing the activation of p53 over the time course (Figure 4-6A, upper panel 
lanes 1-7 compared to lanes 8-14).  p53 activation was estimated to be approximately 
one quarter of that of the AGR2-null cell line after 24 hours treatment (p53/β-actin 
densitometry, 21.2 compared to 5.0 relative units).  Moreover, not only were the 
expression levels of p53 suppressed in wt-AGR2 expressing cells, but p53-dependent 
activity read out of p21, was also significantly decreased compared to the AGR2-null 
cells.  Comparatively, the C-terminal mutants of AGR2 did not exhibit the same p53-
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suppressive nature identified in the wild-type expressing cells and p53 was induced 
in a manner similar to the AGR2-null cells (Figure 4-6A, lower panel compared to 
upper panel), suggesting that the wild-type C-terminal motif is essential to the p53-
suppressive nature of AGR2.  For complete analysis, an end point comparison of no 
treatment and 24 hour cisplatin treated lysates of the cell panel were prepared (Figure 
4-6B).  This established that at basal levels, untreated wt-AGR2 expressing cells did 
not significantly inhibit p53 expression levels detectably, however, p21 expression 
was estimated to be almost 50% reduced compared to the AGR2-null parental and 
AGR2 mutant-expressing cells (Figure 4-6B, lane 2 versus 1, 3 and 4).  So despite 
not directly affecting basal p53 levels, endogenous p53-dependent activity was being 
attenuated.  Following cisplatin treatment, wt-AGR2 expressing cells exhibited 
decreased p53 expression, p53 ubiquitination and subsequently p21 levels (Figure 4-
6B lane 6 vs 5, 7 and 8) compared to AGR2-null and cells expressing mutant AGR2.  
These data suggest that only wt-AGR2 expressing cells can suppress p53 and p53-
dependent activity, consistent with the Ingenuity Pathway Analysis of the triple 
SILAC screen. 
Taking into consideration that the A375-FRT cell panel is a model used for the 
analysis of AGR2 over-expression and function, it is imperative to translate these 
conclusions into endogenous AGR2-expressing cancer cell lines to challenge 
whether the p53/p21-suppressive activity of AGR2 is an authentic signalling activity 
relevant to the cancer cell phenotype.  To avoid inducing stress mechanisms related 
to protein over-expression by transient transfection; siRNA-induced gene silencing 
of AGR2 was employed to suppress the expression of endogenous AGR2 in two 
different cell lines, allowing evaluation and recording of any effect on p53/p21 
signalling axis.  Consistent with previous data described, siRNA-mediated depletion 
of endogenously expressed AGR2 protein in MCF7 or A549 cancer cell lines (both 
having a functional wild-type p53 pathway) resulted in steady state p53 protein 
elevation at time points 72 hours and 96 hours post-siRNA transfection (Figure 4-7).  
After 72 hours of AGR2-targeted and non-targeted nonsense siRNA treatment in 
both cell lines (Figure 4-7A and 4-7B lane 1 compared to 2), AGR2 levels were 
significantly suppressed.  Coupled to this, p53-levels were induced in the AGR2 
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silenced cells, as was the level of p53-dependent p21 activation.  Additionally, after 
96 hours treatment, this trend was still observable (lane 3 vs 4).   
Collectively, these data suggest that the p53-suppressive nature identified by the 
SILAC proteomics screen and in silico bioinformatical analysis could be validated by 
biochemical methods, and indeed held relevance when  the hypothesis was tested in 
endogenously expressing AGR2 cancer cell lines exhibiting a wild-type p53 
pathway. 
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Figure 4-6 Evaluation of p53 levels of the isogenic A375-FRT cell lines expressing wild-type 
AGR2, AGR2-KDEL and AGR2-ΔC.  (A) 24 hour time course of 20 µM cisplatin-induced DNA 
damage, with western blot detection of p53 levels, p21 activation and β-actin for normalisation.  
Densitometry quantitation was carried out using ImageJ, relative to β-actin.  (B) End-point 
comparison of 24 hour no treatment or 20 µM cisplatin treatment of isogenic cell panel of AGR2-null, 
wild-type AGR2, AGR2-ΔC and AGR2-KDEL expressing cells, probed for p53 levels with both a 
short and long exposure, p21-activation and β-actin for normalisation.  Densitometry quantitation was 
carried out using ImageJ, relative to β-actin.   
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Figure 4-7 siRNA mediated AGR2 silencing selected cancer cell lines.  (A) A549 and (B) MCF7 
cancer cell line models and the effect of protein depletion on p53 expression and p53-dependent 
activity of p21 at 72 hours and 96 hours post-siRNA transfection.  siRNA was targeted specifically to 
AGR2, or a non-targeting nonsense control sequence was used.   
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4.2.4 Data-driven analysis of SILAC expression ratios of wt-
AGR2 expressing and AGR2-null isogenic cell. 
Further to the global bioinformatical approach to the effect of wt-AGR2 expression, 
a data-driven methodology was applied to extract as much information from the data 
set as possible.  Significant expression changes (±20%) from the parental cell line 
initially were ranked and the most altered expression levels identified (Table 4-3 and 
4-4).  The first application of this ranked data was to identify if any published 
AGR2-interacting proteins were detected in the proteomic screen and of these if any 
were significantly misregulated to provide an insight into the oncoprotein functions 
of AGR2.  Of the known AGR2 interactome, only five partners were identified and 
quantified by mass spectrometry, these being α-dystroglycan (172), CD59 (the 
human orthologue of newt Prod-1) (154;155), HECTD1 E3 ubiquitin ligase (169), 
Mucin-18 (165;233) and RUVBL2 (Reptin) (199) (Figure 4-8A).  Of these only 
Mucin-18 reached the significance of 20% upregulated (log2 of 1.2-fold up-
regulation = 0.263), dystroglycan and HECTD1 were significantly down-regulated 
(below a log2 = -0.322).  Only dystroglycan has a well validated role in metastatic 
cancer (335) and AGR2 interaction (172) but it’s down regulation does not indicate a 
clear pro-growth effect of AGR2 expression.  The interaction of AGR2 and HECTD1 
has been identified by yeast-2-hybrid yet requires further on-going validation before 
the interaction can confidently studied.  In addition, the up-regulation of mucins are 
not surprising due to the molecular chaperone function attributed to AGR2, 
particularly in the disulphide shuffling of cysteine rich mucin glycoproteins 
(165;233).  This provides an internal control, suggesting that AGR2 is performing a 
previously published function of the native protein in our experimental isogenic 
cells.  
These ranked data were subsequently subject to literature review, and compared to 
the ranked expression changes of AGR2-ΔC expressing cells, in order to highlight 
individual protein expression changes which might influence the observed 
characteristics of wt-AGR2 function in growth promotion, ER stress response and 
p53 suppression.  Two proteins identified whose inferred function may give an 
insight into how wt-AGR2 functions as an oncoprotein, were the two proteins which 
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exhibited greatest upregulation following wt-AGR2 introduction, tumour 
susceptibility gene 101 (TSG101), and Ki-67, which demonstrated a 3.5-fold and 
3.1-fold increase in expression respectively (Table 4-3, Figure 4-8B and C). 
Ki-67 is a nuclear and nucleolar protein, thought to be necessary for cellular 
proliferation and is commonly used in immunohistochemical studies as a marker of 
proliferative growth in clinical tissue (336).  Ki-67 is present in most cell types and is 
detectable during all active stages of the cell cycle, but absent in resting (G0) cells.  
An increase in Ki-67 would suggest that more cell proliferation is taking place in this 
condition, and this may be coupled to the previously identified p53-activity 
attenuation (Figure 4-8B).  Subsequently, validation of the proteomic data analysis 
was sought, to assess whether Ki-67 was reproducibly upregulated in wt-AGR2 
expressing cells.  Due to the large molecular weight of the Ki-67 protein (359 kDa), 
it was decided immunoblot transfer would not be suitable due to inaccuracies reliant 
on the charge mediated transfer of protein to nitrocellulose.  Thus a fluorescence 
activated cell sorting (FACS) methodology was utilised in order to determine 
whether the differential expression of Ki-67 between conditions could be visualised.  
Ki67 expression is indicative of cell proliferation, therefore a comparison was made 
of the proportion of Ki67-positive cells in the experimental population.  
Subsequently, FACS analysis confirmed that compared to AGR2-null A375 cells, the 
wt-AGR2 expressing cell demonstrated an increased expression of Ki-67 (Figure 4-
9).  These results validate Ki-67 as an upregulated effector of AGR2 signalling, and 
are consistent with the enhanced migration activity linked to AGR2 (Figure 3-6, 
Figure 3-9) (164;188;270).  The knowledge of AGR2-induced proliferative activity, 
validated by Ki-67, linked to the p53-suppression drives further interrogation of the 
ranked proteomic data to identify co-factors which may mediate the AGR2-
dependent down-regulation of p53.  Studies of Ki-67 acknowledge the challenging 
puzzle of deciphering Ki-67 function, and it’s up-regulation following wild-type 
AGR2 expression is another attribute of this multifaceted protein whose role is 
clearly essential in cell growth (337). 
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Table 4-3 Ranked SILAC expression data presenting the ten most up-regulated protein 
expression changes as a result of wild-type AGR2 or AGR2-ΔC gene introduction. 
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Table 4-4 Ranked SILAC expression data presenting the ten most down-regulated protein 
expression changes as a result of wild-type AGR2 or AGR2-ΔC gene introduction. 
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Figure 4-8 Expression changes of highlighted proteins as a result of wt-AGR2 or AGR2-ΔC gene 
recombination.    (A) Published interacting partners of AGR2 log2 expression changes as a result of 
experimental gene introduction.  (B) Ki-67 demonstrates significant upregulation, the second most 
increased, following wt-AGR2 gene expression, but is not induced by AGR2-ΔC.  (C) TSG101 is the 
most upregulated protein following wt-AGR2 expression compared to AGR2-null isogenic cells; this 
is specific to the wild-type protein as TSG101 is not upregulated by AGR2-ΔC expression.  
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Figure 4-9 Validation of Ki-67 as a protein upregulated by wt-AGR2.  Fluorescence activated cell 
sorting (FACS) analysis of AGR2-null parental A375 FRT- cells with A375 FRT-wtAGR2 expressing 
cells using a FITC conjugated anti-Ki-67 antibody.  FITC reactivity was detected at 488nm and 
presented as a summary of the percentage of cells expressing Ki-67 protein.  
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4.2.5 Identification and validation of TSG101 as an effector in 
the suppression of p53 dependent activity by wt-AGR2 
expressing cells 
In order to define a mechanism to explain how AGR2 can suppress p53 protein, we 
took advantage of the fact that Ingenuity Pathway Analysis identified components of 
the TP53 pathway (Table 4-1) and subsequent validation (Figure 4-6) collectively 
with the ranked most upregulated protein expression was identified as the previously 
identified p53-inhibitor TSG101 (Table 4-3) (338).  Defects in TSG101 have 
previously been linked to multiple cancers (339;340) and steady state gene 
expression of this gene product has been described as necessary for genome stability 
and cell cycle regulation (341;342).  TSG101 forms part of the endosomal sorting 
complex required for transport-1 (ESCRT-1), and functions as a regulator of 
vesicular trafficking, whose linkage to AGR2 might provide an insight for the role of 
AGR2 as a PDI in protein maturation and protein trafficking (169).  Intriguingly, 
TSG101 has previously been identified as participating in the well studied p53-
MDM2 autoregulatory loop, by affecting protein decay (338).  The Ubc domain of 
TSG101 disrupts the ubiquitination of MDM2, thus inhibiting MDM2 decay and 
elevating its steady state level, and that these events are associated with the down 
regulation of the p53 protein. 
Subsequent biochemical validation of the upregulation of TSG101 in wt-AGR2 
expressing cells, and its role in influencing p53 protein levels was performed.  By 
Western blot, basal TSG101 levels are significantly greater in wt-AGR2 expressing 
cells, compared to the isogenic AGR2-null cells (Figure 4-10A), consistent with the 
conclusions drawn from the SILAC quantitation data.  Due to the cells only differing 
on the expression of the wt-AGR2 gene, we can thus conclude that the upregulation 
is a direct result of AGR2 protein presence.  Further, transient transfection of 
TSG101 (using TSG101-pCMV-CL5 expression plasmid) into A375-FRT-wtAGR2 
expressing melanoma cells suppressed further endogenous p53, and p53-dependent 
activity, particularly when proteosomal degradation was blocked using MG132 
(Figure 4-10B).  Thereby, supporting the hypothesis that the overexpression of 
TSG101, as a result of AGR2 presence, was having an attenuation effect on the 
expression of p53, and p53-dependent proteins.  The blocking of proteosomal 
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degradation in this experiment ensured that the difference in p53 levels could be 
visualised as in non-MG132 treated samples; the endogenous p53 was clearly being 
rapidly turned over.  For confirmation of the p53-suppressive effect of TSG101, 
exogenous TSG101 was titrated into two wild-type p53 cell lines, A375 (AGR2-
negative) and MCF7 (AGR2-positive) and the effect observed (Figure 4-10C).  As 
expected even very small changes in the expression of TSG101 attenuated p53 
expression (342), with as little as 0.4 μg per 2 mL culture, suppressing p53, and 
concurrently p21 levels. This experiment indicated, that AGR2 was not a necessary 
cofactor for the p53-suppressive activity of TSG101, in fact, in AGR2-null A375 
cells, TSG101 suppressed p53 independently of AGR2 expression.  
The p53-suppressive nature of TSG101 was further probed using cisplatin-induced 
DNA damage, and siRNA mediated protein expression silencing in authentic AGR2-
expressing cancer cell lines.  A549 cells have a wild-type p53 pathway and an active 
TGF-β dependent pathway that regulates AGR2 expression in an oestrogen-
independent manner (180).  When these cells were transfected with TSG101, 
whether cells were damaged or not, p53 levels are suppressed (Figure 4-11A, lanes 2, 
4, 6 and 8 vs 1, 3, 5 and 7).  When A549 cells were damaged with cisplatin, there 
was still a remaining dominant effect of TSG101 over p53 protein levels (Figure 4-
11A, lanes 6 vs 5).  When MG132 was added to cells, the effect of TSG101 on p53 
protein turnover can still be seen in the presence of cisplatin (Figure 4-11A lane 8 
versus 7).  These data show that in this cell line, forced expression of TSG101 can 
suppress p53 protein induction and/or increase p53 protein turnover under a set of 
experimental conditions including the basal state or cisplatin damage.  We also 
evaluated the TSG101 effects in MCF7 cells, which also have a wt-p53 pathway but 
the expression of AGR2 protein in this cell line is oestrogen dependent.  Similar to 
A549 cells, under each condition, ectopic expression of TSG101 suppressed p53 
protein levels (Figure 4-11B, lanes 2, 4, 6 and 8 compared to 1, 3, 5 and 7). 
To complement the experiments above that evaluate how ectopic expression of 
TSG101 can impact on cells endogenously expressing both wt-p53 and AGR2, we 
used a targeted siRNA approach to determine whether reduction in endogenous 
TSG101 impacted on p53 protein turnover.  In A549 cell, depletion of TSG101 using 
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siRNA only had a significant impact on stabilising p53 protein levels in the presence 
of MG132 (Figure 4-10C lanes 5 and 6 vs 1-4), which is consistent with the effect of 
transfected TSG101 on p53 levels in A375-FRT-wtAGR2 cells (Figure 4-10B).  
Similarly, in MCF7 cells, TSG101 depletion most impacted on p53 protein in the 
presence of MG132 (Figure 4-11D lanes 5 and 6 vs 1-4), although an effect on p21 
protein was observed under all conditions where TSG101 was silenced.  Together, 
these data suggest that the over-production of TSG101 induced by the reprogrammed 
A375-FRT-wtAGR2 cell can, in part, relate to the ability of TSG101 to stimulate the 
turnover of p53 in a range of cell types. 
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Figure 4-10 The effect of TSG101 expression on p53 protein level.  (A) Basal TSG101is 
upregulated in engineered A375-FRT-wt-AGR2 expressing cells relative to the parental cell line, 
consistent with SILAC data from Table 4-3.  (B)  Transfection of increasing amounts of TSG101-
pCMV-XL5 expression plasmid for 18 hours incubation then followed by 3 hour incubation with 10 
μM MG132 to determine whether TSG101 affects p53 turnover in A375 cells.  Lysates were blotted 
with antibodies against TSG101, p53, p21 and a β-actin loading control.  (C)  TSG101 was titrated 
into transfection of A375 (AGR2-null) and MCF7 (AGR2-positive), wild-type p53 expressing cells, 0, 
0.4, 0.8, 1.2, 1.6 and 2.0 μg expression plasmid DNA per 2 mL 70% culture of cancer cells.  Western 
blot was probed with antibodies as indicated.  
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Figure 4-11 The effects of TSG101 expression on p53 protein levels.    (A) and (B) TSG101 was 
transfected into endogenously expressing AGR2 cells (as indicated A549 or MCF7) and followed by 
addition of carrier (PBS), cisplatin, and MG132, as indicated, to determine whether TSG101 
suppresses p53 protein in response to cisplatin induced DNA damage.  (C) and (D) Targeted siRNA 
was transfected into cells to determine whether depletion of TSG101 in endogenously expressing 
AGR2 cells altered the turnover of p53 protein, as defined by p53 protein levels without or with 
MG132 treatment.  Lysates were blotted with antibodies to p53, p21, TSG101 and a β-actin loading 
control.  
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4.3 Discussion 
 
The aberrant expression of Anterior Gradient-2 is correlated with several human 
pathologies including cancer (169).  The mechanism of the over-expression of AGR2 
in diseased tissue is not clearly understood, with studies highlighting possible 
contribution in endoplasmic reticulum stress response as a molecular chaperone 
(179), misregulated EGF signalling (194) and p53-dependent activity inhibition 
(150;187) driving oncogenic signals in cancer cells, and cell proliferation 
(164;231;244) and cell cycle signalling pathways (231;262).   However, co-factors 
which might mediate these functions are poorly understood.  Initial studies on the 
molecular basis of AGR2 signalling comes primarily from protein-protein interaction 
studies, via yeast-2-hybrid and co-immunoprecipitation experiments which have 
implicated C4.4A, α-dystroglycan (172) and Reptin (199), along with other protein 
interaction hits which remain to be full validated (169).  These studies have not yet 
elucidated a clear signal transduction pathway, or co-factors involved, to explain the 
survival benefit of AGR2 over-expression.  Further, in oncology, AGR2 has been 
implicated in drug resistant tumours against tamoxifen (174;175) and cisplatin (248), 
as a pro-metastatic factor (164;218), as well as disrupting homeostatic signalling 
pathways (150;194) and remains under study in cancer drug discovery programmes 
(169). 
To drive our understanding of the effects of AGR2 overexpression, in Chapter 3, we 
engineered and characterised an isogenic cell panel constitutively expressing our 
gene of interest.  These cells provided an appropriate tool for the study of AGR2 
signalling, since they differ from control cell lines by only a single variable, the 
expression of the AGR2 gene (or mutant AGR2 gene).  In order to utilise this 
experimental tool aptly to give the greatest opportunity of deciphering the molecular 
function of AGR2, we took a systems biology approach to the analysis of the cell 
lines using transcriptomics (Chapter 3) and proteomics, described herein.  The whole 
genome gene expression analysis had given little insight into the function of AGR2, 
leading to the assumption that AGR2 was not driving a direct effect on the 
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transcription of genes or that any effect at the mRNA level of the cell was slight, 
since as highlighted, the cells exhibited a modest level of AGR2 expression.  Since 
AGR2 is predominantly an ER-resident PDI (165;179), it was considered whether its 
chaperone function might have a primary effect on the maturation of endogenous 
proteins.  This was justified since the low level AGR2 expression in the engineered 
A375-FRT-wt-AGR2 cells had previously been identified to supplement the 
homeostatic CHOP response to tunicamycin induced endoplasmic reticulum stress 
(Figure 3-5C).  As such, we evaluated whether the addition of the single AGR2-
expressing allele could reprogram the cellular steady-state proteome under conditions 
where changes in the transcriptome were negligible. 
In order to unravel the mechanism whereby AGR2 gene expression affects cell 
function, a quantitative proteomics approach was sought.  Progress in mass 
spectrometry instruments and data analysis packages mean that there are now several 
different technologies which can be implemented to quantify the protein expression 
landscape of the experimental condition (Table 4-5).  Protein quantitation can be 
broadly split into two categories, those which measure (i) relative quantitation and 
(ii) absolute quantitation.  Relative quantitation methodologies compare two or more 
samples to one another, e.g. to a control, to provide a fold change of the experimental 
condition to the untreated sample.  In its simplest form, 2-dimensional gel 
electrophoresis coupled to fluorescent dyes (as mentioned previously) allow protein 
levels to be quantified using the intensity of the incorporated fluorescent dye relative 
to the same spot from a control lysate.  In MS-based proteomics, the reliance is based 
on stable isotope dilution theory, which states that a stable isotope-labelled peptide is 
chemically identical to its native counterpart; therefore the two peptides also behave 
identically during chromatographic and mass spectrometric analysis.  The sensitivity 
of a MS detector means that the mass difference between the labelled and unlabelled 
isoforms of the peptide can be differentiated, and quantification can be achieved by 
comparing, relatively, their signal intensities.  Isotope labels can be introduced into 
the sample in several ways: (i) metabolically, (ii) through chemical reactivity, (iii) 
enzymatically or (iv) as an external standard of spiked synthetic peptide to normalise 
to (343).  Recently, label free strategies have begun to emerge, such as spectral 
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counting where the number of spectra acquired of a specific peptide/protein are used 
as an estimate of abundance in the sample. 
The earliest possible point for protein labelling is during nascent protein synthesis, 
and thus at the metabolic level, allows for the most accurate quantitative MS method 
(330). The SILAC method used in this study requires the metabolic labelling of cells 
in tissue culture (324), in conditioned media incorporating isoforms of amino acids 
with heavy elements allowing labelling of all nascent proteins in the experimental 
condition.  Following specific trypsin cleavage, every enzymatic product, except for 
the C-terminal most peptide, incorporates an isotopic label.  This method results in a 
mass differences between otherwise identical precursor peptides which can be 
detected, grouped and the spectral peak integrated to provide a measure of 
quantitation.  Some level of multiplexing is possible, limited to three different 
growth media permutations, however up to five is possible in experiments that have 
at least one common sample allowing normalisation (287;344;345).  The key 
advantage of SILAC is that cells from various conditions can be combined as early 
as at the level of intact cells and subject to concurrent processing.  Thereby removing 
sources of quantification error introduced by biochemical or MS procedures as all 
experimental protein populations will be treated in the same manner (330).  
Metabolic labelling was, until recently, limited to cells grown in tissue culture, 
however insights are beginning to overcome the economical and practical constraints 
of labelling whole organisms and in vivo labelling of Drosophila (346), rat (347), 
mice (348) and nematodes (349) are reported. 
Comparatively, proteins, or peptides, from lysates can be labelled post-biosynthesis 
by chemical or enzymatical derivation strategies.  Following proteolytic digestion 
with trypsin or Glu-C, 
18
O can be enzymatically incorporated into the C-terminus of 
peptides of one of the experimental conditions.  Utilising the heavy water in the 
trypsin digestion step, one or two heavy oxygen atoms are incorporated into the 
tryptic peptide (350).  As a  result, a mass shift of 2 Da per oxygen atom incidence 
can be identified (351).  The challenged of 
18
O labelling is that full labelling is 
difficult, and different peptides have different affinities for the 
18
O tag resulting in a 
complex analysis.  Proteins and peptides can be chemically labelled also, ICAT 
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(isotope-coded affinity tag (352)) is one example which labels cysteine side chains 
with deuterium atoms and biotin groups allowing differential quantitation.  Cysteine 
being a rare amino acid means that complex samples are reduced in complexity; 
however, for proteins lacking in cysteine residues the technique has much reduced 
relevance.  A further group of chemical labels target the N-terminal of the peptide 
and the epsilon-amino group of lysine residues, utilising specific NHS chemistry to 
conjugate the isotope tags to the peptide being isotope tags for relative and absolute 
quantification (iTRAQ) (353) and tandem mass tags (TMT) (354).  These concepts 
introduce isobaric tags to label peptides which do not influence chromatographic 
nature and can only be differentiated by MS.  The ratio of detection of the tags can 
then be used as a quantitation measure to detect the difference between the levels of 
proteins from different samples.  iTRAQ and TMT allow significant multiplexing of 
the experimental conditions of up to 8 samples, which is particularly useful in studies 
of time courses or in providing biological replicates.  The chemical labelling step 
however, adds an additional processing step between samples, and thus introduces a 
level of error into the experiment.  Label-free methods can avoid the problems 
caused by the labelling steps.  Label-free techniques however require complex 
algorithms to normalise the quantitation results based on the length of the protein as 
longer proteins have a greater chance of the detection of multiple peptides (355).  
Currently, label-free strategies lack the accuracy of the labelled counterparts yet 
continued development of methodologies is proving fruitful (356).  Absolute 
quantitation (AQUA) uses heavy isotopic peptides of a known protein at standardised 
concentration spiked into the sample and compared to the detected protein, allowing 
determination of how much of that specific protein is present in the sample (357).  
One drawback of this method is that you require knowing which protein you want to 
quantify initially, thus can quantify the abundance of a known biomarker, but cannot 
be used for biomarker discovery. 
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Table 4-5 Summary of quantitative proteomics strategies 
Methodology Labelling 
Strategy 
Relative/Absolute Advantages Caveats 
2-DIGE Spot analysis or 
Fluorescent label 
Relative Simple, measures 
whole protein 
Limited range of 
quantitation 












tissue culture.  
Limited in vivo 
use 
18
O Labelling Heavy oxygen Relative Label during 
trypsin digest 
Complete 
labelling is rare 









Only suitable for 
known targets 
   
The triple labelled SILAC methodology provided the most appropriate platform for 
this study as it not only allowed comparison of AGR2-null and AGR2-expressing 
cells, but also the comparison with the AGR2-ΔC mislocalised gene product to 
control for intracellular specificity.  SILAC quantitation has proven effective in 
numerous publications including a comparable study of engineered isogenic cell 
lines expressing mutant phosphoinositide3-kinase (PI3K) (332).  However SILAC 
does require cells to be propagated in heavy medium for several passages before the 
vast majority of the proteins in the sample are appropriately labelled and thus able to 
be separated by MS.  It is essential that all proteins are metabolically labelled with 
the isotope tag as even a small percentage of unlabelled amino acid in the ‘labelled’ 
population is detrimental to the experiment as this contributes to the unlabelled 
signal, thereby introducing quantitation errors.  Five cell doublings are the generally 
accepted minimum to allow incorporation of the heavy amino acid, as ~97% of 
proteins should be in the heavy state (287), however it is essential to check that there 
are no unlabelled peaks in the labelled samples (data not shown, carried out by R. 
Lenobel, Palacky University, Olomouc, CZ and L. Hernychova, Masaryk Memorial 
Cancer Institute, Brno, CZ) prior to mixing and SILAC analysis of the samples.  This 
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allowed confidence in the quantitation of normalised expression ratios between the 
labelled and unlabeled conditions.  It is worth noting that due to the metabolic nature 
of SILAC (358), it can also be used for quantifying of protein turnover experiments, 
through a spike in of isotope containing media and measurement and analysis of the 
proteome at time points thereafter.  This provides a detection method for the change 
in the incorporation rate of SILAC-labelled amino acids in specific proteins, 
providing a dynamic measure of protein flux in the cellular proteome.  For future 
experiments, it may be relevant to interrogate the effect of AGR2 expression on 
protein flux, however this study presents initial attempts to decipher the steady-state 
effect of AGR2 on protein signalling and thus full labelling was required. 
The choice of the labelling strategy of SILAC amino acids was also taken into 







H multiple options for labelling are available.  The 
SILAC amino acids used for labelling should also be essential for the survival of 
cultured cells, ensuring that the amino acid supplemented into the tissue culture 
media is the only source of that particular amino acid for the growing cells.  Leucine 
(324), lysine (359) and methionine (360) are essential amino acids commonly used 
for SILAC labelling.  Arginine is not strictly an essential amino acid, rather is 
conditionally essential and is mostly obtained through the diet in whole organisms, it 
has been described as essential in many cultured cell lines (361;362) and has 
previously been used successfully in SILAC labelling (345;363).  The most 
important criterion of selecting isotope labelled amino acids, as described by the 
pioneers of the technique (287), is that they should provide a mass difference of at 
least 4 Da from the normal isotope abundance amino acid to avoid overlapping of 
isotopic distributions.  Therefore, we utilised a medium label of 
13
C arginine and 
2
H 




N lysine (R10K8), which met the 
desired 4 Da separation principle.  It should be acknowledged that due to the 
formulation of tissue culture media, such as DMEM, that amino acids and other 
nutrients are generally provided in excess.  This highlights an issue of the labelling 
strategy used, coupled to the molecular basis of arginine that in conditions of excess 
arginine, an arginine to proline interconversion is known to take place.  This may 
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have a downstream influence on protein quantitation accuracy as highlighted by a 
study of HeLa and HEK293 cells (363).  As a result, two distinct peak clusters for all 
proline containing peptides would be identified in the labelled state, however, this 
was not found to be an issue in this study.  If a two-peak cluster was identifiable then 
the arginine concentration of the labelling media could be empirically titrated until 
the proline peak did not indicate two species.   
Two further considerations were required to ensure accuracy in SILAC quantitation 
by minimising the abundance of natural abundance amino acids in the ‘medium’ and 
‘heavy’ labelled metabolic labelling conditions.  Firstly, through the use of dialysed 
serum (324), depleting the media of bioactive peptides below 10 kDa molecular 
weight cut off.  Thereby removing small molecules in the growth supplement 
containing any instance of the normal amino acid residue which may be metabolised 
and used to mis-label nascent peptides.  This step is essential to the accurate 
quantitation of protein expression levels; however, it is widely known that some cells 
do respond anomalously to dialysed sera lacking specific low molecular weight 
factors required for attachment and growth for example.  Fortunately, A375-FRT 
cells did not show any detectable phenotypic response to dialysed serum, there was 
no change in cell morphology, cell proliferation or attachment to the substratum (data 
not shown), thus dialysed serum was appropriate (if necessary publications have 
highlighted that purified growth factors or a small percentage of normal serum can be 
supplemented into the media (364), however this must be acknowledged as a source 
of potential quantitation error).  The second, though generally not followed as strictly 
as other avoidances of unlabelled amino acids, is the use of a PBS-based cell 
dissociation buffer ensures that no external protein is introduced into the 
experimental tissue culture.  Normal 0.05% Trypsin-EDTA enzymatically cleaves 
adhesion proteins allowing detachment of cells from the substrate for propagation; 
however the trypsin enzyme provides a source of normal amino acids which might 
remain in the medium allowing uptake and integration into synthesising proteins.  
Theoretically, it may be sufficient to wash cell pellets with PBS following 
neutralising of the trypsin reaction before re-plating in the specified media; however, 
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in this experiment it was optimal to use the PBS-based dissociation buffer for 
accuracy. 
As a consequence of these factors which may influence accurate SILAC-based 
quantitation, there are several conditions under which the cells must endure without 
exhibiting significant disruption to allow full proteome labelling, and subsequent 
precise quantitation.  Auspiciously, A375-FRT cell panel did not respond 
dramatically to tuned growth conditions optimal for SILAC labelling, allowing 
SILAC to be utilised as the most appropriate method of proteome analysis.  
Initial observation of the SILAC ratios of protein expression indicated that the vast 
majority of proteins quantified in the study did not vary beyond ±20% the expression 
level of the AGR2-null parental cell line (Figure 4-4).  SILAC is the most 
appropriate method of quantitation for detection of small changes in protein 
expression (330), and it was clear that wt-AGR2 recombination was driving a 
specific reprogramming of the cell.  Un-biased pathway analysis allows examination 
of the full scale of proteomic data gathered, without operator prejudice.  Due to the 
vast nature of proteomic data collection, bioinformatics tools provide a key means in 
the deconvolution of raw data.  By submitting the significant expression changes to 
the IPA software tool, we could identify the main biological pathways affected by 
over- or under- representation of their constituent parts, and in certain cases predict 
the activation state of that biological process.  In this experiment, IPA identified that 
the TP53 signalling pathway was most significantly inhibited in the experimental wt-
AGR2 expressing cell line, compared to the proteomic profiles of AGR2-null and 
AGR2-ΔC control cell lines (Table 4-1 and Figure 4-6).  Through the modulated 
expression of 39 proteins linked to p53-signalling function (Table 4-1 and Figure 4-
5), the reprogramming of p53-dependent activity by wt-AGR2 was highlighted.  
Further validation (Figure 4-6) confirmed that the p53-response to DNA damage was 
attenuated by wt-AGR2 expression and not by any of the subcellular mislocalised 
mutants; this indicated that the diverged C-terminal motif of AGR2 was indeed 
necessary for p53-suppressive function, as previously identified for EGFR-activity 
(188).  This complements previous discoveries of the p53 suppressive nature of 
AGR2 and its potential as a novel drug target for p53 reactivation (150;187;275).  
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Further, these data show that the synthetically engineered cells can be utilised in 
unravelling, at least one mechanism of action of AGR2 with regards to it as a proto-
oncoprotein.  It is intriguing that the reliance on the C-terminal motif for EGF 
function (188), along with the variety of subcellular distribution of wild-type AGR2 
in experimental cells (187), that both C-terminal mutants of AGR2 provided a 
growth advantage compared to the AGR2-null cells (Figure 3-9), yet neither 
demonstrated an attenuated p53 response to DNA damage (Figure 4-6).  This may 
highlight a further possible decipherable pro-growth reprogramming in addition to 
p53 suppression.  Other transcriptional pathways disrupted include the E2F1 
(activated) and TFEB (suppressed).  E2F1 plays a significant role in the regulation of 
cell proliferation, the cell cycle and is often misregulated in developing tumours 
(365).  Intriguingly, E2F1 is reported to co-operate with p53, via activation of ARF 
and subsequent inhibition of MDM2, stabilising p53 levels (366).  Our data suggest 
that AGR2 might uncouple this interplay, resulting in p53 levels being attenuated.   
It must be considered that proteomic pathway analysis highlights a suppressive effect 
of wt-AGR2 expression on one of the key homeostatic transcription factors in p53, 
yet this activity did not correlate to any detectable effect when measured at the 
transcriptome level (Figure 3-10).  Surprisingly, in contrast to the underlying 
assumption of the flow of information from DNA to phenotype in which 
perturbations of transcript levels drive protein expression, a lack of correlation 
between mRNA levels and protein levels are not uncommon (367;368).  We must 
therefore assume that low level AGR2 is functioning at the protein level to sequester 
p53 expression, and that downstream transcriptional targets are not being affected to 
such an extent to indicate significance by microarray.  Evidence is garnered with the 
fact that transcripts deemed to be upregulated by the microarray, could not be 
reproduced by the alternative qPCR method.  
Among the proteins whose expression levels were modified by wt-AGR2 (Figure 4-
8) includes Mucin-18, a cysteine rich glycoprotein whose expression is increased by 
36% following wild-type AGR2 expression.  As previously described (165;233), 
AGR2 participates in the disulphide reshuffling of mucin proteins resulting in an 
increase in the abundance of mature mucin proteins and a reduction in the 
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degradation of nascent chains.  Known AGR2-interacting proteins RuvBL-2 
(Reptin), dystroglycan, and CD59 expressions do not modulate significantly in this 
report.  HECTD1, a putative yeast-2-hybrid identified interaction candidate 
demonstrates a reduced expression profile, however the HECTD1-AGR2 interaction 
is still under further study and requires further biochemical validation (169).  Ki-67 
demonstrates expression >3-fold upregulated compared to the parental cell line; the 
Ki-67 protein is associated with cell proliferation and used as an IHC marker of 
active proliferating cells (336).  Previous studies of the oncogenic properties of 
AGR2 make this a relevant over-expressed protein, as it, and subsequent FACS 
analysis validation of expression levels, indicates wt-AGR2 expressing cells have 
enhanced expression of a key immunohistochemical marker of proliferation.  
Coupled to this the observed increase in proliferation and reduction in cell doubling 
time of wt-AGR2 cells compared to the AGR2-null parental cells (Figure 3-9), we 
could confirm that AGR2 is indeed, in line with previous publications 
(164;218;244;249;270) acting as an oncoprotein whose single allele introduction is 
adequate to present a pro-growth phenotype. 
The identification of tumour susceptibility gene 101 (TSG101) as a dominant effect 
of wt-AGR2 remodelling of the proteome prompted further validation.  TSG101 is 
involved in proteostasis, and protein trafficking due to its involvement in the 
ESCRT-1 complex of proteins regulating the transport of components of late 
endosomal compartments (369).  TSG101 contains a ubiquitin conjugating (Ubc)-
like domain which recognises ubiquitylated substrates and incorporates them into the 
multivesicular body (370).  TSG101 over-expression has recently, somewhat 
controversially, been implicated in cancer growth, despite initial characterisation as a 
tumour suppressor gene (371;372).  The majority of literature now describes TSG101 
as a tumour enhancer in various cancers including breast, ovarian and prostate 
cancers (340).  Steady state levels of TSG101 are maintained within narrow limits 
(373), and over-expression of TSG101 can lead to neoplastic transformation (374).  
In complementary studies, tsg101 silencing in mice reported defective cell 
proliferation and p53 protein accumulation (together with subsequent p21
WAF-1/CIP-1
 
activation) (295), while a reported regulatory loop involving TSG101/MDM2 
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resulted in MDM2 degradation modulation with a downstream effect on MDM2/p53 
signalling (338).  Our data also supports the interplay between levels of TSG101 and 
subsequent effect on p53 levels and activity. 
We can therefore summarise that over-expression of AGR2, exhibiting the essential 
KTEL C-terminal motif, drives an upregulation of two identified co-factors 
confirming its role as a proto-oncoprotein.  Ki-67 is upregulated indicating that cells 
have an increased proliferative capacity, as previously reported, and the induction of 
p53-inhibitor TSG101 co-operates to induce p53-dependent activity suppression 
(Figure 4-12).  Further study will therefore begin to interrogate the mechanism 
whereby AGR2 directly or indirectly upregulates or stabilises TSG101 at the protein 
level, although the assumption is that AGR2-mediated chaperone maturation is 
linked to the increased presence of the protein, however this requires further 
validation through a targeted approach.  The complexities lie in unravelling how 
TSG101, an endosomal sorting complex factor that functions in vesicular trafficking 
and other pathways, regulate p53, a nuclear transcription factor.  The fact that 
TSG101 overexpression has been highlighted in the disruption of the cell cycle, 
proliferative capacity and suppression of p53 signalling, coupled to the identification 
as the outlying, most over-expressed protein of a SILAC proteomics screen of 
effectors of AGR2 induced cell reprogramming drives the desire to identify the co-
expression of AGR2 and TSG101 in clinical tissue arrays to determine whether the 
coupling of expression of these co-factors is a contributor to tumour development in 
vivo.  The data gathered presents a new appreciation of our understanding of AGR2 
function in tumour cells, and provides knowledge that may be useful in interrogating 
AGR2 effectors as a potential therapeutic target. 
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Figure 4-12 Summarised illustration of the dominant effects of engineered AGR2 expression on 
the cellular proteome.  1- AGR2 is an ER resident PDI that can regulate the secretion of the mucin 
family of proteins (165;233) as well as pro-oncogenic receptors as defined by yeast-two hybrid, 
including DAG and C4.4A (172) that might contribute to metastatic properties.  2- A second role 
outwith the ER is also reported where AGR2 can signal to nuclear transcription pathways to 
upregulate EGFR receptor pathways (194)  and interact with the chaperone protein Reptin (199).  3- 
The relatively low level AGR2 expression in this report has comparatively minimal effect on the 
transcriptome of the cell, but SILAC analysis has shown the dominant reprogramming of the 
proteome that occurs by virtue of AGR2 production.  This includes upregulation of the proliferation 
associated protein Ki-67 and TSG101, the latter of which provides a signalling mechanism that can 
explain in part how AGR2 can attenuate the specific activity of p53 in response to DNA damage.   
  
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 5 – Molecular Interrogation of AGR2 Confirming a Homodimeric Structure  168 
Chapter 5: Molecular interrogation of AGR2 




The complex properties of the amino acid residues which comprise the building 
blocks of life, their polymerisation into a linear chain of diverse repeating units, and 
the interaction with the surrounding environment provide the structural determinants 
driving the contortion of the polypeptide into the functional protein unit.  The protein 
subunit is stabilised by non-covalent hydrogen bonds, ionic interactions, Van der 
Waals forces and hydrophobic packing, driving secondary structural motifs, the α-
helices and β-sheets.   Additionally, intra-molecular non-covalent and covalent 
interactions determine relationship between interaction partners to form functional, 
3-dimensional bioactive complexes (375). This intricate biomolecular organisation 
drives the final specific spatial conformations, which are essential for the function 
and activity of the derived protein.  The protein structure, therefore, holds the key to 
expressed domains, motifs and functional folds, which enable sub-categorisation of 
the molecule into protein families, allowing initial assumptions to be made regarding 
protein function.   In the case of Anterior Gradient-2, structural interrogation can 
provide us with new information of the possible determinants for functions of AGR2, 
and indicate characteristics which drive its potential as an oncoprotein.  This 
structural knowledge could then be utilised in a drug discovery programme for 
compounds which disrupt motifs or interactions essential for driving its growth 
promoting activity. 
As previously described in Chapter 1, AGR2 protein incorporates several structural 
motifs which have been used to begin to characterise the mature protein function.  
The N-terminal 20 amino acid residue signal sequence, coupled with the atypical C-
terminal endoplasmic reticulum sequence, KTEL (192), and a single CXXS motif 
has incorporated AGR2 as a distant member of the large protein disulphide 
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isomerase (PDI) family.  This has allowed for the identification of the fact that 
AGR2 plays a role in the maturation of cysteine rich proteins, functioning as a 
thiol/disulphide exchange factor implicated in the formation of mixed disulphides in 
MUC2 (165), MUC1 (180) and MUC5AC (233).  However, structure-based analysis 
of AGR2 has been less clear with regards to the role of AGR2 in abnormal cells, 
driving cell proliferation (164;231;249), transformation (164) and metastasis 
(172;208;219;259;270). 
The discovery of protein-protein interactions is a key, fundamental goal in life 
sciences research, and these interactions are emerging as compelling landscapes in 
the drug discovery field (376;377).  The elemental understanding of the nature of 
protein-protein interactions has begun to change, with novel research uncovering 
intrinsically unstructured regions of proteins forming important interfaces for a large 
number of protein-protein interactions (378;379).  To drive comprehensive 
understanding of AGR2 function, protein-protein interaction studies have been 
undertaken to identify interaction partners; the logic being that most proteins are 
incorporated into complexes of other proteins to perform their specific function.  
Therefore, if the function of the complex or of any of the interacting partners is 
known, then inferences on the role of the studied protein can be made (292;380).  A 
number of physiological interactors have been defined for AGR2, utilising yeast-2-
hybrid, including metastasis associated C4.4A and α-dystroglycan (172), and the 
AAA+ chaperone and transcriptional regulator protein RuvBL2/Reptin.  The latter of 
which has been validated both in vitro and in vivo (199). However, how these 
interactions might influence growth regulation is not clear.  AGR2 can also interact 
with the extracellular receptor implicated in limb regeneration Prod1 (154), 
suggesting a link between extracellular protein trafficking or binding and cell 
migration. Thus, although there is no compelling mechanism yet established, that 
would define a key protein-protein interaction important for the oncogenic function 
of AGR2.  Taken together these are four protein-interactors for AGR2 that are 
consistent with a role for AGR2 in promoting cancer associated phenotypes like cell 
growth and/or migration.  
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Two independent studies, concurrently with this study, have identified AGR2 as a 
homodimeric complex.  Ryu et al. (202) identified an intermolecular disulphide bond 
in vivo in a human colon cancer cell line which could be chemically crosslinked 
through the single cysteine residue at position 81.  Further, the dimerisation of AGR2 
could attenuate ER stress induced cell death and only the dimeric complex could 
interact with the Hsp70 molecular chaperone and unfolded protein response signal 
pathway activator, BiP/GRP78.  Agr2 mutant protein, containing cysteine-81 
mutated to serine, exhibited reduced PERK and IREα induction, indicating that 
dimerisation is essential for the activation of the UPR signalling pathway. An 
attenuated interaction with BiP/GRP78, compared to the cysteine containing wild-
type, was also evident.  It is thought that, BiP/GRP78 is associated with PERK and 
IREα in the resting state and upon conditions of ER-stress, dissociates the complex 
triggering phosphorylation of IREα and PERK, resulting in downstream signal 
transduction (381;382).  Thus, AGR2 appears to drive a form of allosteric regulation 
of the complex.  As further validation of the intermolecular disulphide interaction, an 
in vivo cross-linking coupled to mass spectrometry approach has previously 
identified the AGR2 homodimer as the most abundant AGR2 complex (203).   
In addition, a second possible dimerisation interface has been described during the 
course of studies presented herein.  Nuclear magnetic resonance (NMR) studies 
aimed at defining the first illustration of the 3-dimensional organisation of AGR2, 
uncovered that mature AGR2 (lacking the N-terminal signalling sequence) 
spontaneously formed a monomer-dimer equilibrium (PDB code: 2LNS) (201).  This 
heterogeneous nature was found to be shared with AGR3, a protein sharing 65% 
amino acid sequence identity.  This study found that the cysteine-81 to serine mutant 
had minimal effect on dimerisation state, which is in contrast to previous in vivo 
studies (202).  The monomer-dimer distribution model indicated a stable dimer with 
a dissociation constant of 8.83 μM.  Using a truncated mutant to remove the unstable 
N-terminus of the protein, a dimerisation interface of AGR241-175 was identified 
through the anti-parallel arrangement of the α-1 (residues 58-67) helix (Figure 5-1).  
An alanine point mutagenesis strategy of residues comprising the arrangement, 
namely, E60, K63 and K64, identified E60A as a monomeric unit by NMR (PDB 
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code: 2LNT).  The K64A-mutant also had disrupted dimerisation, as detected by 
analytical ultracentrifugation and gel permeation chromatography, confirming an 
E60-K64 salt bridge interaction essential in maintenance of dimer structure.  This 
report also attributed the twenty amino acid unstructured N-terminal motif (21-40) as 
required for changes to the rates of cell adhesion, but not for influencing 
dimerisation.  Only a limited number of PDIs exist as dimers, significantly, it should 
be noted that the parental ERP18 protein was originally thought to exist as a dimer 
through cysteine residues in the thioredoxin-domain (383); this was later disproven 
by NMR structural studies which determined ERP18 as a monomer (200).  ERP18 
shares the thioredoxin fold characteristic of AGR2 and AGR3 however lacks the 
tyrosine and lysine residues corresponding to positions 64 and 63 of AGR2 
respectively, which may be enough to promote the monomeric structure.   
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Figure 5-1 Illustration of AGR2 homodimer interface.    Wild-type AGR2 dimer structure solved 
by NMR (PDB code: 2LNS). By point alanine mutation scan, the dimer interface is thought to form 
through an anti-parallel interaction between α-helices and stabilised through salt-bridge interactions of 
residues between the carboxylate group of E60 and the ammonium group of K64, with a hydrophobic 
interaction between Y63 residues having some influence on dimer stability.  Highlighted are monomer 
1 in blue and monomer 2 in green.  The dimer interface defined by Patel et al. (201) of 60-EALYK-64 
is indicated in red.  
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 5 – Molecular Interrogation of AGR2 Confirming a Homodimeric Structure  173 
Structure-based lead molecule discovery remains a fundamental mechanism to 
exploit protein structure, develop small molecule leads and manipulate allostery in 
proteins (384).  There are many examples of developing small molecule regulators of 
protein oligomerisation based on structure-function or in silico guided studies (385-
388).  Amongst the many emerging models in the cancer field, for example, small 
molecules exist that stabilise the tetramer-dimer/monomer conversion of pyruvate 
kinase that has the potential to regulate metabolism in cancer cells (389;390).  This 
highlights the possibility to exploit the allosteric regulatory nature of many proteins 
through the development of small molecule tools or drug leads.  The understanding 
of the quaternary structure of AGR2, how the monomer-dimer equilibrium influences 
its biomolecular activity and the development of tools to bias the equilibrium, guides 
an approach for reagents to interrogate AGR2 allostery and provide possible novel 
drug leads. 
This chapter presents a His-tag based cloning and purification strategy allowing the 
purification of large quantities of recombinant, active AGR2.  The protein was 
characterised and identified as a homodimer by size exclusion chromatography 
methods. During the scope of this research, structural data defining the 3-
dimensional organisation of the AGR2 homodimer was published (201) coupled with 
a supplementary, somewhat conflicting report of AGR2 dimerisation (202), thus we 
set up a fluorescent microtiter based assay (two-site ‘sandwich’ microtiter assay, 
2S
MTA) that measured AGR2 oligomerisation.  This was used to determine whether 
the AGR2 dimer can be regulated in trans by self-peptides, and whether this 
information can be used to create mutants with altered dimer-monomer equilibrium.  
This information could then be used to evaluate the specific activity of such dimer 
mutants to determine whether the dimer is required for its protein-interaction 
functions.  Further, the 
2S
MTA could be further utilised for preliminary screens for 
natural compound molecules which could mediate the monomer-dimer equilibrium 
of AGR2 as novel drug leads for modulation of AGR2 function. 
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5.2 Results 
 
5.2.1 Preparation of AGR2 pEHISTEV expression vector and 
purification of recombinant protein 
Utilising a novel histidine-tagged expression vector methodology (pEHISTEV) 
developed by Liu and Naismith (286), an AGR2 expressing construct was cloned for 
protein purification  (Figure 5-2A).  The construct incorporates an amino-terminal 
hexa-histidine for nickel-based isolation from bacterial lysate, upstream of a tobacco 
etch virus (TEV) protease cleavage site.  As a result the recombinant protein can be 
purified and the tag cleaved resulting in only a four amino acid residue overhang N-
terminally of the desired protein sequence.  The AGR2 sequence cloned into the 
expression plasmid lacked the disordered N-terminal cleavable signal peptide (Figure 
1-4), such that the expressed product would be a representation of the mature 
functional protein from in vivo studies.  Following transformation into E. coli BL21 
(DE3) bacteria and selection, isolated colonies were cultured in LB and induced with 
IPTG.  The induced his-tagged AGR2 fusion product, with a molecular mass of 21.2 
kDa, was evident in crude bacterial lysate (Figure 5-2B).  Following clearing of the 
bacterial lysate of membrane fragments and unlysed cells, the bacterial slurry was 
incubated with nickel-agarose beads. Beads were washed and eluted as described in 
Chapter 2.8.2 (Figure 5-2C).  The eluted protein was pooled, dialysed to remove 
imidazole, and subject to a time course cleavage using TEV protease (Figure 5-2D).  
TEV protease incorporates a non-cleavable his-tag for downstream removal, and the 
fusion protease protein was present throughout as a 27 kDa band visualised by 
Coomassie staining.  The fusion and cleaved AGR2 proteins, of 21.2 kDa and 18.3 
kDa respectively, were also visible by Coomassie stain, and indicated that the His-
tag was almost completely removed from AGR2 following one hour incubation.  The 
cleaved protein solution was again run over a nickel column to remove the TEV 
protease, the cleaved tag and any uncleaved protein resulting in a preparation of pure 
cleaved AGR2 protein for further analysis.    
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Figure 5-2 Purification strategy of recombinant AGR2.  (A)  Highlighted are the essential motifs 
of AGR2 including the E60-K64 dimerisation interface (201), the thioredoxin-like motif (202;215), 
the divergent substrate interaction loop (199) and the ER retention sequence (188).  (B) SDS-PAGE 
separated IPTG-induced bacterial lysates expressing His-tagged AGR2 visualised with Coomassie 
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staining.  A band representing the 21.2 kDa fusion protein is highlighted.  (C)  SDS-PAGE and 
Coomassie staining of wash and elution fractions of the His-AGR2 bacterial lysate incubated with 
nickel-agarose beads. To allow a visual estimate of protein concentration 10, 1 and 0.1 μg samples of 
BSA were loaded onto the gel also.  (D) Purified protein was incubated with His-tagged TEV protease 
(10 μg per 1 mg protein, Life Technologies) and the cleavage carried out at 4⁰C over a 24 hour time 
course.  Following Coomassie staining, 3 distinct bands were evident the largest of 27 kDa represents 
the TEV protease, the 21.2 kDa corresponds to the size of the TEV-AGR2 fusion product, and the 
smallest 18.3 kDa band indicates the cleaved AGR2 product.   
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It was imperative following the purification protocol that that the recombinant 
protein was functional and that there was no detrimental effect on activity as a result 
of bacterial expression, the non-expression of the N-terminal signalling sequence, the 
additional 4 N-terminal amino acids and the cleavage of the fusion tag.  Previously, it 
was published that AGR2 exhibited a defined specific affinity for interaction with a 
peptide aptamer containing the canonical TxIYY motif.  This peptide could 
precipitate AGR2 from crude lysate, and as a result could reactivate p53 activity in 
vivo (187;275).  The 12mer (HLPTTIYYGPPG) and truncated 6mer (PTTIYY) have 
previously been identified as exhibiting the optimal affinity for AGR2 binding, 
therefore these were utilised in an ELISA based assay to confirm the activity of the 
purified recombinant AGR2 protein.  Biotinylated peptide aptamers were 
immobilised on the substrate of a streptavidin-coated 96 well plate and incubated 
with the titrated recombinant protein, prior to detection with an AGR2 specific 
antibody (Figure 5-3).  Compared to control conditions (no peptide and non-
interacting peptide), AGR2 exhibited an increase of specific binding to the 
interacting peptides of between 5-6 fold.  Exemplifying that recombinant AGR2 
purified in this method retains a previously published biochemical activity (187;275)   
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Figure 5-3 ELISA based analysis of recombinant AGR2 interaction with biotinylated peptide 
aptamers.    96-well plate was coated with streptavidin, prior to incubation with 5 μg per well of 
biotinylated peptide.  Following incubation, washing and blocking steps, a dilution series of AGR2 
protein was applied (1000, 500, 250 and 125 ng) and incubated.  Interaction was detected with 
primary AGR2 polyclonal antibody (K47) and swine anti-rabbit HRP conjugated secondary antibody.   
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 5 – Molecular Interrogation of AGR2 Confirming a Homodimeric Structure  179 
Gel-filtration size exclusion chromatography of purified recombinant mature 
AGR221-175 protein was used to provide insight into the quaternary structure of the 
protein (Figure 5-4A).  At highest concentrations (2500 μg/mL, 136 μM), the protein 
eluted with a calculated molecular mass of 34.8 kDa (Figures 5-4B), significantly 
greater than the theoretical monomeric molecular mass of 18.3 kDa (Figure 5-4C, 
Expasy Compute pI/MW tool, http://web.expasy.org/compute_pi/), more closely 
resembling a dimer structure relative to the theoretical mass of 36.5 kDa (Figure 5-
4C).  The relationship between the concentration of protein injected and integrated 
area of the GF peak is linear, with an R
2
 of 0.9995 (Figure 5-4D).  The elution 
profiles of globular proteins used for calibration are summarised in Figure 5-4E and 
5-4F.  By comparison, a prior analysis of AGR221-175 by SEC-MALLS gave a 
dimeric mass of 30.5 kDa from a protein with a monomeric mass if 17.8 kDa and a 
predicted dimeric mass of 32.2 kDa (201).  AGR2 was diluted from 2500 μg/mL 
(136 μM) to 250 μg/mL (13.6 μM), 25 μg/mL (1.36 μM) and 5 μg/mL (0.27 μM) 
prior to injection on the Sephadex-75 column to determine whether there is a 
concentration-dependence to dimerisation (Figure 5-4A, 5-4B ad 5-4C).  AGR2 
protein injected at a concentration of 250 μg/mL eluted with an estimated mass of 
32.4 kDa, while protein at 25 μg/mL exhibited a slower eluting species with an 
estimated mass of 29.1 kDa and 5 μg/mL protein injected resulted in a calculated 
molecular mass of 26.1 kDa, suggesting that the protein can exist in a dimer-
monomer equilibrium as it approaches the predicted monomeric mass of 18.3 kDa at 
lower concentrations.  These data are consistent with reports suggesting that a stable 
dimeric species of AGR2 exists (201;202) and requires an in vitro concentration of 
the pure protein in the low μM range (201). 
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Figure 5-4 Investigating the quaternary structure of AGR221-175.  (A) Gel filtration size exclusion 
chromatography trace of AGR221-175 protein, injected at the indicated concentrations, using an 
analytical Superdex PC 75 and detected by ultraviolet absorbance at wavelength of 214 nm 
(corresponding to the peptide bond).  Traces have been normalised for ease of visual comparison. (B) 
Calculation of molecular mass of the peaks of AGR2 using the elution volume (C) The calculation of 
the elution volume of the monomeric (18.3 kDa) and dimeric (36.5 kDa) species of the recombinant 
protein.  (D) Illustration of the integrated area of the AGR2 protein peak (from A), as a function of 
AGR2 protein concentration at the time of injection, highlighting the highly significant linearity 
between protein absorbance upon elution (at 214 nm) and protein (concentration) injected.  (E & F) 
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Calibration of the Superdex PC 75 column with the indicated gel filtration markers (GE) in SEC 
buffer (50 mM Tris pH 7.5, 200 mM NaCl).  These could be plotted to allow the calculation of the 
linear relationship between the logarithm of the molecular weight and the partition coefficient (Kav, 
where Kav = elution volume/void volume, void volume of Superdex PC 75 is 0.81 mL).  
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5.2.2 Characterisation of antibody reagents for AGR2 
detection 
Due to the significant similarity between AGR2 and AGR3 proteins, a panel of 
monoclonal antibodies were raised against AGR3 with the aim of defining the level 
of independence of expression between AGR2 and AGR3 in tumour biopsies (248).  
These four antibodies were subject to an ELISA-based study to determine their 
specificity for cross-reactivity between AGR3 and AGR2 (Figure 5-5).  Two of the 
antibodies raised to be specific to AGR3, MAB3.1 and MAB3.2 (Figures 5-5A and 
5-5B), indeed showed selectivity for the AGR3 protein, as titration of the antibody 
resulted in increased detection when AGR3 was immobilised on the substrate. 
Comparatively, these did not have any increased affinity above background for 
AGR2.  However, through these studies it was apparent that one monoclonal 
antibody, MAB3.4, exhibited selective cross-reactivity with AGR2 (Figure 5-5C and 
5-5D).  This cross-reactivity, while not beneficial for in vivo studies for the 
differentiation of AGR2 from AGR3, could be utilised for in vitro studies where only 
the recombinant protein of interest is present. 
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Figure 5-5 Analysis of bespoke monoclonal antibodies raised against AGR3 for cross-reactivity 
with AGR2.   (A and B) MABs 3.1 and 3.2 AGR3 specific monoclonal antibodies bind to AGR3 
protein (black line) immobilised on to the ELISA plate substrate but not the AGR2 (grey line).  (C)  
One of the monoclonal antibodies, MAB 3.4, exhibits cross-reactivity with AGR2.  (D) The cross 
reactivity of MAB3.4 (red line) was confirmed by immobilising the monoclonal antibodies on the 
substrate and titrating recombinant AGR2.  
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It was then endeavoured to fine map the AGR2 epitope recognised by MAB3.4 using 
an overlapping peptide scan.  15mer biotinylated peptides from the AGR2 (and 
AGR3) primary sequence, with a 5 amino acid overlap, were synthesised 
incorporating an SGSG spacer (Table 5-1).  The peptide library was immobilised in a 
96 well ELISA plate and incubated with the MAB3.4 antibody (Figure 5-6A).  Non-
specific interactions were removed with multiple wash steps prior to incubation with 
an HRP-conjugated rabbit anti-mouse secondary antibody.  Concurrently, the 
alternative commercial anti-AGR2 monoclonal antibody (Abcam) was also epitope 
mapped (Figure 5-6B).  However, this antibody exhibited a discontinuous non-linear 
epitope, thus the recognition site on AGR2 could not be identified.  The MAB3.4 
antibody showed a robust binding to a linear motif present in peptides 6 and 7 from 
AGR2 and peptides 21 and 22 of AGR3.  The shared sequence present in the 4 
positive peptide hits was PLMII, from AGR2, and PLMVI, from AGR3 (Figure 5-
6C) resulting in the mapping of the MAB3.4 epitope as PLMxI (Figure 5-6D) 
(independently, phage display data confirmed these epitopes, data not shown, (248)).  
The epitope for the MAB3.4 antibody was also found to be spatially distinct from the 
proposed AGR2 dimerisation interfaces (201;202) (Figure 5-6E).  By thoroughly 
characterising the AGR2 epitope recognised by MAB3.4, we could identify that the 
epitope (residues 71-75) was distinct to the perceived dimerisation interfaces of 
residues 60-64 (201) and cysteine-81 (202).  It was therefore considered whether this 
nature could be utilised in the development of assays to measure AGR2 
oligomerisation status.  
Currently, it is not clear which of the functions of AGR2 the oligomeric state might 
regulate.  It is described that monomeric AGR2 lacks the ability to interact with 
BiP/GRP78 (202) activating the UPR, yet this is reliant on the formation of the dimer 
through cysteine-81.  However, given that an additional dimer interface (201) has 
been described, this may impinge on the conclusions of the aforementioned study.  In 
order to develop sensitive and quantitative assays to measure AGR2 protein specific 
activity in a variety of protein-protein interactions, we sought to develop an assay 
that measures, in a microplate format, the oligomeric structure of AGR2.  Such a 
small-scale assay could facilitate determining whether more information could be 
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derived from the competing dimerisation interface hypotheses, while also 
investigating if interacting proteins or additional allosteric effectors can alter the 
oligomerisation of the protein. 
 
Table 5-1 Overlapping peptide libraries of AGR2 and AGR3 consisting of biotinylated 15 amino 
acid residue peptides, with 5 amino acid overlap, from the primary sequence of AGR2 (1-16) and 
AGR3 (17-31).  The C-terminal residue of the putative cleavage site of the N-terminal signalling 
sequence has been highlighted in red.  
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Figure 5-6 Epitope mapping of monoclonal anti-AGR2 antibodies.  (A) Peptide scan (Table 5-1) 
ELISA of AGR2 and AGR3 highlighting the linear motifs recognised by the MAB3.4 antibody.  
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Peptides 6 and 7 or AGR2 and peptides 21 and 22 of AGR3 were identified as binding significantly 
above background.  (B)  The peptide scan of the commercial monoclonal anti-AGR2 antibody 
(Abcam) did not identify a linear epitope, rather this antibody recognises a discontinuous epitope 
conformed by higher order protein structure.  (C) Box shade alignment 
(http://www.ch.embnet.org/software/BOX_form.html )of AGR2 and AGR3 proteins highlighting the 
shared residues of AGR2 and AGR3 from peptides 6, 7, 21 and 22 (black arrows), the red arrows 
indicate which of these are also shared among the 4 peptides.  (D) Illustration of the derived AGR2 
epitope recognised by MAB3.4 as 71-PLMxI-75.  (E) Illustration of the spatial distribution of the 60-
EALYK-64 dimerisation interface (201) (red) and the MAB3.4 epitope (248) (pink) PDB code: 2LNS.  
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5.2.3 Developing a quantitative microtiter assay to measure 
AGR2 oligomerisation 
We aimed to determine whether a quantitative two-site sandwich microtiter assay 
(
2S
MTA) could be used to quantify oligomerisation. Such an assay would then be 
amenable to evaluate, in the first instance, whether self-peptides of the interfaces 
could abolish the multimeric structure through direct competition, whether any of 
these self peptides may function in trans to allosterically regulate the structure of 
AGR2 and, utilising chemical libraries for small molecules and/or natural products, 
could alter the stability of the oligomer.  The premise of the 
2S
MTA is that the same 
immobilised monoclonal antibody used to capture an AGR2 molecule could then be 
used to detect the corresponding epitope in the liquid phase if the protein was 
oligomeric, e.g. monomers cannot be detected by this assay (Figure 5-7).  Using a 
fluorescent labelling method would allow for quantitative detection of oligomers 
over monomers.  This capture assay is limited in distinguishing monomeric 
arrangement from oligomeric arrangement.  Therefore, it can only comment on the 
formation of higher order structures and not definitively ascribe a dimer. 
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Figure 5-7 Theoretical illustration of the ELISA-based oligomerisation assay.  The predicted 
generic emission of an 
2S
MTA to measure AGR2 oligomerisation using MAB3.4 to both immobilise 
the AGR2 protein on the solid phase, and, through a fluorescent labelling step, also detect the epitope 
on the corresponding interaction partner(s).  
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In order to determine whether this monoclonal antibody could be used in an assay to 
measure AGR2 oligomerisation, a near infrared DyLight800 (DyL800, Thermo) 
fluorophore conjugation strategy, together with the Licor Odyssey imaging system 
for detection, was used to label a population of the MAB3.4 antibody.  The labelling 
reaction proceeds through NHS (N-hydroxysuccinimide) ester of the fluorophore 
reacts randomly through modification of primary amines of the lysine residues side 
chain, forming a stable covalent amide bond between the antibody and the 
fluorophore.  This enables capture of AGR2 using immobilised unlabelled MAB3.4, 
and detection of oligomeric (dimeric or larger order) complexes using the DyL800-
labelled version of the same MAB3.4 antibody.  Consequently, this allows 
quantitation of the extent of oligomerisation, as the detection of higher order 
assemblies is proportional to the amount of DyL800-MAB3.4 bound (as per Figure 
5-7). 
To develop this 
2S
MTA, the fluorescent probe labelling strategy must not interfere 
with the interaction of MAB3.4 with recombinant AGR2 protein.  It is essential that 
the amide bond between lysine and DyL800 probe does not diminish the antibodies 
complementary determining region (epitope recognition site) such that labelled 
MAB3.4 retains functionality.  A titration of MAB3.4 and DyL800-MAB3.4 
revealed that the labelled antibody retained affinity for its epitope in AGR2 protein 
and that binding could be quantified in a dose dependent manner (Figure 5-8A and 5-
8B).  The AGR2 protein-monoclonal antibody interaction in Figure 5-8B measured 
the binding of the MAB3.4 or DyL800-MAB3.4 using peroxidase-labelled anti-
mouse IgG secondary antibody and detection using enhanced chemiluminescence.  
The DyL800-labelled antibody appeared to have a slight attenuation of affinity 
compared to the unlabelled control, which could be anticipated since the antibody 
has been covalently modified.  Importantly, however, it retained considerable 
selectivity for AGR2. 
Following this, we evaluated the binding reaction using Licor Odyssey instrument 
and near infrared detection by excitation at 750 nm and fluorophore emission at 800 
nm (Figure 5-8C, Figure 5-9).  The binding of DyL800-MAB3.4 to AGR2 protein 
adsorbed onto the solid phase could be detected in a positive correlation manner with 
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increasing AGR2 concentration (Figure 5-8D), relative to the unlabelled MAB3.4 
which did not give rise to any signal.  The binding reaction appeared more linear 
using DyL800-MAB3.4 in the direct excitation-emission assay (Figure 5-8D) than 
when the indirect peroxidase-labelled secondary antibody assay (Figure 5-8B) was 
used.  There are two explanations for this phenomenon. Firstly, the 
chemiluminescence assay (in Figure 5-8D) uses “enhanced” enzymatic conversion 
by the antibody-peroxidase conjugate of substrate to create light that is quantified as 
a function of a fixed time.  As a result, the data do not reflect a reaction rate but a 
final product accumulation.  This “enhancement” of the primary signal may produce 
results that deviate from linearity.  By contrast, the DyL800-conjugated monoclonal 
antibody emits a signal that is detected directly and the results are presumably more 
linear. Secondly, the indirect enhanced chemiluminescence assay incorporates an 
additional 75 minutes of incubation with secondary antibody, washings, and 
chemiluminescence substrate addition and this incorporates an unquantified effect of 
antibody off rate on the signal intensity. By contrast, after incubations with the 
DyL800-conjugated antibody, the reaction is washed rapidly, and fluorescence 
intensity is read immediately thus minimising effects of the antibody off rate on the 
signal intensity.  This validates the DyL800-MAB3.4 excitation emission assay as a 
bioactive probe.   
As such, we next evaluated whether DyL800-MAB3.4 could detect oligomeric forms 
of AGR2 in a sandwich-ELISA style quantitative assay to measure oligomerisation 
of the protein using an unlabelled population of MAB3.4 as the capture antibody (as 
outlined in Figure 5-7).  A summary of the approach using DyL800-MAB3.4 to 
detect an oligomeric (potentially dimeric) species of AGR2 is presented in Figure 5-
8E.   Full reactions were assembled with or without the adsorption of unlabelled 
MAB3.4 on the solid phase to compare the relationship between MAB3.4 capture 
and DyL800 detection.  Subsequent incubation with titrated recombinant AGR2 
protein allowed immobilisation of the protein by the capture antibody, followed by 
detection with fixed concentration of DyL800-MAB3.4 with near IR fluorescent 
quantitation.  A dose-dependent signal could be observed (Figure 5-8F), suggesting 
that this assay can indeed capture and measure levels of oligomeric AGR2 protein.   
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It can be concluded from these experiments that: (i) The DyL800-labelling does not 
abrogate the AGR2 epitope recognition by the MAB3.4 monoclonal antibody.  (ii) 
The DyL800-label appropriately labels MAB3.4 such that the complex linearly 
detects AGR2 protein, and this interaction can be detected using near-IR methods.  
(iii) Finally, that MAB3.4 adsorbed onto the substrate can immobilise AGR2 from 
the solution phase, and detection of higher order structures can be quantified by the 
interaction of DyL800-MAB3.4 with the epitope recognition site of oligomeric 
subunits.     
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Figure 5-8 Developing a quantitative microtiter assay to measure AGR2 oligomerisation.  (A) 
Evaluation of the bioactivity of fluorescently labelled MAB3.4 in a luminescence based ELISA.  (B) 
Titration of unlabelled MAB3.4 and DyLight800-conjugated MAB3.4 in the mobile phase into wells 
of a 96-well plate adsorbed with AGR2 in the solid phase.  The binding of MAB3.4 to AGR2 was 
measured using an anti-mouse IgG secondary antibody conjugated to horseradish peroxidase.  The 
bioactivity of the monoclonal antibody (in RLU) is measured as a function of increasing MAB3.4 
concentration.  (C)  Assessing of the bioactivity of fluorescently labelled MAB3.4 in a near infrared 
detection assay.  (D) Unlabelled and DyL800-labelled MAB3.4 were titrated into wells containing 
AGR2 adsorbed in the solid phase.  The monoclonal antibody-AGR2 complex was detected and 
measured as levels of emission at 800 nm (following excitation at 750 nm) as a function of antibody 
concentration.  (E)  The ability of unlabelled MAB3.4, in the solid phase, to capture mobile 
recombinant AGR2. (F)  Unlabelled MAB3.4 was coated onto the 96-well plate, and increasing 
amount of AGR2 protein titrated to allow capture onto the solid phase.  Fixed amounts of DyL800-
MAB3.4 were added into reactions to detect the epitope of interacting units.  The extent of 
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oligomerisation was quantified as levels of emission at 800 nm as a function of increasing AGR2 
protein concentration.  All data is presented as a mean of triplicate titrations (± standard deviation) 
and is representative of multiple labelled DyL800-MAB3.4 populations.  
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Figure 5-9 Confirmation of DyL800-labelling of MAB3.4 and specificity for AGR2.  Visualisation 
of the level of AGR2 detection in the solid phase by titrated unlabelled and DyL800-labelled MAB3.4 
and detected by excitation at 750 nm and emission at 800 nm, converted to black and white for clarity 
(As per Figure 5-8C and 5-D).  
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5.2.4 Identification of linear motifs which stabilise or disrupt 
the oligomer equilibrium of AGR2. 
The literature describes that AGR2 can exist as a dimer (201-203) (Figure 5-4), thus 
antibody reagents and an assay to quantify AGR2 oligomerisation have been 
developed.  Subsequently, it was sought to determine whether the oligomeric 
equilibrium of AGR2 can be attenuated using dimer interface self-peptides or indeed 
stabilised in trans by regulatory motifs (Figure 5-10).  In stage I of the assay, 
oligomeric AGR2 is captured on the surface of the well using the immobilisation 
properties of MAB3.4 (Figure 5-8E and 5-8F).  Utilising the overlapping peptide 
library derived from the open reading frame of AGR2 (Table 5-1) in stage II, self 
peptides are pre-incubated with the recombinant protein allowing interaction with the 
oligomeric complex.  Finally, in stage III the DyL800-MAB3.4 fluorophore 
conjugated to the antibody could be used to detect the exposed epitope of the 
interacting subunits allowing quantitation of the AGR2 population which is in the 
oligomeric state. Thus, allowing the identification of the effect of interaction of 
AGR2 proteins with linear motifs which might allosterically contribute to protein 
structure and dimerisation could be identified. 
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Figure 5-10 Illustration of the hypothesis of using the 
2S
MTA coupled with an overlapping 
peptide library of the AGR2 protein to identify peptides which function in trans to allosterically 
regulate the proteins oligomeric state.  The immobilisation of the recombinant protein with the 
same antibody used to detect it (MAB3.4) means that the level of fluorescent dye detected is a 
function of the level of AGR2 protein quaternary structure.  
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Indeed, the incubation of AGR2 (5.5 pmol) with self-peptides (1.25 nmol) at 
significant molar excess resulted in perceived allosteric modulation resulting in 
variation in the level of oligomer detected (Figure 5-11).  Relative to the 
oligomerisation state of the DMSO control, several peptides indicated significant 
stabilisation of the oligomer, while others indicated slight effects in dissociation of 
the dimer (Figure 5-11A).  Incubation with peptides 6 and 7 (Figure 5-6) increased 
binding of the labelled DyL800-MAB3.4.  This was surprising as these peptides 
contain the epitope site for recognition by MAB3.4 antibody and were therefore 
expected to compete with the linear binding site of the recombinant AGR2 protein 
for interaction with MAB3.4.  If this was the case, a reduction in capture by 
unlabelled MAB3.4 on the plate and/or detection by DyL800-MAB3.4 would have 
been observed.  However this was not the case.  It was hypothesised that the increase 
in detection was not definitively as a result of stabilisation of the oligomer, rather 
might be an effect of modification of the epitope recognition for the antibody. Thus 
peptide 6 and 7 were not subject to further investigation in the study. Stabilisation of 
the multimer was evident in conditions where the protein has been incubated with 
peptides 1, 2 and 3 of AGR2, indicating that the linear motifs of these peptides may 
function as allosteric promoters of the oligomer.  These peptides are derived from the 
N-terminal disordered region of AGR2 (Figure 1-4A) which provides an interesting 
insight into the effect of disordered motifs in the allosteric modulation of the protein.  
As 11 of 15 residues of peptide 1 are cleaved in vivo during the trafficking of the 
protein to the endoplasmic reticulum, this peptide was also removed from future 
deeper analysis.  Titration of peptides 2 and 3 (Figure 5-11B) indicated a dose 
dependency of oligomerisation stabilisation.   This was, particularly evident in the 
case of peptide 3, at the concentration ranging from 50 to 12.5 mM.  High levels of 
variation in lower concentrations of peptide contribute to loss of sensitivity in 
detection.  Peptides 2 and 3 incorporate the majority of the unstructured N-terminal 
domain identified in Figure 1-5, and thus because of recent research of the level of 
protein disorder in allosteric regulation and the utilisation of this in drug discovery 
leads (391-393), highlighted it as a potential regulatory motif essential for the 
stabilisation of the quaternary structure. 
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The remaining peptides do not appear to have a significant influence on the 
oligomeric equilibrium of AGR2, with only minor modulations detected particularly 
in the C-terminal portion of the protein.  However, it is important not to discard these 
without further consideration.  Peptides overlapping the dimerisation interface do not 
stabilise the signal in the assay.  Rather, peptides 4 and 5 reduce the fluorescence 
(Figure 5-11A) with peptide 5 containing the interface sequence 60-EALYK-64 
inducing the greatest degree of oligomer de-stabilisation.  In fact, further titration of 
the peptides surrounding dimer interface (Figure 5-11C) indicate peptide 5 as a 
significant destabilising factor in the oligomeric state of AGR2.   The ability of 
peptide 4 to similarly destabilise the oligomer suggests other motifs in AGR2 in 
close proximity can be targeted to affect the intersubunit E60-K64 interface.  The 
common amino acid sequences of peptides 4 and 5 that attenuate the oligomer 
stability include 51-QLIWT-55 (Figure 5-12A), whilst the more bioactive peptide 
has the additional 56-QTYEEALYK-64 linear motif that comprises the dimer 
interface.  This may explain why peptide 5 is more active at disrupting the AGR2 
oligomer using the 
2S
MTA.   
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Figure 5-11 Quantification of the effect of self peptides on the oligomerisation state of AGR2  
(A) Peptides derived from the open reading frame of AGR2 (Table 5-1) were incubated at a mass of 
1.25 nmol with 5.5 pmol recombinant AGR2 protein prior to being subject to 
2S
MTA oligomerisation 
assay.  Briefly, after washing, the DyL800-MAB3.4 probe was added for 1 hour and the extent of 
oligomerisation plotted as a function of fluorophore emission at 800 nm.  Data is presented 
normalised to the no peptide (DMSO) control and the mean of three replicates with ± standard 
deviation.  Highlighted are the peptides which derive the MAB3.4 antibody recognition site.  (B) A 
titration of peptides 2 and 3 from the N-terminal disordered region indicates a dose dependent 
stabilisation of the oligomeric AGR2 population.  Peptides were titrated from 50-3.125 μM (5-3.125 
nmoles per well) normalised to DMSO control ± standard deviation. (C) Titration of peptides 3 
(stimulatory), 4 (inhibitory) and 5 (inhibitory, incorporating the 60-EALYK-64 motif.  Indicating that 
increased concentration of peptides 4 and 5 reduce the detection of the oligomeric species.   
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Figure 5-12 Defining and visualising the residues which comprise the AGR2 homodimeric 
interface.  (A) Illustration of the sequence of bioactive peptides (from figure 5-11) derived from the 
disordered and dimerisation regions of AGR2 protein.  Highlighted are minimal motifs predicted to 
drive stimulation (KDTKD from peptides 2 and 3) and inhibition (QLIWT from peptides 4 and 5).  
The dimer interface (201) in peptide 5 60-EALYK-64 is shaded pink.  (B)  Summary of the positions 
of residues Y58, E59 and E60 across the dimer interface (PDB: 2LNS).  The whole EALYK motif is 
highlighted in purple, but the key residues (bulky hydrophobic or charged) in close proximity for 
mutation coloured red   
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Utilising the knowledge of motifs from self-peptides which could regulate the 
oligomerisation of AGR2, a panel of mutants was created to analyse the application 
of the 
2S
MTA on full length mutant proteins to further study changes in 
oligomerisation state.  Visualising the AGR2 structure using NMR structural data 
(Figure 5-12B) (PBD: 2LNS) (201),  we chose to mutate bulky hydrophobic, and 
highly charged amino acid residues from the interface inferred by self-peptide 
disruption.  Tyrosine residue 58 was mutated to alanine, since it protrudes into the 
adjacent internal β-sheet and might be required for stabilising the dimer interface.  In 
addition, residue E59 was mutated as it protrudes outward into the solvent, while E60 
forms an intramolecular salt bridge with K64 across the adjacent monomer and 
constitutes an important feature of the dimer interface (201).  Also created was an N-
terminal truncation mutant lacking the initial 45 amino acid residues (Δ45), as this 
served two purposes: both peptides 2 and 3, covering residues 21-45, had a 
stabilising effect on the AGR2 oligomer (Figure 5-11), and the N-terminal region up 
to residue 45 has been identified as unstructured by the disorder predictor software 
(Figure 1-5) as showing a high level of disorder.  Therefore, removal of these 
residues removes the potential regulatory domain which may stabilise the protein.  
These mutants would allow progression of oligomerisation modulation, identified 
through self-peptide analysis, and subsequent identification and validation of 
residues essential for the formation and stabilisation of the dimer interface in whole 
proteins. 
The mutant DNA constructs were created by site directed mutagenesis (Y58A, E59A 
and E60A), while the truncated mutant (Δ45) required re-cloning into the pEHISTEV 
backbone. These were then transformed into E.coli strain BL21 (DE3) and 
successfully induced with IPTG, as previously (Figure 5-13A).  Bacteria were then 
lysed, cleared and 10 µL of each sample was separated on a 12% polyacrylamide gel, 
before transferred to nitrocellulose.  Immunoblots were then probed using DyL800-
MAB3.4, and detected on the 800-channel of the Licor Odyssey, allowing relative 
quantitation of the AGR2-isoform concentration from the crude bacterial lysate using 
Odyssey Sa software package (Licor) (Figure 5-13B).  The crude lysates were then 
normalised to the same concentration of induced protein for downstream 
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experiments.  This crude lysate normalisation allowed rapid and efficient testing of 
mutant AGR2 constructs compared to complete nickel-affinity chromatography 
purification of each isoform. 
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Figure 5-13 Creation of AGR2 mutants to investigate the modulation of oligomer stability.   (A) 
Coomassie Blue stain of bacterial samples of wild-type AGR2, the three alanine point mutants, Y58, 
E59 and E60, and the N-terminal truncation, Δ45, pre- and post- IPTG induction, showing the 
induction of expression of the protein isoforms of interest. (B) Following lysis and clearing, 10 µL of 
each crude lysate was separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted using 
DyL800-MAB3.4 and direct detection by excitation at 750 nm and emission at 800 nm.  Densitometry 
of bands using Odyssey Sa (Licor) allowed quantitation of protein concentration and normalisation as 
indicated.  
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A titration of AGR2-E59A revealed it has an oligomer stability profile similar to that 
of wt-AGR2 (Figure 5-14A), which might be expected since the side chain of the 
E59 is thought to project away from the interaction interface toward the solvent 
(Figure 5-12B).  Thus, mutation to alanine is having minimal effect on the stability 
of the quaternary structure.  In the wild type protein, the Y58 side chain projects into 
the secondary structure motif of the interaction partner for possible stability.  The 
data revealed that the AGR2-Y58A mutant was attenuated as an oligomer with a 
signal in the 
2S
MTA only seen at higher concentrations of the protein (Figure 5-14A).  
This indicates that Y58 may not be an essential residue for interaction to form the 
homodimer, but that it may perform an additional stabilising constraint assisting the 
dimer formation.  When comparing the AGR2-E60A mutant protein oligomeric state 
with that of the wt-AGR2, demonstrates a clear diminishing of the detection of the 
oligomer.  The mutation of glutamate-60 to alanine abrogates the described salt-
bridge formed between E60 of one monomer with K64 of the second subunit (201).  
This glutamic acid residue is thus thought to be essential for the stability of the 
oligomeric complex.  By contrast to these loss-of-function mutants AGR2-Δ45 exists 
as a more stable oligomer.  The enhanced stability of the oligomer by deletion of the 
disordered region is consistent with prior research showing that deletion of the amino 
acids 21-40 increased dimer stability and facilitated structural analysis of AGR2 as a 
dimeric species (201). 
The presentation of oligomerisation data of wt-AGR2, AGR2-E60A and AGR2-Δ45 
as a function of increasing protein concentration (Figure 5-14B) demonstrates the 
contrasting effect of the removal of essential residues in the formation of the higher 
order assemblies.  The mutation of E60 clearly has a significant detrimental effect on 
the formation of oligomers, whereas deletion of the unstructured N-terminal residues 
allows realisation of an oligomer with increased stability compared to the quaternary 
structure of the wild-type protein. 
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Figure 5-14 Determination of motifs influencing dimer stability of AGR2 protein using a 
mutagenesis and truncation strategy.  (A) Dimer stability derived by 
2S
 MTA in the AGR2 mutant 
panel (wild-type, Y58A, E59A, E60A and Δ45).  Increasing amounts of normalised wild-type and 
mutant AGR2 induced crude bacterial lysate (20-, 10-, 5-, 2.5- and 1-fold normalised) were captured 
using unlabelled MAB3.4 immobilised on the plate.  Following one hour incubation, the extent of 
oligomerisation was quantified using DyL800-MAB3.4 coupled to emission of the fluorophore at 800 
nm.  The data is presented as an average of triplicate titrations, and representative of two repeated 
experiments.  The no protein control background signal is represented by the dashed line.  The ratio of 
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perceived dimer to monomer is described above.  (B)  Oligomerisation data for wt-, E60A- and Δ45- 
are presented as a function of protein concentration indicating the evidence for essential (E60) and 
destabilising (N-terminal) motifs of AGR2 affecting the quaternary structure.  
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A secondary assay was sought to validate the conclusions of linear motifs 
influencing AGR2 oligomerisation derived from the 
2S
MTA.  The use of a DSS 
chemical crosslinking assay has previously been described to covalently trap dimeric 
AGR2 species and detected using Western blotting (202;203).  Mapping of this using 
mass spectrometry has identified lysine residue 95 as the dominant crosslinking site 
(203).  This knowledge was used to determine whether the dimeric mutant panel 
exhibited altered dimerisation using the DSS crosslink assay (Figure 5-15).  A 
titration of DSS into reactions containing constant normalised concentration of wt-
AGR2, AGR2-E60A and AGR2-Δ45 confirmed that AGR2-E60A is attenuated in 
dimer formation in response to DSS compared to the wild-type protein (Figure 5-15B 
compared to 5-15A).  At all DSS concentrations, the AGR2-E60A mutant was 
discovered to be less readily covalently linked to form a dimer (and other higher 
order species) than the wild-type protein, indicating that the K95 residues were not 
within the 11.4 Å proximity of the DSS linker as frequently.  This suggests that the 
dimer was less available for crosslinking and consequently less stable during the 
incubation.  In addition, the Δ45 N-terminal truncated mutant exists in a more stable, 
spontaneous dimer, even in the absence of crosslinker under these conditions (Figure 
5-15C lane 1).  This implies that deletion of the N-terminus can allow the formation 
of the stable dimer even in the presence of 0.1% SDS of the running gel.  It was 
subsequently discovered that the titration of DMSO into recombinant AGR2-Δ45 
drove the stabilisation of the dimer at 10% DMSO (Figure 15-5D).  The effect of 
DMSO on protein stability has been observed before (394), however it is intriguing 
to discover that the Δ45 mutant can be significantly stabilised by high concentrations 
of DMSO such that it is not disrupted in a denaturing gel separation system.  This 
may give an insight into the importance of the disordered N-terminal linear motif in 
the allosteric regulation of AGR2 protein.  This is consistent with the results of the 
2S
MTA as well as with the recent publication of AGR2 structure (201), showing that 
the deletion of the N-terminal 40 amino acids of the protein stabilises the dimer 
(201).  These data together demonstrate that Δ45-AGR2 forms a more stable dimer 
whilst AGR2-E60A is predominantly monomeric. 
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Figure 5-15 The effect of DSS on the dimerisation of AGR2 mutants.  The indicated proteins (A) 
wt-AGR2, (B) AGR2-E60A and (C) AGR2-Δ45, were incubated with increasing concentrations of 
DSS and separated by electrophoresis on a 0.1% SDS gel.  AGR2 was detected using MAB3.4 by 
immunoblotting.  The positions of monomeric, dimeric and higher order species are highlighted.  (D) 
AGR2-Δ45 was incubated with increasing concentrations of DMSO prior to immunoblot as above, 
indicating a stabilising effect of the dimeric species at high concentrations of DMSO. 
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5.2.5 Evaluating the role of the AGR2 dimer 
The only described function of the AGR2 homo-dimer is the recent publication of the 
dimeric species being essential for the interaction with BiP/GRP78, allowing the 
AGR2-dependent mediation of the ER stress signalling pathway (202).  However, the 
monomeric mutant was dependent in that study on the mutation of the cysteine-81 
residue removing the intermolecular disulphide interaction and did not take into 
account the 60-EALYK-64 subsequently reported (201).  Having created a series of 
AGR2 mutant proteins with altered oligomeric equilibrium, it could be investigated 
whether these have any gain-of-function or loss-of-function role in known AGR2 
activities.  The activities investigated were the specific binding of wt-AGR2 to the 
TxIYY peptide consensus docking motif (187;275) and the interaction with the 
AAA+ chaperone protein Reptin (199).  A titration of wt-AGR2, AGR2-E60A and 
AGR2-Δ45 indicates that all three exhibited relatively similar activity in binding to 
the peptide substrate (Figure 5-16A).  This implies that, with respect to the consensus 
peptide binding site on AGR2 (currently undefined at the structural level), peptide 
binding is independent of quaternary structure.  By contrast, the Reptin-AGR2 
interaction is substantially stabilised using the gain-of-function, more stable dimer 
mutant AGR2-Δ45, whilst the monomer-biased AGR2-E60A mutant is attenuated in 
Reptin binding, when compared to the wt-AGR2-Reptin relationship (Figure 5-16B).  
The importance of the AGR2-Reptin interaction is not fully elucidated at present, 
however study of their co-expression in tumour biopsies is underway and AGR2-
Reptin expression is linked in commonly used cancer cell lines (199), indicating a 
possible role of AGR2 allosteric modulation in cancer progression studies. 
These data provide the biochemical evidence to suggest that AGR2 protein 
dimerisation can play a role in its affinity for a client protein.  Since there are several 
other binding proteins identified as AGR2 interactors by yeast-2-hybrid (169), this 
panel of AGR2 oligomerisation mutants can be used to access the role of the AGR2 
dimer in protein-protein interactions in vitro and in cells.   
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Figure 5-16 Analysis of the biochemical function of AGR2 mutants with diverged oligomer-
monomer bias.  Examination of the interaction of wild-type AGR2 and oligomerisation/dimerisation 
mutants with (A) the biotinylated TxIYY consensus binding motif and (B) the AAA+ chaperone 
protein Reptin.  TxIYY or Reptin was adsorbed in the solid phase and incubated with increasing 
concentrations of wt-AGR2 or E60A (monomeric) and Δ45 (dimeric) mutant.  Binding was then 
detected using MAB3.4 and quantified using anti-mouse secondary IgG coupled to peroxidase and 
chemiluminescence.  The data are depicted as binding activity (in relative light units) as a function of 
increasing AGR2 protein concentration (in triplicate, presented as an average ± standard deviation).  
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5.2.6 Utilising oligomerisation assays to investigate the use 
of natural compound libraries to manipulate AGR2 
quaternary structure. 
Since the development of the 
2S
MTA and the DSS-crosslinking assay had highlighted 
its utility for the detection of the oligomeric state of AGR2, it was endeavoured to 
discover whether a natural or small molecule with bioactivity to modulate the 
oligomeric stability of AGR2 could be identified.  Utilising chemically diverse 
natural compound libraries (Strathclyde Natural Products Library, Strathclyde 
Innovations in Drug Research (SIDR), University of Strathclyde) extracted from a 
broad range of plant families, a high-throughput screen to identify potential 
regulators of AGR2 was devised.  Initially, 70 crude plant lysates from SIDR library 
0900.004D3 were prepared into 35 cocktails containing 200 µM of each library 
condition (final concentration of 400 µM of additive cocktail) and incubated with 
500 pM AGR2.  These were then subject to the capture by unlabelled MAB3.4 and 
detection of DyL800-MAB3.4 in the 
2S
MTA (Figure 5-17A).  Raw data was 
compared to a DMSO-only control and deviation tested for significance using a two-
tailed unpaired T-test at 95% confidence interval (a two-tailed test was used since 
any deviation from the control, either stabilisation of dissociation of the dimer, were 
of interest).  The data suggests that none of the extracted plant lysates could 
significantly stimulate the formation of AGR2 higher order quaternary structures.  
Interestingly, however two conditions, containing A4/B4 and C3/D3, presented 
disruption of the AGR2 oligomer sufficiently to meet the constraints of the statistical 
analysis. 
To identify which of the components of the cocktails were responsible for the 
bioactive disruption of the AGR2 oligomer, the four possible positive conditions 
(A4, B4, C3 and D3) were titrated (200, 100 and 50 µM) into the 
2S
MTA 
experimental set up.  This allowed the identification of the plant extract for further 
investigation (Figure 5-17B).  Compared to DMSO, extracts A4 and C3 did not show 
any deviation of the oligomer detection from the control; by contrast B4 and D3 
exhibited a quaternary structure destabilising activity.  Interestingly, extract D3 
demonstrated this effect in a dose-dependent manner, where the higher 
concentrations of compound considerably destabilised the dimer.  At the lowest 
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concentration (50 µM) this disruption was no longer deemed significant.  Somewhat 
confusingly, compound B4 also exhibited a reduction in detection of the oligomer, 
yet only passed statistical testing at the upper (200 µM) and lower (50 µM) 
concentrations of the additive, and not at the intermediate (100 µM).  What this 
experiment did confirm was that B4 and D3 were the bioactive components of the 
oligomer destabilising cocktails identified.  For specificity, a further 80 compounds 
from an additional library (0299.009D3) were tested and compared to the inhibition 
of the previously identified B4 and D3 conditions of 0900.004D3 library and the 
inhibitory self-peptide 5 (Figure 5-11) from previous investigations. (Figure 5-17C).  
Of those tested, none exhibited any stimulation or disruption of the AGR2 oligomeric 
complexes. 
The bioactive compounds which indicated an allosteric modulation of the AGR2 
quaternary structure were then compared to the previously discovered modulating 
self-peptides of AGR2 at 200 µM (Figure 5-18).  As expected the stimulatory self-
peptide 3 of AGR2 was the only additive which significantly stimulated AGR2 
oligomer detection compared to the DMSO control.  Disruptive peptide 5, along with 
the identified natural compound disrupters B4 and D3 exhibited significant reduction 
in the amount of oligomeric AGR2 detected compared to both the DMSO control and 
the A4 (non-bioactive) negative control. 
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Figure 5-17 Application of the two site microtiter assay in the identification bioactive 
compounds influencing the stability of the AGR2 oligomer using a natural compound library of 
plant extracts.  (A) Testing of 70 compounds of library 0900.004D3 in 400 µM cocktails of doublets 
of conditions by 
2S
MTA.  Compounds were pre-incubated with recombinant AGR2 for one hour 
before sandwich capture on MAB3.4 and detection by DyL800-MAB3.4.  Significance was tested by 
a two-tailed unpaired T-test (p-value < 0.05).  (B) Individual titrated compounds, A4, B4, C3 and D3, 
from the positive cocktails (from Figure 5-17A) at 200, 100 and 50 µM tested by 
2S
MTA. Tested for 
significance with a one-tailed (less than DMSO control) unpaired T-test at 5%.  (C) Testing of a 
second natural compound library 0299.009D3 compared to the oligomer disruption by AGR2 self-
peptide 5 and conditions B4 and D3 from 0900.004D3, significance was tested two-tailed unpaired T-
test (p-value < 0.05) as above.  
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Figure 5-18 Comparison of the level of oligomer allosteric modulation detected by two site 
microtiter assay of AGR2 by using self-peptide 3 (stimulatory), peptide 5 (disrupting) compared 
with natural product lysates A4 (negative control), B4 and D3 (both disrupting) from library 
0900.004D3.  Significance was tested by tested two-tailed unpaired T-test (p-value < 0.05).  
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As a further validation, the DSS-crosslinking assay was subsequently applied to 
AGR2 protein (500 pM) incubated with titrated (400, 200 and 100 µM) additions of 
the positive crude natural compounds (B4 and D3) and a non-bioactive control (A4).  
Crosslinking at 50 µM was carried out for 30 minutes prior to SDS-PAGE separation 
and immunoblotting with MAB3.4 (Figure 5-19).  The bioactive plant lysates appear 
to significantly reduce the crosslinking and detection of the dimeric and oligomeric 
structures of AGR2 compared to the non-interacting control (A4).  Compound D3 
appears to diminish the monomer to the greatest extent suggesting it exhibits the 
greatest affinity for the disruption of the AGR2 dimer. 
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Figure 5-19 DSS induced crosslinking of AGR2 in the presence of natural product compounds 
determining the effect of bioactive natural products on the oligomeric status of AGR2.  AGR2 
protein (500 pM) was incubated with 400, 200 and 100 µM natural products A4 (negative control) and 
B4 and D3 (oligomer disrupters) for one hour prior to 30 minute incubation with 50 µM DSS.  
Samples where then separated by SDS-PAGE and immunoblotted with MAB3.4 and a peroxidase 
conjugated rabbit anti-mouse secondary antibody and chemiluminescence.   
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Since library compound D3 was determined as the most bioactive oligomer/dimer 
disrupter of AGR2, this crude lysate was then fractionated by high performance 
liquid chromatography into 4 fractions containing active molecules.  These fractions 
(7, 8, 9 and 10) were again subject to the two oligomerisation assays, 
2S
MTA and 
DSS-crosslinking assay, to identify which fractions contained the bioactive molecule 
for disruption of AGR2 quaternary structure.  The 
2S
MTA (Figure 5-20A) indicated 
that fractions 7 and 10 exhibited the greatest level of dimer disruption compared to 
DMSO.  Fractions 7 and 10 of D3, at the greatest concentration (400 µM), also 
demonstrated oligomer disruption greater than the positive control crude lysate D3.   
Fractions 8 and 9 did not appear to have any effect on the oligomer detection, with a 
nature similar to the DMSO control.  For further investigation of fractions 7 and 10, 
they were subject to the DSS-crosslinking assay (Figure 5-20B).  In this assay, the 
disruption of the oligomer by fraction 7 was not apparent, and the level of 
dimerisation was comparable to the DMSO control and greater than the fraction 8 
non-bioactive control.  Fraction 10, however, demonstrated a dose-dependent 
disruption of the AGR2 dimer, by both assays and thus is the prime candidate for 
further work and structural identification.   
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Figure 5-20 Identification of the bioactive fraction of SIDR compound D3 in the disruption of 
AGR2 oligomeric complexes. Testing of high performance liquid chromatography separated 
fractions of compound D3 on the oligomerisation of AGR2 by (A) two site microtiter assay at 50, 25 
and 12.5 µg of fractions with 100 ng of AGR2 and detection by DyL800-MAB3.4. and (B) DSS-
crosslinking assay with 50 µM DSS incubation for 30 minutes.  Detection was by imuunoblot by 
MAB3.4 and peroxidase conjugated secondary antibody and chemiluminescence.  Significance was 
tested by tested one-tailed unpaired T-test (p-value < 0.05). 
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5.3 Discussion 
 
Understanding the properties of AGR2 at the molecular level has become a key aim 
of research to understand the bioactivity of this novel oncoprotein.  Until recently, 
the majority of structural knowledge of AGR2 was through interactomic studies 
which had identified, using yeast-2-hybrid (169;199) and co-immunoprecipitation 
(172) studies, a number of interaction partners of AGR2.  Novel research methods 
however identified a homo-dimeric structure of AGR2, putatively through two 
complementary interfaces, the 60-EALYK-64 interface (201), or an intermolecular 
disulphide interaction between cysteine-81 (202;203).  Our initial biochemical 
characterisation, prior to the publication of the above reports, by size exclusion 
chromatography indicated that recombinant AGR221-175 protein exhibited an apparent 
mass greater than that expected of the monomeric subunit on molecular sizing 
columns, and was more consistent with a homodimeric quaternary structure of the 
protein.  In contrast to the publication by Patel et al. (201), initially we resisted the 
truncation of the protein to remove the unstructured N-terminal 45 amino acid 
residues of AGR2. In vivo, following the cleavage of the signal peptide recognition 
sequence (amino acid residues 1-20), 25 remaining residues of this disordered motif 
and may contribute to the physiological instability induced by protein disorder, and 
this is essential for thorough biochemical characterisation, particularly with respect 
to the establishment of monomer-dimer equilibrium.  Subsequently, the purification 
of the homodimeric protein retaining the affinity for TxIYY binding (187;275), it 
was hypothesised that the quaternary structure may influence, or be essential for the 
biochemical functions of AGR2, as is seen in the recent publication regarding 
BiP/GRP78 interaction (202).  Therefore, the objective was to create an assay which 
could be used to determine the oligomeric state of the protein of interest, and utilise 
this assay in the creation of mutants with altered oligomeric equilibrium, and to drive 
the application of natural compound libraries to uncover small molecules which 
could modulate the balance of monomer-dimer. 
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Monoclonal antibodies derived against the open reading frame of AGR3 protein, 
were tested for cross reactivity with AGR2 (Figure 5-5 and 5-6) and MAB3.4 was 
found to exhibit a strong affinity for AGR2 (248).  The epitope for this antibody 
could be mapped to a linear site in AGR2 protein (PLMxI, Figure 5-6A and 5-6D), 
unlike the commercially available AGR2 monoclonal antibody (Figure 5-6B), thus 
the antibody could be used for specific detection of this epitope in biochemical 
assays.  Thorough characterisation of the antibody was necessary to ensure 
selectivity of the defined epitope for downstream studies. 
The assay devised measures oligomer stability via a two-site microtiter assay, or 
modified sandwich assay,  in which an oligomeric protein can be captured in the 
solid phase and detected in small volume liquid phase using a well characterised 
monoclonal antibody that binds to the same linear epitope.  Therefore, this assay 
cannot detect monomeric species, but rather detect the level of protein 
oligomerisation (Figure 5-7).  Assays targeted at deciphering oligomer formation 
using a similar principle have previously been reported in the Alzheimer’s research 
field studying the formation of amyloid plaques (395;396).  Prior to applications of 
the assay in the analysis of bioactive molecules, the assay was validated to ensure 
that the DyL800 labelling strategy did not detrimentally affect epitope recognition, 
that following conjugation the DyL800 fluorophore was functional (with 750 nm 
excitation and 800 nm emission) and was detectable using the 800 nm channel of the 
Licor Odyssey, and that the capture-detection hypothesis using the same monoclonal 
antibody allowed capture and detection of the oligomeric protein.  Therefore, a range 
of titrations of the detection antibody were tested in preliminary studies to ensure that 
the optimal antibody concentration was being used; enough DyL800-labelled 
antibody to allow detection but not excessive amounts which would compete with 
the unlabelled-MAB3.4 capture on the substrate.  This also allowed the appreciation 
of association and dissociation constants (on- and off-rates) of the affinity of the 
antibody, which could be affected by incubation time, concentration of oligomeric 
protein and concentration of detection antibody.  A comparable assay to this involves 
the use of Surface Enhanced Raman Spectroscopy (SERS) in an aggregation based 
assay, which measures the oligomerisation of the ubiquitin ligase MDM2 through the 
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congregation of Raman active particles conjugated to MDM2 to provide a read-out 
of oligomerisation (397).  Similarly, this Raman based assay was used in competition 
to identify self-peptides from MDM2 which interfere with oligomerisation and 
attenuate the SERS signal.  Both SERS and 
2S
MTA described here have advantages 
over each other.  The main advantage of SERS is that biochemical effects can be 
measured in real-time, unlike 
2S
MTA where incubation to allow the interaction of 
antibody and epitope is required.  However, 
2S
MTA can detect oligomerisation in the 
absence of any ligand thus this assay measures the quaternary structure more 
directly.  
2S
MTA was able to detect attenuation of AGR2 oligomerisation using self-
peptides from the published dimer interface from amino acids 60-EALYK-64 (201).  
Amino acids outwith this motif also attenuated oligomer stability (e.g. peptide 4, 
Figure 5-11), suggesting that the dimer motif requires the stability of adjacent 
peptide chains to allow the formation of the homodimer.  Surprisingly, peptides were 
also identified that could function in trans to stimulate the oligomerisation of AGR2 
in the 
2S
MTA.  These peptides are derived from the intrinsically disordered region of 
the N-terminal domain of AGR2 (Figure 1-5) and have the ability to act as positive 
effectors of oligomerisation suggesting they can disrupt the function of the natural N-
terminal sequence in cis.  There is a growing field in the understanding and use of 
and function of unstructured peptide motifs in driving the weak, regulatory, but 
highly specific protein-protein interactions so necessary and important in cell 
signalling (376).  Interesting comparisons can also be made with peptides and 
mimetics which can allosterically stimulate protein-protein interactions (398), and 
whether AGR2 dimerisation/oligomerisation stimulatory peptides have any influence 
on the manipulation of AGR2 biochemical function remains to be elucidated. 
Using the 
2S
MTA as a rapid screen for oligomerisation capacity in whole proteins, 
coupled to the data from self-peptide disruption of the oligomerisation equilibrium, a 
site directed mutation strategy targeting the bulky, hydrophobic or charged residues 
of peptide 5, thought to be essential in the formation of the dimer interface (Y58, E59 
and E60), were subject to alanine mutation.  This confirmed that the mutation of 
glutamic acid residue 60 to alanine resulted in a protein species with a quaternary 
structure equilibrium skewed toward the monomeric form (Figure 5-14).  This feeds 
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into the concurrent publication that glutamate-60 forms an intermolecular salt bridge 
interaction with lysine-64 of the adjacent interacting partner (201).  This could be 
confirmed using the DSS crosslinking assay (Figure 5-15), which allows covalent 
binding of lysine residues within an 11.4Å proximity.  The AGR2-E60A mutant was 
less readily available than the wild-type protein for DSS-induced chemical 
crosslinking, suggesting that this mutant exhibited a spatial distribution of protein 
molecules distinct to that of wt-AGR2.  As such, the key crosslinked site between 
lysine-95 residues, previously mapped by mass spectrometry (203), were not within 
the necessary distance of the crosslinking spacer, thus AGR2-E60A exhibited an 
attenuated dimer conformation.  By contrast, the truncation of the N-terminal 
disordered region of the mature AGR2 protein, residues 21-45, as suggested by the 
self-peptide 2 and 3 stabilisation of recombinant AGR2 protein (Figure 5-11 and 5-
14), resulted in detection of increased oligomerisation by 
2S
MTA.  This conclusion 
was supported by the supplementary DSS crosslinking assay (Figure 5-15C), and 
DMSO stabilisation of AGR2-Δ45 (Figure 5-15D), which indicated that AGR2-Δ45 
exhibits a dimer with significantly increased stability.  The role of intrinsically 
disordered regions of proteins involved in protein-protein signalling has recently 
come to light, and a significant level of research effort is driving the understanding of 
these motifs of complex function (399-402).  Over the past decade, this has driven 
somewhat of a paradigm shift away from proteins adopting highly ordered structures 
and interacting through a ‘lock and key’ mechanism (403), where the interacting 
proteins must exhibit the correct conformation before the formation of the interaction 
interface.  Instead, due to the observation of a significant number of proteins 
exhibiting numerous conformations, and are likely to have some fluidity in 
secondary, tertiary and quaternary structure to allow a mechanism of interaction 
termed ‘induced fit’ (404;405), where the structure of interacting motifs are 
malleable thus can form the most stable interaction of lowest energy state.  There is a 
growing body of evidence of intrinsic disorder found in cell signalling proteins and 
transcription factors, suggesting an important role in their regulatory capacity (406).  
Indeed from structural studies of AGR2 it has been uncovered that deletion of amino 
acids 21-40 considerably increases the stability of the AGR2 dimer by as much as 3 
orders of magnitude (201).  Indeed, when comparing the greatest concentrations of 
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DSS-crosslinking (Figure 5-15A, 5-15B and 5-15C, far right lanes), both wt-AGR2 
and AGR2-E60A exhibit higher molecular mass adducts which are not prevalent in 
the crosslinking of the AGR2-Δ45 mutant.  This may be due to the enhanced 
instability of the former two proteins due to the presence of the disordered N-
terminal domain that might affect the protein structure, whereas AGR2-Δ45 may be 
more rigid and resist such non-specific higher molecular mass species.  Taken 
collectively, these data suggest that the disordered N-terminus of AGR2 may form a 
regulatory cis-acting element allowing modulation of the dimer status.   
Following the cloning of AGR2 constructs with stabilised and depleted dimerisation, 
it was important to determine whether the contribution of the quaternary structure is 
important for known bioactive properties of AGR2. In small volume, microtiter 
assays, the mutants were tested to identify whether dimerisation was required for the 
interaction with the TxIYY peptide motif (187;275) and the validated interaction 
with Reptin (199) (Figure 5-16).  The TxIYY peptide was identified in a peptide-
phage display interaction screen as a highly specific peptide ligand that can interact 
with AGR2 in vitro (275) and in vivo (187) and presumably reflects an intrinsic 
peptide docking motif on its client proteins.  Interestingly, the AGR2 monomeric 
mutant, E60A, bound as stably as wild-type AGR2 or the enhanced dimer mutant, 
AGR2-Δ45.  This data indicates that if the TxIYY docking site represents a cellular 
binding interface for AGR2 client proteins, a study which is still underway 
(unpublished data), then the monomeric form of AGR2 has the potential to be 
equally active in this assay.  Contrastingly, the binding of AGR2 to Reptin was 
stabilised by the creation of the enhanced dimer protein (AGR2-Δ45) and attenuated 
by the monomeric E60A mutant.  Thus the determinant in AGR2 that interacts with 
Reptin (primarily within amino acids 104-111 (199)) exploits the dimeric subunit 
structure of AGR2 protein for Reptin interactions.  Solving the interface of AGR2-
Reptin may facilitate the development of biologics that disrupt this protein 
interaction to determine how it might contribute to cancer cell growth.  With 
reflection of a recent publication on  the functional role of dimeric AGR2 in the 
attenuation of endoplasmic reticulum induced cell death (202), the interaction of 
dimeric AGR2 with Reptin mirrors that of the AGR2-BiP/GRP78 interaction.  Both 
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require AGR2 to be in a dimeric structure for the interaction to take place.  The study 
presented herein and this publication (202), use different mutant constructs to reach 
the conclusions of the functional role of the dimer, however both provide evidence of 
the disruption of the dimer, suggesting that both the cysteine-81 residue (202;203) 
and the 60-EALYK-64 motif (201) act in a complementary fashion to drive the 
interaction of the AGR2 subunits, and are not mutually exclusive. 
Since we now know that the dimerisation of AGR2 is necessary for at least some of 
the biochemical functions of the proteins, with particular reference to the oncogenic 
properties of AGR2, it was endeavoured to undertake a methodology to provide a 
natural compound lead for potential drug development studies.  Natural products 
have been described as the single most productive source of leads for the 
development of drugs (407) and in particular cancer drug discovery (408).  Thought, 
at least in part, to be as a result of the chemical properties of small molecule natural 
products found that the majority of successful compounds developed into drugs are 
closely complaint with Lipinski’s Rule of Five and thus more pharmacologically 
suitable for therapeutics than synthetic drugs (409).  Novel approaches for natural 
product screens begin with crude extracts of plant or microbial lysates, resulting in a 
complex mixture of perhaps several hundred different compounds (410) which can 
then be applied as a crude cocktail in biochemical assays, removing the need for 
expensive, intensive synthesis to purify a library of pure small molecules for 
screening, instead the natural product extracts can be used early in the screening 
process (Figure 5-17, 5-18 and 5-19).  Once bioactive lysates have been identified, 
and validated by a secondary assay (and compared to a positive control, e.g. the self-
peptides of AGR2 which modulate dimerisation/oligomerisation), these crude lysates 
can be fractionated into simplified reagents for further screening (Figure 5-20).  
Presented here is that fraction 10, from compound D3 of 0900.004D3 from the 
academically available SIDR library (University of Strathclyde), contains an active 
molecule which can dissociate the AGR2 dimer to a statistically significant effect.  
Further studies are required to identify the bioactive small molecule within this 
fraction, by techniques such as mass spectrometry.  Subsequently, this compound 
could be purified or chemically synthesised for bioactivity in further assays, such as 
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thermal denaturation assays (TDA) to determine whether the molecule drives a shift 
in the melting temperature, and thus structure of the AGR2 protein.  Subsequent 
NMR or crystallography studies would allow structural mapping of the interaction, 
and downstream optimisation of the chemical structure of the compound for 
increased efficacy.  Finally, biomolecular in vitro and in vivo assays should be 
exploited to determine whether the bioactive compound can influence the interaction 
of AGR2 with Reptin or BiP/GRP78.  This would provide information on the 
effectiveness of AGR2 oligomer targeting in a drug development scenario, for 
example in the reactivation of p53. 
In conclusion, presented here is the development of a microtiter based assay that can 
be used to measure the oligomerisation state of AGR2 in small volumes, utilised in 
the study of motifs necessary for the stabilisation and destabilisation of the AGR2 
oligomer.  Such an assay was used to identify ligands, like self-peptides, that can 
allosterically regulate positively multimer stability thus forming a proof-of-concept 
assay for screening for cellular proteins or ligands that might be natural regulators of 
AGR2 dimer stability.  Using this knowledge we identified a biochemical function of 
the dimeric protein in the interaction with Reptin, and subsequently begun a drug 
discovery program to utilise natural compound libraries in the disruption of the 
AGR2 quaternary structure. 
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Chapter 6: Final Conclusions and Future 
Perspectives 
Aberrations in the function of p53 is one of the key outlying features of many 
manifestations of human cancer.  p53 is a central hub protein, collaborating with 
numerous interaction partners, to protect the cell from propagating erroneous genes 
and suppressing tumour formation by controlling cell cycle and proliferation.     The 
majority of these dysfunctional phenotypes are as a result of the expression of a 
mutant form of the p53 hub protein, yet a significant number of cancer types exhibit 
the wild-type p53 gene product, resulting in p53-dependent activity being modulated 
at the post-transcription level.  Thus, the reactivation of wild-type p53 has become a 
key strategy targeted by anti-cancer therapeutic programs.  The discovery that the 
overexpression of AGR2 is apparent in a significant number of cancers, its 
expression predicts poor prognosis, is linked to resistance of a number of current 
chemotherapeutic compounds, and has a suppressive effect on the p53 response to 
DNA damage has driven research investment in this field as a potential drug target 
for the reactivation of p53. Subsequently, AGR2 has been found to stimulate cancer 
cell proliferation, invasion and survival, influence chemotherapeutic resistance in in 
vivo models and highlighted as a pro-metastatic factor in the progression of disease.  
Yet, prior to this study, little was known about the molecular arrangement, 
regulation, subcellular function or signalling pathway components of the protein.  
The data presented herein proposes a reliable in vitro model of AGR2 expression 
which exhibits several of the published functions of AGR2 in cancer cells including 
the enhanced the unfolded protein response to endoplasmic reticulum stress, 
appropriate subcellular distribution as a result of the non-canonical ER retention 
motif and significant proliferative advantage over an isogenic cell line lacking the 
subtle constitutive expression of low levels of AGR2.  Further, a panel of cell lines 
were developed for the interrogation of the function of AGR2 with modified 
subcellular distribution to unravel the hypothesis of AGR2 as an autocrine/paracrine 
signalling factor, and as an ER-localised protein disulphide isomerase molecular 
chaperone, together with an isogenic cell line expressing a closely related gene of 
interest, (AGR3).  These models demonstrated that wild-type AGR2 overexpression 
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did not have a significant consequence on the transcriptional landscape of the cell, 
suggesting that any pro-oncogenic activity may manifest at an alternative stage, such 
as at the protein level.  It may be pre-emptive to suggest that AGR2 does not have 
any effect on the transcriptional machinery of the cell, as these cells were engineered 
to express AGR2 protein below the endogenous levels seen in AGR2-positive cancer 
cell lines, but it may highlight that the dominant effect of AGR2 overexpression is 
not expected at the mRNA stage.  To investigate the transcriptional effect of AGR2 
further, for example to identify misregulated p53-dependent gene targets, models 
expressing greater levels of AGR2 are required.  This cell panel however does 
provide an excellent representation for future studies requiring an in vitro model of 
AGR2 expression since the mechanism of gene recombination and expression levels 
of gene of interest mean that this is a more reliable and reproducible methodology 
than the more frequently used transient transfection. 
In addition to the development and validation of the experimental cell line panel, a 
proteomics approach was utilised in the application of mass-spectrometry based 
quantitative protein expression methods to assess the effect of low-level, stable 
expression of AGR2 at the protein level.  This study aimed to define a mechanism 
for how the emerging oncoprotein, AGR2, can remodel the cancer landscape.  Using 
blind, unbiased bioinformatical data analysis these data confirmed that expression of 
wild-type AGR2 protein in this cell line had a suppressive effect on the 
transcriptional activity of p53, and this could be validated using immunoblot and 
gene silencing methods in additional endogenous AGR2 expressing cell lines.  This 
suppression of p53-dependent activity was further supported by the upregulation of a 
key protein marker, used in immunohistochemistry of cell proliferation, Ki-67.   
Further, data-driven studies identified the expression of the previously published p53 
inhibitor, TSG101, as the outlying most misregulated protein expression level 
following AGR2 introduction.  Subsequent manipulation of TSG101 levels in a 
range of cell lines indeed confirmed the negative correlation between TSG101 
protein expression with p53 levels and p53-dependent activity.  Therefore, a model is 
proposed where AGR2 presence drives the expression of TSG101 to negatively 
regulate the expression and activity of p53.  Further immunohistochemical studies 
Structural and Functional Interrogation of Anterior Gradient-2 
Chapter 6 – Final Conclusions and Future Perspectives  231 
are required to assess the co-expression of AGR2 and TSG101 in human tumour 
biopsies, allowing analysis of whether TSG101-mediated suppression of p53 is an 
observable trait.   The next steps of this study are to define the mechanism whereby 
AGR2, predominantly an ER-resident molecular chaperone, promotes the expression 
of TSG101.  It is hypothesised that this may be through the appropriate maturation of 
nascent TSG101 gene products, however based on the non-exclusive ER localisation 
of AGR2 it is possible that TSG101 is stabilised in a non-ER related manner.  
Further, it is essential to understand how TSG101, an endosomal trafficking 
associated protein influences the activity and expression of the nuclear transcription 
factor, p53.  Previous studies in the AGR2 field have proposed that transient AGR2 
expression results in the nuclear exclusion of p53 in the cytoplasm, and as a result 
attenuated p53-dependent transcriptional activity.  TSG101 may perform some role 
in the re-localisation or compartmentalisation of p53, or alternatively other studies 
suggest that TSG101 participates with MDM2 in an autoregulatory loop to modulate 
cellular levels of both proteins, and of p53, by affecting protein decay.  On that basis, 
there are several hypotheses to challenge to uncover the mechanism of AGR2-
TSG101-p53 signalling.  The elucidation of a mechanism of this signalling axis is the 
key point in defining whether this pathway provides a possible target for therapeutic 
intervention allowing the reactivation of wild type p53 activity.   
Along with the pro-oncogenic signalling of AGR2, a molecular interrogation screen 
was devised, engineered and optimised to allow analysis of the oligomeric status of 
AGR2 protein.  This oligomerisation assay allowed the examination of AGR2 as a 
dimeric unit and the interface forming cofactors, the requirement of the dimeric 
structure for Reptin interaction and the first study of potential AGR2 dimer 
stabilising or disrupting bioactive compounds.  The dimeric arrangement was 
concurrently uncovered by several groups during the scope of this study, each with a 
variation on the proposal of the amino acid determinants required for dimer 
formation.  This study, using an overlapping self-peptide library, concurred that 
dimeric AGR2 required the glutamate residue 60 to form an intermolecular salt 
bridge interaction to maintain the structure, and in addition brought adjacent lysine-
95 molecules in close enough proximity to be crosslinked by DSS.  The study also 
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independently suggests that the unstructured N-terminal domain, cleaved in previous 
studies to aid structural determination, plays a destabilising role in the formation of 
the quaternary structure.  Utilising a natural product library screen, presented herein 
is the first suggestion of a bioactive compound which can disrupt the monomer-
dimer equilibrium of AGR2.  The essential progressions of these results are to 
analyse the significance of the mutated proteins with modulated quaternary 
equilibrium, and the bioactive compounds, on the activity of AGR2 in vitro and in 
vivo.  To this end, in the subsequent chapter 7-1, preliminary data has been collected 
regarding the development of a crystal structure of native AGR2.  Further 
optimisation of crystallisation conditions, and resultant high resolution structure of 
AGR2, will allow the soaking in of potential bioactive compounds followed by 
characterisation of the resultant interacting complex.  Subsequently, the global 
structural changes required to promote a shift in the equilibrium of the monomer-
dimer balance can then be defined.  These follow up studies will begin to provide 
structural assessment of the AGR2 dimer/monomer, and how destabilisation will 
affect characteristics such as interaction partner binding.    What remains unclear is 
what role the monomer-dimer equilibrium plays in the normal and pro-oncogenic 
properties of AGR2 (Figure 6-1).  Utilising the Flp-In methodology of low level 
stable gene expression, an experimental cell line expressing AGR2-E60A and 
AGR2-Δ45 mutants should be constructed for comparison with the normal function 
(CHOP response to ER stress) and pro-oncogenic properties of the wild-type gene in 
assays presented in this study, such as cell growth advantage over AGR2-null cells 
and p53-inhibition through response to cisplatin damage.  As a result, the 
biomolecular function of the monomer-dimer equilibrium could begin to be 
understood, and investigated whether manipulating this balance influences the 
oncogenic properties of AGR2 and as a result could be targeted for novel anti-cancer 
therapeutics. 
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Figure 6-1 Schematic of AGR2 monomer-dimer equilibrium and tools to investigate the role of 
equilibrium shift on the in vivo functions of AGR2. 
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Chapter 7: Preliminary Data 
 
7.1 Developing optimal conditions for AGR2 protein 
crystallisation  
 
The structural characterisation of the wild-type AGR2 protein is essential for further 
understanding of function, and further for the development of novel, high affinity 
interacting compounds which may allow attenuation of activity in human diseases.  
X-ray diffraction studies are useful in revealing information about the dynamics and 
heterogeneity of protein structures, through the highly accurate determination of 
well-refined, high resolution crystal structures (411).  More than 85% of the 
macromolecular structures currently in the Protein Data Bank (PDB) have been 
determined by X-ray diffraction, making it the most successful method for 
determining structures of large molecules (412).  The vast majority of protein 
structures determined to date curated in the PDB are at medium to high resolution 
(2.8 to 1.5 Å) (411).  This resolution is highly important since it provides greater 
accuracy sub-2Å (413), allowing a reduction in errors of atomic positions and 
reduces misinterpretation of structure.  Accurate atomic positions allow optimal 
evaluation of hydrogen bonding interactions and subsequent derivation of essential 
stabilising interactions. 
In order to begin to develop a screen for crystallisation conditions for AGR2, several 
conditions were required to be met: (i) Protein sample must be pure and free from 
contaminants; (ii) active in a functional assay; and (iii) sample must be 
homogeneous, chemically (free from proteolytic fragments) and conformationally 
(oligomerisation, aggregation, denaturation).  From Chapter 5, we can confirm that 
the sample is indeed pure and can be synthesised and purified in large quantities 
(Figure 5-2).  The protein also demonstrates a functional activity in binding to the 
previously published AGR2 interacting aptamer (Figure 5-3) (187;275).  However, 
the sample is not fully homogeneous, with populations exhibiting different 
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oligomerisation statuses evident by size exclusion chromatography (Figure 5-4).  At 
high concentrations (>2.5 mg/mL), AGR2 exists predominantly as a dimeric species 
as calculated from the size exclusion chromatography (Figure 5-4B and 5-4C).  
While not being most favourable, this could be overcome through optimisation of 
crystallisation and buffer conditions to assist in homogenous crystal packing. 
The method used for crystallisation was the most commonly used method termed 
vapour diffusion.  The protein solution (5-20 mg/mL) is prepared in a hanging or 
sitting drop that equilibrates against a reservoir containing crystallising agents such 
as precipitants (polyethylene glycol, PEG) or additives, at conditions greater or less 
the concentration in the droplet, in a system closed from the external environment.  
Initially, the droplet of protein solution contains an insufficient concentration of 
precipitant for crystallisation, over time water vaporises from the drop and transfers 
to the reservoir (mother liquor) and the precipitant concentration increases to a level 
optimal for crystallisation.  The protein solution can exist in 4 different conditions: 
(i) precipitated, where the protein aggregates into a non-uniform structure, (ii) 
nucleation zone, where the protein begins to form needles, micro-crystals or 
nucleates but most of the protein is still in solution, (iii) the metastable zone of 
crystals, the goal condition or (iv) under-saturation, where the protein remains in 
solution (414).  The aim of vapour diffusion is to prepare a solution where the 
solution is initially under-saturated, that the protein is in solution, and as the water 
diffuses out of the droplet, the concentration of precipitants increase gradually, and 
the protein solution moves to the metastable zone, resulting in the formation of 
compact crystals.  The inclusion of additive molecules (such as ammonium sulphate) 
provides minute variations in the physiological conditions, whether these vary the 
intermolecular contacts between macromolecules or eliminate intermolecular 
interactions, to drive crystal nucleation allowing stabilisation and promotion of 
crystal lattice formation.   Vapour diffusion format lends well to multi-well plate 
arrangement where conditions such as precipitant concentration, additive 
concentration and pH of the buffer solution can be manipulated in a matrix such that 
the conditions can be simply monitored (415).  
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Early results of this study exhibited small crystals, larger than microcrystals, (Figure 
7-1) consisting of small nucleated protein products at conditions of 100 mM Tris pH 
7.5, 25% PEG4000 supplemented with 5% ammonium sulphate.  Following 
isolation, freezing in liquid nitrogen and X-ray diffraction, this crystal diffracted to 
15 Å, suggesting that molecules are not closely enough packed into a crystal lattice 
such that X-ray diffraction provides information at significant resolution. Further 
precise modification and analysis of these conditions did not exhibit significant 
improvement on the resolution of the crystals thus further optimisation strategies 
were sought. 
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Figure 7-1 Microcrystal formation of AGR2.  Mother liquor was comprised of 100 mM Tris pH 
7.5, 25% PEG4000 and 5% ammonium sulphate.  Protein was concentrated to 10 mg/mL and 1.5 µL 
was mixed with 1.5 µL of well solution in a hanging drop for 5 days.  Crystal was isolated, frozen in 
liquid nitrogen and diffracted using synchrotron X-ray source (Diamond) and diffracted to 15 Å.  
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Sparse matrix screens were prepared using commercially available kits which 
incorporate empirical conditions varying a broad range of salts, polymers of different 
molecular weights, organic solvents and varying pH.  Kits used were Morpheus, 
JCSG+, Clear Strategy Screen 1, Clear Strategy Screen 2 and PGA (all from 
Molecular Dimensions).  Each of these contains 96 pre-formulated conditions in 
matrices of protein crystallisation conditions which were suitable for sitting drop 
analysis in a 96 well microplate arrangement.  Coupled to the Oryx 8 robot (Douglas 
Instruments), CrysCam X-Y stage and CrysScore software (Art Robbins 
Instruments), these could be prepared in a high throughput arrangement and 
incubated for 3 (Figure 7-2) and 7 days (Figure 7-3), followed by rapid imaging of 
the 96-well crystallisation plates.  The CrysScore software scores the droplet from 
(low) red to blue (high) based on phase separation, micro-crystal or small crystal 
formation.  Several conditions highlighted in Figure 7-3 were isolated and made into 
seeding stocks which could be reseeded with protein into the same condition to 
provide a nucleation point for new crystals, however this proved unsuccessful.   
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Figure 7-2 Sparse matrix screens using Morpheus, JCSG+, Clear Strategy 1, Clear Strategy 2 
and PGA with 48 hour incubation.  100 µL of each condition (Molecular Dynamics). was 
transferred to the corresponding well in a 96-well microplate. 0.5 µL of 10 mg/mL protein was mixed 
with 0.5 µL of mother liquor using the Oryx8 robot (Douglas Instruments) and incubated for 3 days.  
Plates were then screened with CrysCam X-Y stage, and scored using CrysScore software (Art 
Robbins Instruments).  CrysScore ranks conditions based on the phase separation, micro-crystal or 
small crystal formation of the protein solution.  Blue indicates a better droplet for crystal production 
and red colouration demonstrates conditions less conducive to crystal formation.  Conditions circled 
were removed and provided seeding stocks for downstream analysis. 
1 2 3 4 5 6 7 8 9 10 11 12
A 3 3 3 2 3 3 3 2 3 3 3 2
B 3 3 3 2 3 3 3 2 3 3 3 3
C 3 3 3 3 4 3 3 3 3 3 3 3
D 3 3 3 2 3 3 3 2 3 3 3 3
E 3 3 3 2 4 3 3 2 3 3 3 3
F 3 3 2 2 3 3 3 2 3 3 3 2
G 3 3 3 2 3 3 3 2 3 3 3 2
H 4 2 3 1 4 3 3 2 4 3 3 2
A 4 2 1 3 2 1 4 2 1 2 2 2
B 4 1 3 3 1 1 3 2 1 1 1 3
C 1 1 1 2 3 2 3 3 1 3 1 1
D 3 1 1 1 1 1 1 1 2 1 3 4 Seeded back in to JCSG+ (drop+well = cell stock)
E 3 4 3 2 2 2 2 3 3 2 3 3
F 2 1 3 2 1 3 3 5 5 3 3 2
G 3 3 2 2 3 3 2 2 4 4 4 1
H 3 3 2 2 2 2 3 4 3 3 1 4
A 2 1 1 1 1 1 2 1 1 1 1 1
B 2 1 1 1 1 1 2 1 1 1 1 1
C 3 1 2 3 2 3 3 1 2 2 2 3
D 3 1 2 3 2 3 4 5 2 2 2 3 Seeded back in to Clear Strategy 1
E 3 1 3 3 3 3 3 1 3 3 3 3
F 3 1 1 1 3 3 3 3 3 3 3 3
G 3 1 0 3 0 3 0 3 3 3 3 3
H 3 3 5 3 0 0 0 0 3 3 3 3
A 1 3 3 1 1 1 1 2 1 3 1 5
B 1 1 1 1 1 1 1 1 1 1 1 1
C 3 3 3 2 2 2 3 1 2 1 1 1
D 1 1 4 2 2 2 3 1 3 2 3 3
E 2 3 3 1 1 2 3 1 2 2 1 1 Seeded back in to Clear Strategy 2
F 2 2 4 3 3 3 1 1 4 3 2 5
G 3 3 3 3 0 2 0 1 2 1 1 1
H 2 1 3 3 3 2 3 1 4 2 2 2
A 3 3 3 1 2 1 1 3 1 1 1 1
B 1 1 1 1 1 1 1 1 1 1 1 1
C 1 1 1 1 1 1 1 1 2 2 2 3
D 3 2 3 3 3 4 2 4 4 3 3 3
E 2 2 1 2 2 2 2 2 3 3 1 3
F 3 3 3 3 2 2 2 2 3 2 2 3
G 3 4 1 4 4 2 2 2 2 2 1 2
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Figure 7-3 Sparse matrix screens using Morpheus, JCSG+, Clear Strategy 1, Clear Strategy 2 
and PGA with with 7 days incubation.    A heat map was produced from CrysScore analysis 
packacge.  CrysScore ranks conditions based on the phase separation, micro-crystal or small crystal 
formation of the protein solution.  Blue indicates a better droplet for crystal production and red 
colouration demonstrates conditions less conducive to crystal formation.Circled are the conditions 
which were previously removed for seeding stocks.  
1 2 3 4 5 6 7 8 9 10 11 12
A 2 2 3 1 3 2 3 1 3 3 3 1
B 2 2 3 1 4 3 3 1 3 3 3 2
C 3 3 3 2 4 3 3 2 3 3 3 2
D 3 2 3 1 4 3 3 2 3 3 3 2
E 4 2 3 1 4 3 3 2 4 3 3 2
F 4 2 2 1 4 3 3 1 4 3 3 2
G 4 2 3 1 4 3 3 2 3 3 3 2
H 1 1 2 1 4 3 3 1 4 3 3 2
A 4 2 1 2 2 1 4 1 1 2 1 2
B 2 1 2 4 1 1 3 1 1 1 1 3
C 1 1 1 1 3 1 3 3 1 2 1 1
D 3 1 1 1 1 1 1 1 2 1 3 4
E 3 3 3 1 1 1 1 3 3 2 2 2
F 1 1 2 2 1 3 3 0 1 1 1 1
G 3 3 1 2 2 2 4 4 4 2 4 1
H 3 3 1 3 1 1 2 4 3 2 1 1
A 2 1 1 1 1 1 2 1 1 1 1 1
B 2 1 1 1 1 1 1 1 1 1 1 1
C 3 1 1 4 2 3 3 1 1 1 1 3
D 3 1 1 3 1 3 3 0 1 1 1 3
E 3 1 3 3 3 3 3 1 5 5 3 3
F 3 1 1 1 3 3 3 6 3 4 5 3
G 3 1 0 3 0 3 0 3 4 3 4 3
H 3 3 5 3 0 0 0 0 3 3 3 3
A 1 3 2 3 1 1 1 2 1 3 1 5
B 1 1 1 1 1 1 1 1 1 1 1 1
C 4 3 3 1 5 2 2 1 2 1 1 1
D 1 1 4 2 2 2 1 1 5 2 5 2
E 2 3 3 1 1 1 2 1 5 3 1 1
F 1 1 4 3 3 3 1 1 4 3 4 0
G 3 3 3 2 0 1 0 1 2 1 1 1
H 2 1 5 3 3 4 3 1 4 2 1 1
A 3 3 2 1 1 1 1 2 1 1 1 1
B 1 1 1 1 1 1 1 1 1 1 1 1
C 1 1 1 1 1 1 1 1 2 2 2 2
D 3 1 2 3 2 4 2 4 4 3 2 2
E 1 2 1 2 2 2 2 2 2 2 1 3
F 3 3 3 3 2 2 5 2 3 2 2 3
G 2 4 1 4 4 2 2 2 2 2 1 2
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Subsequently, several crystals from these screens were stored in liquid nitrogen prior 
to X-ray diffraction data collection.  Data analysis on the CrysScore derived highest 
scoring (most blue in Figure 7-3) Clear Strategy 1 condition F8 (Figure 7-4A) 
disappointingly resulted in limited diffraction and suggested a level of precipitation.  
However, a poorer scoring crystal from Morpheus condition C3 demonstrated data of 
better resolution at 5Å (Figure 7-4B).  Whilst being a significant improvement on 
initial studies, this was not sufficient to resolve amino acid side chain arrangements 
and hydrogen bond interactions (bearing in mind that maximum hydrogen bonds are 
3.3Å in length).  Literature review (416) identified the Morpheus C3 condition to 
contain 10% PEG4000, 20% glycerol, 0.03 M of NPS additive (containing NaNO3, 
Na2HPO4 and (NH4)2SO4)  and 0.1 M MES/Imidazole pH 6.5.  Ongoing studies are 
currently optimising these conditions within a narrow matrix, including seeding 
techniques, in order to produce crystals which diffract to less than 3Å. 
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Figure 7-4 Images of crystals derived from the sparse matrix screens .  (A) Image of the highest 
CrysScore scoring condition of Crystal Strategy 1 condition F8, which yielded poor X-ray diffraction 
data.  (B) Image of the Morpheus C3 condition, which while not exhibiting a high score by CrysScore 
provided diffraction data resolving to 5Å.   
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During the progress of this study, the NMR solution structure of AGR41-175 (2LNS 
(201)) and the crystal structure of the highly similar AGR3 protein (3PH9, (417)) 
were published.  These are useful in the visualisation of structural conformation of 
the AGR2 protein; however, the field still lacks the complete structure of the mature 
AGR221-175, functional unit for analysis of compounds which can be visualised to 
manipulate the oligomeric structure of AGR2.  This preliminary data provides the 
first steps of optimising the conditions for the reproducible development of AGR2 
crystals which allow high resolution X-ray diffraction which can subsequently be 
used for the development of a highly accurate crystal structure.  An accurate crystal 
structure could then be subject to in silico screening for novel interacting compounds 
(418), hydrogen-deuterium exchange mass spectrometry (419) to analyse the binding 
interactions with Reptin and other yeast two hybrid protein hits, as well as 
identifying the interface with the natural compound present in fraction 10 of the D3 
condition of the SIBR library (Chapter 5). 
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7.2 Analysing the effect of AGR2 expression on the 
profile of secreted proteins 
 
There is a substantial amount of evidence to suggest that AGR2 functions as a pro-
metastatic factor in several cancers including breast cancer (420).  Transfection of 
AGR2 cDNA into a benign rat mammary cell line, Rama 37, induced a metastatic 
phenotype in vivo, and these cells injected into the mammary fat pads of syngenic 
rats had the propensity to develop lung metastasis (219).  Over-expression of AGR2 
was also identified in metastatic hepatocellular carcinoma (HCC), and an increase in 
AGR2 expression increased invasion of HCC cell in vitro and in vivo (208).  While 
in prostate cancer, over expression is reported in metastatic tumours (246), such that 
AGR2 is being explored as  a potential urine- (245) and blood- (259) based 
diagnostic marker of metastatic prostate cancer.  What remains unclear is how AGR2 
functions to promote metastatic activity.  Some reports suggests that AGR2 itself is 
secreted into the extracellular milieu (as in Xenopus (149)), and functions as a 
signalling molecule promoting the invasiveness of cancer cells (204).  Others, based 
on the increased expression AGR2 following physiological stress (178), propose that 
AGR2 expression can enhance ER folding capacity, allowing increased protein 
production and secretion (179).  While microarray studies have suggested that AGR2 
signals to upregulate genes involved in proliferation, invasion and angiogenesis, 
factors important for metastasis and tumour progression. 
Utilising the isogenic A375 cell line experimentally constitutively expressing AGR2 
(Chapter 3), we aimed to interrogate whether it was possible to use proteomic 
methods to identify how AGR2 modified the secretome, that is the landscape of 
proteins secreted by the cell, resulting in a cell with increased metastatic potential.  
Recently, proteomics has been utilised in the detection of proteins in conditioned 
media from cells grown in culture, which have subsequently been used to identify 
changes in the secretome of the experimental cell, for example comparing inactive 
and active immune cells (421).  Subsequently, this has been applied to oncology  
analysing for protein candidates which influence the metastatic characteristics of a 
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progressing colorectal tumour (422).  It was hypothesised that an increase in AGR2 
protein expression would consequently influence the maturation of client proteins in 
the ER, it was thought that some of these client proteins may be secretory in nature 
and these may be detected and quantified.   
Preliminary studies required the seeding of FRT- and FRT-wtAGR2 cells at identical 
cell number, which were incubated for 24 hours to allow cell attachment.  Next, cells 
were incubated with serum free media for 30 mins to remove any signalling 
molecules bound to the surface, followed by incubation with serum free media for 24 
hours.  This media, while lacking in key small molecules for cell growth and 
survival, would give the best opportunity to identify proteins secreted by the two cell 
lines.  At timed intervals, samples of media were collected and snap frozen to avoid 
proteolytic action.  Samples were concentrated using 10 kDa molecular weight cut 
off filters, to 1/10 of the starting volume.  Subsequently, samples were boiled in SDS 
sample buffer and separated by SDS-PAGE.  Gels were silver stained or optimal 
sensitivity.  Observed results (Figure 7-5) suggested that proteins could be detected 
from the concentrated media (however it was not clear whether these were cell 
synthesised proteins, or as a result or cells dying through serum withdrawal, or 
bovine compounds retained from the FBS).  wtAGR2 expressing cells suggest an 
increased number of protein bands identified in the first 6 hours in particular, 
however, it is not expected that this assay is sensitive enough to be used to quantify 
protein bands. 
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Figure 7-5 Silver staining of concentrated conditioned media from isogenic A375 cells ± AGR2 
gene expression.  Identical numbers of cells were plated and attached to substrate overnight.  
Following PBS washes, serum free media was incubated for 30 minutes before removal and 
replacement with fresh serum free media for the time course.  At intervals 500 µL of media was 
removed and flash frozen for storage at -80⁰C, following collection all samples were concentrated 
using 10 kDa MWCO centrifugal filters to 50 µL, before boiling in SDS sample buffer and 25 µL 
loaded onto a 12% SDS-PAGE gel.  Once separated gels were silver stained and imaged on a lightbox  
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Following these primary studies, a further experiment was prepared.  Cells were 
similarly plated and allowed to attach to the tissue culture vessel.  Following 
attachment, cell lines were incubated with methionine-depleted DMEM tissue culture 
media for 30 minutes to allow the emptying of endogenous methionine pools.  Media 
was removed and cells were subsequently incubated with methionine-depleted media 
supplemented with 10% dialysed FBS and 30 µL 35S-labelled methionine and 
incubated for 24 hours.  Following 
35
S-methionine labelling, media was removed and 
cells incubated with serum free media for a 24 hour time course.  Samples were 
aspirated following 25 minutes of incubation and at time points throughout the 
experiment.  As previously, samples were concentrated using centrifugal filters, SDS 
sample buffer boiled and separated by SDS PAGE.  Gels were stained with 
Coomassie blue, and dried using a gel drier.  Once dry, gels were exposed to 
phosphoimager screen for 16 hours before analysis on the phosphoimager (Figure 7-
6).  This experiment allowed labelling only of the synthesised proteins secreted from 
the cell and confirmed that it was possible to identify cellular proteins isolated from 
the media using this protocol.  In addition in triplicate, 10 µL of each sample was 
mixed with 2 mL of Optiphase scintillation fluid and read on the scintillation counter 
(Figure 7-7).  This indicates that synthesised proteins secreted into the media are 
detectable by this method, suggesting that it may be possible to quantify the protein 
profile of these cells allowing analysis of the effect of AGR2 expression on secreted 
proteins. 
It is proposed that further quantitative mass spectrometric analysis, such as SILAC or 
ITAQ, may highlight important changes in the abundance of proteins secreted from 
the cell and whether these have a bearing on the metastatic potential of the cell as a 
result of AGR2 gene expression. 
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Figure 7-6 Phosphoimager screen of FRT- and FRT-wtAGR2 cells incubated with 
35
S-
methionine supplemented DMEM tissue culture media.   Following labelling cells were washed 
and incubated with serum free DMEM for 24 hour time course.  Samples presented here were prior to 
incubation (media only) and following 15 minutes and 24 hours of incubation with serum free media.  
Media was concentrated to 1/10
th
 of starting volume using centrifugal filters prior to SDS-PAGE and 
the gel dried.  To detect dried gels were exposed to the phosphimager screen for 16 hours before 
analysis on the phosphoimager. 
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Figure 7-7  Scintillation count analysis of FRT- and FRT-wtAGR2 cells incubated with 
35
S-
methionine supplemented DMEM tissue culture media.  Following labelling cells were washed 
and incubated with serum free DMEM for 24 hour time course.  In triplicate 10 µL of each sample 
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Chapter 8: Appendices 
 
Compact disc attached to back cover 
 
8.1 Appendix 1 – Illumina HT-12 microarray data 
Microsoft Excel file: Appendix 1 Microarray Table.xlsx 
 
8.2 Appendix 2 – SILAC protein expression data  
Microsoft Excel file: Appendix 2 Supplementary SILAC table.xlsx 
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